



HU000031614T2

(19) **HU****MAGYARORSZÁG****Szellemi Tulajdon Nemzeti Hivatala**(11) Lajstromszám: **E 031 614**(13) **T2**

EURÓPAI SZABADALOM SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 09 705327**(22) A bejelentés napja: **2009. 01. 29.**(51) Int. Cl.: **A61K 38/16** (2006.01)**C07K 14/31** (2006.01)(96) Az európai bejelentés bejelentési száma:
EP 20090705327(86) A nemzetközi (PCT) bejelentési szám:
PCT/EP 09/051033(97) Az európai bejelentés közzétételi adatai:
EP 2244722 A1 **2009. 08. 06.**(87) A nemzetközi közzétételi szám:
WO 09095453(97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2244722 B1 **2016. 07. 27.**(30) Elsőbbségi adatok:
20080070 **2008. 01. 31.** **IE**
0801768 **2008. 01. 31.** **GB**(72) Feltaláló(k):
FOSTER, Timothy, Dublin 16 (IE)
HIGGINS, Judy, Dublin 12 (IE)
JOSEFSSON, Elisabet, S-413 23 Goteborg (SE)
GEOGHEGAN, Joan, Dublin 7 (IE)
Tarkowski, Andrej, deceased (SE)(73) Jogosult(ak):
**The Provost, Fellows, Foundation Scholars, &
the other members of Board, of the College of
the Holy & Undiv. Trinity of Queen, Dublin 2
(IE)**(74) Képviselő:
**Kovári Szabadalmi és Védjegy Iroda Kft.,
Budapest**

(54)

Mikrobiális fertőzések kezelése

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11)

EP 2 244 722 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
27.07.2016 Bulletin 2016/30

(21) Application number: **09705327.6**

(22) Date of filing: **29.01.2009**

(51) Int Cl.:
A61K 38/16 (2006.01) C07K 14/31 (2006.01)

(86) International application number:
PCT/EP2009/051033

(87) International publication number:
WO 2009/095453 (06.08.2009 Gazette 2009/32)

(54) TREATMENT OF MICROBIAL INFECTIONS

BEHANDLUNG VON MIKROBIELLEN INFEKTIONEN

TRAITEMENT D'INFECTIONS MICROBIENNES

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK TR**

(30) Priority: **31.01.2008 IE 20080070**
31.01.2008 GB 0801768

(43) Date of publication of application:
03.11.2010 Bulletin 2010/44

(60) Divisional application:
16173940.4

(73) Proprietor: **The Provost, Fellows, Foundation
Scholars, & the
other members of Board, of the College of the
Holy
& Undiv. Trinity of Queen Elizabeth near Dublin
Dublin 2 (IE)**

(72) Inventors:
• **FOSTER, Timothy**
Dublin 16 (IE)
• **HIGGINS, Judy**
Dublin 12 (IE)
• **JOSEFSSON, Elisabet**
S-413 23 Goteborg (SE)
• **GEOGHEGAN, Joan**
Dublin 7 (IE)
• **Tarkowski, Andrej**
deceased (SE)

(74) Representative: **Hally, Anna-Louise**
FRKelly
27 Clyde Road
Dublin 4 (IE)

(56) References cited:
• **LIU ET AL: "A segment of Staphylococcus aureus
clumping factor A with fibrinogen-binding
activity (ClfA221-550) inhibits platelet-plug
formation in mice" THROMBOSIS RESEARCH,
TARRYTOWN, NY, US, vol. 121, no. 2, 1 January
2007 (2007-01-01), pages 183-191, XP022360853
ISSN: 0049-3848**
• **JOSEFSSON E ET AL: "PROTECTION AGAINST
EXPERIMENTAL STAPHYLOCOCCUS AUREUS
ARTHRITIS BY VACCINATION WITH CLUMPING
FACTOR A, A NOVEL VIRULENCE
DETERMINANT" JOURNAL OF INFECTIOUS
DISEASES, UNIVERSITY OF CHICAGO PRESS,
CHICAGO, IL, vol. 184, no. 12, 15 December 2001
(2001-12-15), pages 1572-1580, XP009028976
ISSN: 0022-1899**
• **MIAJLOVIC HELEN ET AL: "Both complement-
and fibrinogen-dependent mechanisms
contribute to platelet aggregation mediated by
Staphylococcus aureus clumping factor B." INFECTION AND IMMUNITY JUL 2007, vol. 75, no.
7, July 2007 (2007-07), pages 3335-3343,
XP002523688 ISSN: 0019-9567**
• **DEIVANAYAGAM C C S ET AL: "A novel variant
of the immunoglobulin fold in surface adhesins
of Staphylococcus aureus: Crystal structure of
the fibrinogen-binding MSCRAMM, clumping
factor A" EMBO JOURNAL 20021216 GB, vol. 21,
no. 24, 16 December 2002 (2002-12-16), pages
6660-6672, XP002523689 ISSN: 0261-4189**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 244 722 B1

- | | |
|---|--|
| <ul style="list-style-type: none"> • LOUGHMAN ANTHONY ET AL: "Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A." MOLECULAR MICROBIOLOGY AUG 2005, vol. 57, no. 3, August 2005 (2005-08), pages 804-818, XP002523690 ISSN: 0950-382X • KEANE FIONA M ET AL: "Fibrinogen and elastin bind to the same region within the A domain of fibronectin binding protein A, an MSCRAMM of Staphylococcus aureus." MOLECULAR MICROBIOLOGY FEB 2007, vol. 63, no. 3, February 2007 (2007-02), pages 711-723, XP002523691 ISSN: 0950-382X | <ul style="list-style-type: none"> • KEANE FIONA M ET AL: "The N-terminal a domain of Staphylococcus aureus fibronectin-binding protein a binds to tropoelastin" BIOCHEMISTRY, vol. 46, no. 24, June 2007 (2007-06), pages 7226-7232, XP002523692 ISSN: 0006-2960 • JOSEFSSON ELISABET ET AL: "Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for Staphylococcus aureus virulence." PLOS ONE 2008, vol. 3, no. 5, 2008, page e2206, XP002523693 ISSN: 1932-6203 |
|---|--|

Description

INTRODUCTION

[0001] The present invention relates to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin.

[0002] Multiple drug resistance (MDR) is an increasing problem amongst gram positive bacteria, particularly in hospitals. The widespread use of antibiotics and other agents to treat bacterial infections has led to the rapid development of bacteria resistant to the agents and many bacteria have multiple drug resistance. Thus, there is now a need to provide improved therapies for dealing with such drug resistant infections.

[0003] Staphylococci are Gram-positive bacteria of spherical shape, usually arranged in grape-like irregular clusters. Some are members of the normal flora of the skin and mucous membranes of humans, others cause suppuration, abscess formation, a variety of pyogenic infections, and even fatal septicaemia. Pathogenic staphylococci often hemolyze blood, coagulate plasma, and produce a variety of extracellular enzymes and toxins.

[0004] The genus *Staphylococcus* has at least 30 species. The three main species of clinical importance are *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Staphylococcus saprophyticus*. *Staphylococcus aureus* is coagulase-positive, which differentiates it from the other species. *S. aureus* is a major pathogen for humans. Almost every person has some type of *S. aureus* infection during a lifetime, ranging in severity from food poisoning or minor skin infections to severe life-threatening infections. The coagulase-negative staphylococci are normal human flora which sometimes cause infection, often associated with implanted devices, especially in very young, old and immunocompromised patients. Approximately 75% of the infections caused by coagulase-negative staphylococci are due to *S. epidermidis*. Infections due to *Staphylococcus warneri*, *Staphylococcus hominis*, and other species are less common. *S. saprophyticus* is a relatively common cause of urinary tract infections in young women. Staphylococci produce catalase, which differentiates them from the streptococci. *S. lugdunensis* is also relevant in a clinical and is present in approximately 5 to 10% of cases of infective endocarditis.

[0005] *S. aureus* colonization of the articular cartilage, of which collagen is a major component, within the joint space appears to be an important factor contributing to the development of septic arthritis. Hematogenously acquired bacterial arthritis remains a serious medical problem. This rapidly progressive and highly destructive joint disease is difficult to eradicate. Typically, less than 50% of the infected patients fail to recover without serious joint damage. *S. aureus* is the predominant pathogen isolated from adult patients with hematogenous and secondary osteomyelitis.

[0006] In hospitalized patients, *Staphylococcus* bacteria such as *S. aureus* are a major cause of infection. Initial localized infections of wounds or indwelling medical devices can lead to more serious invasive infections such as septicemia, osteomyelitis, mastitis and endocarditis. In infections associated with medical devices, plastic and metal surfaces become coated with host plasma and matrix proteins such as fibrinogen and fibronectin shortly after implantation. This ability of *S. aureus* and other staphylococcal bacteria to adhere to these proteins is essential to the initiation of infection. Vascular grafts, intravenous catheters, artificial heart valves, and cardiac assist devices are thrombogenic and prone to bacterial colonization. Of the staphylococcal bacteria, *S. aureus* is generally the most damaging pathogen of such infections.

[0007] A significant increase in *S. aureus* isolates that exhibit resistance to most of the antibiotics currently available to treat infections has been observed in hospitals throughout the world. The development of penicillin to combat *S. aureus* was a major advance in infection control and treatment. Unfortunately, penicillin-resistant organisms quickly emerged and the need for new antibiotics was paramount. With the introduction of every new antibiotic, *S. aureus* has been able to counter with β -lactamases, altered penicillin-binding proteins, and mutated cell membrane proteins allowing the bacterium to persist. Consequently, methicillin-resistant *S. aureus* (MRSA) and multidrug resistant organisms have emerged and established major footholds in hospitals and nursing homes around the world (Chambers, H.F., Clin Microbiol Rev, 1:173, 1988; and Mulligan, M.E., et al., Am J Med, 94:313, 1993). Today, almost half of the staphylococcal strains causing nosocomial infections are resistant to all antibiotics except vancomycin, and it appears to be only a matter of time before vancomycin will become ineffective as well.

[0008] Thus, there remains a very strong and rapidly growing need for therapeutics to treat infections from staphylococci such as *S. aureus* which are effective against antibiotic resistant strains of the bacteria.

[0009] In gram positive pathogens, such as Staphylococci, Streptococci and Enterococci, proteins, called adhesins, mediate such infections, for example by promoting colonization, attachment to blood clots and traumatized tissue. These specific microbial surface adhesins are termed MSCRAMMs (microbial surface components recognizing adhesive matrix molecules) (Patti, J., et al., Ann Rev Microbiol, 48:585-617, 1994; Patti, J. and Hook, M., Cur Opin Cell Biol., 6:752-758, 1994). MSCRAMMs specifically recognize and bind to extracellular matrix (ECM) components, such as fibronectin, fibrinogen, collagen, and elastin. These MSCRAMMs are found in many gram positive pathogens and their amino acid sequences are related, they have similar modular design and common binding domain organization.

[0010] MSCRAMMs on the bacterial cell surface and ligands within the host tissue interact in a lock and key fashion resulting in the adherence of bacteria to the host. Adhesion is often required for bacterial survival and helps bacteria evade host defence mechanisms and antibiotic challenges. Once the bacteria have successfully adhered and colonized host tissues, their physiology is dramatically altered and damaging components such as toxins and enzymes are secreted. Moreover, the adherent bacteria often produce a biofilm and quickly become resistant to the killing effect of most antibiotics.

[0011] A bacterium can express MSCRAMMs that recognize a variety of matrix proteins. Ligand-binding sites in MSCRAMMs appear to be defined by relatively short contiguous stretches of amino acid sequences (motifs). Because a similar motif can be found in several different species of bacteria, it appears as though these functional motifs are subjected to interspecies transfer (Patti and Hook, Cur Opin Cell Biol, 6:752-758, 1994). In addition, a single MSCRAMM can sometimes bind several ECM ligands.

[0012] MSCRAMMs can mediate infection by binding to proteins including Fibrinogen (Fg) and/or Fibronectin (Fn) etc. Fibrinogen and Fibronectin are proteins found in blood plasma and play key roles in hemostasis and coagulation.

[0013] Fibrinogen is composed of six polypeptide chains, two A α , two B β and two γ -chains. The C-terminal part of the γ -chain is biologically important and interacts with the platelet integrin during platelet adherence and aggregation. It is this region which is also targeted by *Staphylococcus aureus* resulting in Fibrinogen-dependant cell clumping and tissue adherence.

[0014] *Staphylococcus aureus* has several surface expressed proteins which stimulate platelet activation and aggregation. The *Staphylococcus aureus* MSCRAMM proteins include but are not limited to the following:

- Fibrinogen binding protein clumping factor A (ClfA);
- Fibrinogen binding protein clumping factor B (ClfB);
- Fibronectin-fibrinogen binding protein A (FnBPA);
- Fibronectin-fibrinogen binding protein B (FnBPB); and
- *S. aureus* surface proteins SasA, SasG, SasK etc.

[0015] Table 1 below outlines a selection of various *Staphylococcus aureus* cell wall-anchored surface proteins.

TABLE 1

Surface protein	aa ^a	Ligand(s) ^b	Motif ^c	Sortase ^d
Protein A (Spa)	508	Immunoglobulin, von Willebrand Factor, TNFR ^e	LPETG	A
Fibronectin binding protein A (FnbpA)	1,018	Fibronectin, fibrinogen, elastin	LPETG	A
Fibronectin binding protein B (FnbpB)	914	Fibronectin, fibrinogen, elastin	LPETG	A
Clumping factor A (ClfA)	933	Fibrinogen, complement factor I	LPDTG	A
Clumping factor B (ClfB)	913	Fibrinogen, cytokeratin 10	LPETG	A
Collagen adhesion (Cna)	1,183	Collagen	LPKTG	A
SdrC	947	Unknown	LPETG	A
SdrD	1,315	Unknown	LPETG	A
SdrE	1,166	Unknown	LPETG	A
Pls	1,637	Unknown	LPDTG	A
SasA	2,261	Unknown	LPDTG	A
SasB	937	Unknown	LPDTG	A
SasC	2,186	Unknown	LPNTG	A
SasD	241	Unknown	LPAAG	A
SasE/IsdA	354	Heme ^f	LPKTG	A
SasF	637	Unknown	LPKAG	A
SasG/Aap	1,117	Unknown ^g	LPKTG	A
SasH	308	Unknown	LPKTG	A
SasI/HarA/IsdH	895	Haptoglobin	LPKTG	A
SasJ/IsdB	645	Hemoglobin, heme	LPQTG	A
SasK	211	Unknown	LPKTG	A

(continued)

Surface protein	aa ^a	Ligand(s) ^b	Motif ^c	Sortase ^d
IsdC	227	Heme	NPQTN	B
^a aa, protein length in amino acids. ^b Molecular component(s) recognized and bound by protein. ^c Consensus motif recognized by sortase and present in C-terminal cell wall sorting signal. ^d Sortase for which cell wall surface protein is substrate. ^e TNFR, tumor necrosis factor receptor ^f also binds to proteins in desquamated epithelial cell. Promotes resistance to bactericidal lipids and lactoferrin ^g also binds to desquamated nasal epithelial cells. Involved in biofilm formation.				

[0016] Other Staphylococcal bacteria express surface expressed proteins (MSCRAMMs) which are similar to the clumping factors or binding proteins listed above. These include but are not limited to:

- SdrF, SdrG and SdrH from *S. epidermidis* wherein SdrG/F have been shown to bind fibrinogen and collagen.
- Fbl from *Staphylococcus lugdunensis* is a fibrinogen-binding protein. Fbl is a member of the Sdr-family, a group of staphylococcal cell surface proteins containing a characteristic serine-aspartate repeat region. The fibrinogen-binding domain of Fbl has been mapped to 313 amino acids, and shows 62% identity to the corresponding region in clumping factor A (ClfA) from *Staphylococcus aureus*.

[0017] Other ligand-binding proteins/adhesins include Isd proteins (iron-regulated surface determinants), which although all of them are not MSCRAMMs *per se* (e.g. IsdB and IsdH) promote adhesion of bacteria to extracellular matrix components and are referred to herein as "MSCRAMM-like proteins". It is known that IsdA promotes adhesion to squamous cells, and has weak affinity for fibrinogen and fibronectin, so may technically be defined as an MSCRAMM.

[0018] Clumping factor A (ClfA) was the first Fibrinogen γ -chain-binding *S. aureus* adhesin identified. Fibronectin-fibrinogen binding protein A (FnBPA) and Fibronectin-fibrinogen binding protein B (FnBPB) were subsequently recognized as bi-functional proteins found to bind the same C-terminal peptide segment in the γ -chain of Fg. ClfA and FnBPs have structural features that are common to all cell-wall anchored proteins expressed in Gram-positive bacteria, including ClfB.

[0019] Clumping factor A (ClfA), for example, is a surface located protein of *Staphylococcus aureus*. ClfA is an important virulence factor of *S. aureus*. It contributes to the pathogenesis of septic arthritis and endocarditis. ClfA is the archetype of a family of surface-associated proteins with similar structural/modular organization, including but not limited to ClfB, SdrD, SdrE etc,

[0020] ClfA contains a 520 amino acid N-terminal A domain (the Fibrinogen Binding Region), which comprises three separately folded subdomains N1, N2 and N3. The A domain is followed by a serine-aspartate dipeptide repeat region and a cell wall- and membrane-spanning region, which contains the LPDTG-motif for sortase-promoted anchoring to the cell wall. ClfA is present in practically all *S. aureus* strains (Peacock SJ, Moore CE, Justice A, Kantzanou M, Story L, Mackie K, O'Neill G, Day NPJ (2002) Virulent combinations of adhesin and toxin genes in natural populations of *Staphylococcus aureus*. Infect Immun 70:4987-4996). It binds to the C-terminus of the γ -chain of fibrinogen, and is thereby able to induce clumping of bacteria in fibrinogen solution (McDevitt D, Nanavaty T, House-Pompeo K, Bell E, Turner N, McEntire L, Foster T, Höök M (1997) Characterization of the interaction between the *Staphylococcus aureus* clumping factor (ClfA) and fibrinogen. Eur J Biochem 247:416-424 and McDevitt D, Francois P, Vaudaux P, Foster TJ (1994) Molecular characterization of the clumping factor (fibrinogen receptor) of *Staphylococcus aureus*. Mol Microbiol 11:237-248).

[0021] 3D Structural analysis of ClfA and the related fibrinogen-binding proteins SdrG and ClfB has revealed that the ligand-binding A domain in all these related proteins are all composed of three subdomains N1, N2 and N3, with residues 221-559 corresponding to Regions N2-N3 being the smallest truncate that retains the ability to bind fibrinogen. It has been found that amino acid residues 532 to 538 correspond to the latching peptide region of ClfA. Each subdomain comprises nine β -strands that form a novel IgG-type fold. The fibrinogen γ -chain peptide-binding site in these proteins is located in a hydrophobic groove at the junction between N2 and N3. It has been found that there is significant structural similarity between the 3d structure of these proteins, this is due to one or more of related amino acid sequence, similar modular design and common binding domain organization.

[0022] SdrC, SdrD, SdrE, FnBPA-A (all seven isoforms) and FnBPB-B (all seven isoforms) have similar modular organization, thus using PHYRE molecular modeling, these proteins would be expected to have the same 3D structure.

[0023] IsdA and IsdB do not have the same type of structure as Clf or Sdr proteins. They have a novel motif called NEAT which is involved in ligand binding. However, the NEAT motif is similar to the 3D structure of Clf or Sdr, in that is

composed of a sandwich of beta strands (beta sandwich fold that consists of two five-stranded antiparallel beta sheets) and is a member of the Ig-superfamily (Pilpa et al "Solution Structure of the NEAT (NEAr Transported) Domain from IsdH/HarA: the Human Hemoglobin Receptor in *Staphylococcus aureus*" J. Mol. Biol. (2006) 360:435-447) The 3D structure of the NEAT motif of IsdH has been solved and residues in loop 1 b-2 predicted.

[0024] Expression of ClfA on *S. aureus* hampers phagocytosis by both macrophages and neutrophils (Palmqvist N, Patti JM, Tarkowski A, Josefsson E (2004) Expression of staphylococcal clumping factor A impedes macrophage phagocytosis. Microb Infect 6:188-195 and Higgins J, Loughman A, van Kessel KPM, van Strijp JAG, Foster TJ (2006) Clumping factor A of *Staphylococcus aureus* inhibits phagocytosis by human polymorphonuclear leukocytes. FEMS Microbiol Lett 258:290-296). In neutrophils this is due to both a fibrinogen-dependent mechanism and to a fibrinogen-independent mechanism. In contrast, platelets are activated by bacteria expressing ClfA through its interaction with GPIIb/IIIa leading to aggregation. This is most efficiently executed when fibrinogen is present, but there is also a fibrinogen-independent pathway for platelet activation (Loughman A, Fitzgerald JR, Brennan MP, Higgins J, Downer R, Cox D, Foster TJ (2005) Roles of fibrinogen, immunoglobulin and complement in platelet activation promoted by *Staphylococcus aureus* clumping factor A. Mol Microbiol 57:804-818 and O'Brien L, Kerrigan SW, Kaw G., Hogan M., Penadés J., Litt D., Fitzgerald D.J., Foster T.J. & Cox D. (2002) Multiple mechanisms for the activation of human platelet aggregation by *Staphylococcus aureus*: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. Mol Microbiol 44, 1033-1044).

[0025] ClfA is a virulence factor for induction of septic arthritis in mice (Josefsson E., Hartford O., O'Brien L, Patti JM, Foster T (2001) Protection against experimental *Staphylococcus aureus* arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184:1572-1580). In addition, elimination of ClfA together with another fibrinogen binding protein ClfB protected against systemic inflammation at the early stages of infection (Palmqvist N, Foster T, Fitzgerald R, Josefsson E, Tarkowski A (2005) Fibronectin-binding proteins and fibrinogen-binding clumping factors play distinct roles in staphylococcal arthritis and systemic inflammation. J Inf Dis 191:791-798).

[0026] The *Staphylococcus aureus* fibrinogen binding protein ClfA has been isolated and characterized and is the subject of, for example, US Patent Nos. 6, 008, 341 and 6,177,084.

[0027] ClfA and ClfB have an identical structural (3D) organization and approximately 27% amino acid identity. FnBPA has an approximately 25% amino acid identity to ClfA.

[0028] At present there are no MSCRAMM based vaccines approved and on the market. Veronate®, a donor-selected staphylococcal human immune globulin intravenous (IGIV) targeting ClfA and SdrG, performed poorly in phase III clinical trials and was withdrawn from trials. It is currently being re-evaluated to determine whether it is a viable treatment for *Staphylococcal* infections.

[0029] WO 2005/116064 is directed to FnBPA, which is a multifunctional binding protein of *S. aureus*. The N-terminal A domain of FnBPA resembles ClfA and has been found to bind fibrinogen. However, the C-terminal BCD domains of FnBPA bind fibronectin, hence, FnBPA is a bifunctional MSCRAMM.

[0030] WO 2005/116064 is based on the finding that in the presence of transglutaminase, covalent linkages are formed between the bacterial adhesin FnBPA and the host protein fibronectin, rendering the association much stronger and essentially irreversible. Fibrinogen is a major component (~3mg/ml) in blood where it serves as the final target of the coagulation cascade. Fibronectin is less abundant, ~0.3mg/ml or one molecule of Fn for every 10-15 of fibrinogen. Fibrinogen and fibronectin are not thought to be associated in blood where they circulate independently.

[0031] Importantly, WO 2005/116064 specifically relates to Factor XIIIa-catalyzed covalent cross-linking. WO 2005/116064 isolates multiple mutants in a recombinant FnBPA where residues with positively charged side chains (i.e. transglutaminase substrates) were altered. Furthermore, WO 2005/116064 is directed to mutants which have altered covalent fibronectin not fibrinogen binding properties only. Additionally, this document does not demonstrate experimentally whether the binding of the mutant protein to the ligand is reduced and does not provide any supporting immunogenicity data.

[0032] Thus, in view of the prevalence of multiple drug resistance in gram positive bacteria and the lack of successful therapies and vaccines for these multi-drug resistant bacteria, any alternative therapy which can deal with such bacterial infections without using antibiotics will be of significant value.

[0033] Furthermore, any improvements in efficacy over any known treatments or vaccines will be of particular importance, especially in a clinical setting.

[0034] Thus, the present invention is directed to providing an alternative and improved therapy for such treating such bacterial infections.

STATEMENT OF THE INVENTION

[0035] According to a first general aspect of the invention, there is provided a recombinant staphylococcal clumping factor A (ClfA) according to SEQ ID No. 1 or a sequence with at least 85%, preferably at least 95% sequence identity to the sequence of SEQ ID No. 1 or fragment thereof comprising at least amino acid residues 221 to 531 of the fibrinogen

binding region (Region A), characterized by at least one amino acid residue substitution or deletion at amino acid residue Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527 to result in a recombinant fibrinogen binding protein with reduced ability or lacking the ability to non-covalently bind fibrinogen which stimulates a greater immune response than the wild type ClfA protein, for use in the treatment or prophylaxis of Staphylococcal infections.

[0036] According to a second aspect of the invention, there is provided a vaccine comprising a recombinant staphylococcal clumping factor A (ClfA) of the invention..

[0037] According to a third aspect of the invention, there is provided a nucleic acid construct, expression vector or host cell expressing a recombinant staphylococcal clumping factor A (ClfA) of the invention.

[0038] According to a fourth aspect of the invention, there is provided an immunogenic pharmaceutical composition comprising a recombinant staphylococcal clumping factor A (ClfA) of the invention..

DETAILED DESCRIPTION

[0039] In this specification, the terms "adhesin", "MSCRAMM" and "cell-wall anchored proteins" will be understood to be interchangeable and cover all microbial derived ligand binding proteins. Ideally, these proteins bind fibrinogen, heme or haemoglobin, haptoglobin-haemoglobin, haemin, collagen and other such ligands. The term "MSCRAMM-like" proteins are intended to cover proteins or adhesins which have related amino acid sequences, similar modular design and/or common/similar binding domain organization to such MSCRAMM proteins, such as Isd proteins. Ideally, the MSCRAMM-like proteins have similar binding domain organization/modular design. Additionally, the MSCRAMM-like proteins may have at least 50%, preferably 60%, preferably 75%, more preferably 85%, even more preferably 95%, still more preferably 99% or more amino acid sequence identity with the MSCRAMM proteins.

[0040] It will also be understood that any of the percentage identities or homologies referred to in the specification are determined using available conventional methods over the entire/whole length of the sequence.

[0041] The term "micro-organism", "microbe", "microbial" or the like includes but is not limited to organisms including bacteria, fungi, viruses, yeasts and/or moulds.

[0042] The term "immunologically effective amount" covers those amounts which are capable of stimulating a B cell and/or T cell response.

[0043] According to a first general aspect of the invention, there is provided a recombinant staphylococcal clumping factor A (ClfA) of the invention for use in the treatment of microbial infections, such as the treatment of sepsis, septic arthritis and/or endocarditis or other similar conditions or disease states. Such microbial infections may ideally be caused by Staphylococci or other similar micro-organisms.

[0044] According to one particular embodiment of this aspect of the invention, the recombinant clumping factor A (ClfA) of the invention has reduced or lacks the ability to non-covalently bind its host ligand.

[0045] Thus, it will be understood that the recombinant staphylococcal clumping factor A (ClfA) of the invention may have reduced binding with its host ligand or binding with the host ligand may be prevented.

[0046] It is postulated, according to the invention, that the non-covalent binding that takes place during binding, via Dock, Lock and Latching (DLL), of the protein of the invention to its ligand may be reduced or prevented. It is established that the first step in binding of an MSCRAMM to its ligand involves a non-covalent interaction via the DLL model. These are the primary non-covalent MSCRAMM interactions with the ligand. The final stages in MSCRAMM-ligand binding involve covalent interactions. In this particular embodiment, the recombinant clumping factor A (ClfA) of the invention, has reduced or lacks the ability to non-covalently bind its host ligand due to altered dock, lock and latching. One or more of the dock, lock or latching steps may be altered.

[0047] The DLL model was elucidated from the 3D structure of SdrG in complex with its ligand. ClfA has now been shown to act by a minor variation of the DLL mechanism (Ganech et al (2008) "A structural model of the *Staphylococcus aureus* ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics". PloS Pathog 4(11); e1000226). The DLL model specifically relates to the non-covalent interactions involved in ligand binding. The DLL model is inferred for all other proteins of similar structural type (whether by amino acid similarity/homology or structural organization homology), including but not limited to MSCRAMM or MSCRAMM-like proteins.

[0048] In relation to MSCRAMMs ClfA/ClfB in particular, it has been found that the minimal ligand binding domain comprises Region A subregions N1 to N3, specifically subregions N2 and N3 which comprise a variant Dev-IgG Ig fold. The variant Dev-IgG Ig fold is new variant of the immunoglobulin motif also called the DE-variant. It is postulated that a hydrophobic pocket formed between the two DEV-IgG domains of ClfA/B is the ligand-binding site for the fibrinogen γ -chain. Essentially, the ligand binds to the hydrophobic groove separating N2 and N3. Specifically, during ligand binding the unfolded peptide component of the ligand inserts into the groove located between the N2 and N3 subdomains. The latching peptide at the C-terminus of subdomain N3 undergoes a conformational change and inserts between two beta strands in subdomain N2, thus, locking the ligand in place. Indeed, mutagenic substitution of residues Tyr256, Pro336, Tyr338 and Lys389 in the clumping factor, which are proposed to contact the terminal residues ⁴⁰⁸AGDV⁴¹¹ of the fibrinogen γ -chain, resulted in proteins with no or markedly reduced affinity for fibrinogen. Further details of this specific

embodiment are expanded on later.

[0049] Thus, in order to provide recombinant staphylococcal clumping factor A (ClfA) of the invention, with reduced binding to its host ligand, the full length protein, ligand binding domain, minimal ligand binding domain or fragment thereof may be altered to reduce or prevent binding to its host ligand. Ideally, for ClfA, Region A subregion N2 and N3, which ideally comprise a variant Dev-IgG Ig fold, may be altered to prevent or reduce binding to its host ligand. Such an alteration is designed to prevent the ligand binding to the hydrophobic groove separating minimal ligand binding domains needed for DLL.

[0050] Such alterations in the ligand binding domain may take place at the amino acid level, by amino acid substitution or deletion, using either the full length protein, ligand binding domain, minimal ligand binding domain or fragment thereof. It will be understood that proteins or fragments thereof with sufficiently high homology to the ligand binding protein may also be used. High homology as defined herein occurs when at least 50%, preferably 60%, preferably 70%, preferably 80%, more preferably 90%, even more preferably 95%, still more preferably 95% to 99%, still more preferably 99% or more of the nucleotides or match over the entire length of the DNA sequence or when used in connection with amino acid sequences when the amino acid sequences are not identical but produce a protein having the same functionality and activity. It will be understood that these comments about high homology may also relate to the 3D structure of the protein, i.e. modular binding domain organization.

[0051] It will be understood that the complete ligand binding protein, the ligand binding domain, the minimal ligand binding domain or a fragment thereof may be used.

[0052] The use of truncated proteins of the ligand binding protein such as the ligand binding domain, the minimal ligand binding domain, or the use of fragments thereof is advantageous for ease of manufacture and overcoming other problems such as unwanted cleavage of the protein. For example, the latching peptide, present in the minimal ligand binding domain, may be deleted/removed or altered. For example, the latching peptide in ClfA corresponds to Region A amino acids 532 to 538. These residues may be altered, substituted or removed/deleted in order to prevent the ligand binding to the MSCRAMM via DLL. In this way the DLL "latching" of the MSCRAMM to its ligand is prevented. This "latching" occurs by way of a non-covalent interaction. In one embodiment, the latching peptide is removed in its entirety along with the remaining Region A C-terminal amino acid residues. According to another embodiment, the latching peptide region only is removed. According to yet another embodiment, the latching peptide region undergoes amino acid substitution to result in the reduction or prevention of ligand binding/latching. These comments are applicable to all MSCRAMM or MSCRAMM-like proteins with bind ligands by the DLL or similar models.

[0053] By altering the recombinant staphylococcal clumping factor A (ClfA) of the invention in this manner, it is possible to provide a ligand binding protein without the ability to bind its ligand, which stimulates a greater immune response upon immunization than the wild type protein. Advantageously, this reduces systemic inflammation, thereby decreasing microbial virulence. Consequently, this altered ligand binding protein which lacks the ability to bind its ligand can be advantageously used in the treatment of microbial infections. Thus, these findings present a new and valuable vaccine/immunization therapeutic against bacterial infections which provides better results when compared to a vaccine or immunization therapeutic derived from the wild type protein.

[0054] Also disclosed herein is a method of inducing an immune response in an individual and/or treating a patient having a microbial infection, comprising administering to the individual a recombinant staphylococcal clumping factor A (ClfA) of the invention, or vaccine comprising the recombinant staphylococcal MSCRAMM or MSCRAMM-like protein, or fragment thereof with reduced binding to its host ligand.

[0055] According to another embodiment of this aspect of the invention, there is provided a vaccine comprising a recombinant staphylococcal clumping factor A (ClfA) of the invention, with reduced binding to its host ligand.

[0056] Also disclosed herein is an antibody raised against a recombinant staphylococcal clumping factor A (ClfA) of the invention, preferably in the form of a hyperimmune serum

[0057] According to another embodiment of this aspect of the invention, there is provided an immunogenic pharmaceutical composition comprising a recombinant staphylococcal clumping factor A (ClfA) of the invention, with reduced binding to its host ligand

[0058] According to a preferred embodiment of the invention, there is provided a recombinant staphylococcal clumping factor A (ClfA) of the invention comprising at least the part of fibrinogen binding region, without the ability to bind fibrinogen for use in therapy.

[0059] It will be understood that the recombinant Staphylococcal clumping factor A (ClfA) of the invention may be used in the treatment of Staphylococci infections such as in the treatment of sepsis, septic arthritis and/or endocarditis or other similar conditions or disease states.

[0060] The fibrinogen binding region of the protein is altered so that it no longer binds fibrinogen. As stated above, the alteration may take place at the nucleotide or amino acid level. It will be understood that proteins or fragments thereof with sufficiently high homology to the fibrinogen binding protein may also be used. High homology as defined herein occurs when at least 50%, preferably 60%, preferably 70%, preferably 80%, more preferably 90%, even more preferably 95%, still more preferably 95% to 99%, still more preferably 99% of the nucleotides match over the entire length of the

DNA sequence or when used in connection with amino acid sequences when the amino acid sequences are not identical but produce a protein having the same functionality and activity. It will be understood that these comments about high homology may also relate to the 3D structure of the protein.

[0061] It will be understood that the complete fibrinogen binding protein, the fibrinogen binding region, the minimal fibrinogen binding region, or a fragment thereof may be used. The use of truncated proteins or fragments thereof is advantageous for ease of manufacture and overcoming other problems such as unwanted cleavage of the protein. This is expanded on below.

[0062] Such fragments should ideally comprise at least part of the fibrinogen binding region of the protein. The advantages of using a truncated protein or fragment thereof of the, comprising for example one or more subdomains of the ligand-fibrinogen binding region only, relate to the ability to purify the protein at high yields without degradation. The ClfA protein fibrinogen binding region, otherwise referred to as the A Region, comprises 3 subregions, N1, N2 and N3. Thus, the immunogenic fragment may comprise subregions N1, N2 and/or N3 of the ClfA A Region or a fragment thereof. Thus, for example, in relation to ClfA, the fragment may comprise one or more of subdomains of Region A, N1, N2 or N3. Ideally, N2 and N3 may be used as this truncate is less likely to undergo proteolysis (a protease cleavage site has been reported between N1 and N2 in ClfA and ClfB) and can be expressed at higher levels in *E. coli*. N2 and N3 are the minimal fibrinogen binding region of Clf proteins.

[0063] We have unexpectedly found that this altered fibrinogen binding protein, truncate or fragment thereof, without the ability to bind fibrinogen stimulates a greater immune response upon immunization than the wild type protein which binds to fibrinogen in the normal manner. Advantageously, this altered fibrinogen binding protein does not provoke systemic inflammation when expressed by *S. aureus*, thus, microbial virulence is decreased. Consequently, this altered protein which lacks the ability to bind fibrinogen can be advantageously used in the treatment of microbial infections. We have also found contrary to expectations that the protection effect of the altered fibrinogen binding protein is greater than the wild type protein. We have found that a pharmaceutical composition or vaccine comprising such an altered recombinant protein is more effective than a pharmaceutical composition or vaccine comprising the same recombinant protein in an unaltered (wild type) form, such as ClfA, ClfB, SdrG etc.

[0064] Thus, these findings present a new and valuable vaccine/immunization therapeutic against bacterial infections which provides better results when compared to the wild type protein when also used as a vaccine/immunization therapeutic.

[0065] It will be understood that the altered protein, may be used in the generation of antibodies, including monoclonal, polyclonal, chimeric, humanized antibodies or fragments thereof, for use in the treatment of such microbial infections. Compositions may then be provided which include such antibodies, such as a hyperimmune serum, and these compositions may be used in the treatment of patients infected with *Staphylococcus* infections.

[0066] Thus, the proteins or active fragments thereof may be used to inhibit the binding of Staphylococci to the extracellular matrix (ECM) and to prevent/treat Staphylococci infections in a patient.

[0067] Furthermore, the proteins or active fragments thereof, and antibodies to the proteins are useful in the treatment of infections from Staphylococcal infections, for the development of vaccines for active or passive vaccination, and when administered as a pharmaceutical composition to a wound or a medical device, both the proteins and antibodies are useful as blocking agents to prevent microbial infection. For example, these proteins or fragments thereof may be used in active vaccines, and the antibodies to these proteins in passive vaccines.

[0068] These vaccines and products described herein present a significant improvement over the prior art, which teaches the general use of MSCRAMMs to impart immunization, but does not teach the unexpected and improved vaccines or products described herein.

[0069] The preparation of proteins, DNA and antibodies are well known in the art and will not be described in detail herein. Conventional techniques are ideally used in the generation of these molecules. The invention will also be understood to cover nucleic acid constructs containing the nucleic acid or amino acid sequence of interest, recombinant host cells containing such nucleic acid constructs to express the protein of interest, and immunogenic compositions.

[0070] For administration, the protein composition may be dispersed in a sterile, isotonic saline solution or other pharmaceutically acceptable adjuvant.

[0071] It will be understood that the vaccine may be a DNA or protein vaccine.

[0072] Immunization may take place by the injection of DNA, protein or antibodies. Alternatively, an attenuated live organism that includes and expresses the DNA may be administered.

[0073] The amount of DNA, protein or antibodies that may be administered will depend on several mitigating factors, including dependence on the promoter strength, protein expression and immunogenicity of the expressed gene. These may be altered for each new application to obtain the desired immunologically effective amount required.

[0074] Also disclosed herein is a method of inducing an immune response in an individual and/or treating a patient having a microbial infection, comprising administering to the individual a recombinant Staphylococcal clumping factor A (ClfA) of the invention comprising at least the fibrinogen binding region, without the ability to bind fibrinogen.

[0075] According to further preferred embodiment of the invention, there is provided a vaccine comprising a recombinant

Staphylococcal clumping factor A (ClfA) of the invention comprising at least part of the fibrinogen binding region, without the ability to bind fibrinogen.

[0076] Also disclosed herein is an antibody raised against a recombinant Staphylococcal clumping factor A (ClfA) of the invention comprising at least part of the fibrinogen binding region, without the ability to bind fibrinogen, preferably in the form of a hyperimmune serum.

[0077] According to a yet further preferred embodiment of the invention, there is provided an immunogenic pharmaceutical composition comprising a recombinant Staphylococcal clumping factor A (ClfA) of the invention comprising at least part of the fibrinogen binding region, without the ability to bind fibrinogen and a pharmaceutically acceptable adjuvant.

[0078] Ideally, the recombinant Staphylococcal fibrinogen binding protein or fragment thereof is derived from *S. aureus*, *S. epidermidis* and/or *S. lugdunensis*.

[0079] It will be understood that nucleotide or amino acid substitutions or deletions within the fibrinogen binding region of such fibrinogen binding proteins result in a recombinant protein without the ability to bind fibrinogen.

[0080] ClfA-fibrinogen binding has been elucidated to occur by a dock, lock and latch (DLL) mechanism similar to that of SdrG. The DLL model was expanded on above. Region A of ClfA is responsible for the protein-ligand interaction. As shown in Figure 11, the modular structure of several fibrinogen binding MSCRAMM are similar and all contain Region A similar to ClfA.

[0081] The fibrinogen γ -chain peptide-binding site is located in a hydrophobic groove at the junction between N2 and N3 of ClfA. Thus, the substitutions or deletions mentioned above are designed to alter the MSCRAMM protein-ligand interaction and prevent the non-covalent binding of ClfA to fibrinogen.

[0082] According to one specific embodiment of the present invention, the recombinant Staphylococcal fibrinogen binding protein is a fibrinogen binding-deficient mutant of ClfA. In this embodiment, Fibrinogen Binding Region A of ClfA is altered by any means (such as substitution or deletion mutations) so that it no longer binds fibrinogen.

[0083] Ideally, the fibrinogen binding protein is ClfA, however, ClfA bears 3D structural similarity to many other fibrinogen binding proteins.

[0084] ClfA is a 993 amino acid protein, comprising a 520 amino acid fibrinogen binding domain (from amino acids 40 to 559). This fibrinogen binding domain is the N Terminal A domain comprising subregions N1, N2 and N3. The entire fibrinogen region spanning N1 to N3 from amino acid 40 to amino acid 559 may be used in the invention. Alternatively, a truncate of the N1 to N3 region may be used, e.g. 221 to 559 (the minimal fibrinogen binding region), 221 to 531 (the minimal fibrinogen region without the latching peptide and following residues) etc. Ideally, subregions N2 and N3, the minimal fibrinogen binding region, may be used which correspond to amino acid residues 221 to 559. Alternatively, a fragment of these subregions may be used.

[0085] It has been established that amino acid residues 221 to 559, covering the N2 and N3 regions, of ClfA play an important part in the binding to fibrinogen and are the minimal fibrinogen binding region. We also have unexpectedly found that mutation of amino acid residues in this region results in an expressed protein which can be recognized by the host immune defences but lacks fibrinogen binding and hence, reduces the associated virulence. This region (the 339 amino acid fibrinogen binding domain) of ClfA has a specific 3D structure, a so-called DE-variant IgG fold, and is the minimum Fg-binding truncate which if altered (via substitution or deletion etc) can provide an improved therapy.

[0086] The alteration to result in the loss of fibrinogen binding activity may take place by substitution, addition or insertion or deletion at either the nucleotide or amino acid level. Ideally, the substitution negatively affects the 3D structure (e.g. of the a so-called DE-variant IgG fold) of the protein or fragment so it can no longer bind fibrinogen.

[0087] Ideally, the nucleotide or amino acid substitution reduces the non-covalent interaction with fibrinogen, preferably by preventing ligand binding to the hydrophobic pocket separating N2 and N3 of Region A of the fibrinogen binding protein. Alternatively, the latching peptide region corresponding to amino acids 532 to 538 may be altered by substitution or deleted to prevent ligand binding. Additionally, a truncate/fragment lacking the latching peptide region and optionally the remainder of the C-terminal protein residues, i.e. lacking amino acid residues 532 to 559, may be used.

[0088] According to one specific embodiment of this aspect of the invention, the fibrinogen binding-deficient mutant of ClfA may be constructed by exchanging amino acids P₃₃₈ for serine and/or Y₃₃₈ for aspartate, respectively. The choice of residues was based on the X-ray crystal structure of ClfA and the observation that individual changes to the proline or the tyrosine reduced binding affinity. Surprisingly, we found that this mutant ClfA protein (rClfA_{P338S} Y_{338A}) stimulated an immune response and can be used in the generation of a much more effective vaccine or antibody therapy. This substitution may take place in the full length fibrinogen binding protein, the fibrinogen binding region, the minimal fibrinogen binding region, or a fragment thereof.

[0089] According to another specific embodiment of this aspect of the invention, the fibrinogen binding-deficient mutant of ClfA may be constructed by exchanging amino acids P₃₃₆ for aspartate and/or Y₃₃₈ for serine, respectively. As with the previous embodiment, this mutant ClfA protein (rClfA_{P336S} Y_{338S}) can also be used in the generation of a much more effective vaccine or antibody therapy.

[0090] Alternatively, the alteration may be in the form of a deletion, comprising the fibrinogen binding region without the latching peptide sequence (amino acids 532 to 538), to result in a recombinant fibrinogen binding protein without

the ability to non-covalently bind fibrinogen. In this embodiment, amino acid residues 221 to 531 of Region A of ClfA are used, which lack the latching peptide and following C-terminal residues. Alternatively, an amino acid substitution in the latching peptide amino acids 532 to 538 which prevents the DLL of the fibrinogen may be contemplated.

[0091] It is understood that all proteins in the Clf-Sdr family binds ligands by the DLL model. By modelling the 3D structure, it is possible to predict the latching peptide and make a truncate that lacks it, either in the full length (N1 to N3) or the minimal ligand binding truncate N2-N3, or a fragment thereof.

[0092] We found that these substitution rClfA proteins (whether deletion mutants, substitutions or truncates) reduced virulence and disease outcome, and surprisingly induced less systemic inflammation than the wild type protein.

[0093] Thus, immunization with these mutant proteins is expected to, based on the proteins tested, enhance the level of antibodies which recognized both the mutant and wild type protein and to provide for a greater immune response than the wild type protein.

[0094] Thus, ClfA which has been altered so that it no longer binds fibrinogen is a useful therapeutic candidate for active or passive immunization. In this way, the altered ClfA protein itself may be used as a vaccine or antibodies raised to this altered ClfA protein may be used. As above the vaccine may be a DNA or protein vaccine.

[0095] The following sequences outlined in the table below may be used in accordance with the invention.

SEQ ID No	Description	Length	A Region
1	wt rClfA - full length aa sequence (Example 1)	933 aa	-
2	wt rClfA A Region - full length DNA sequence (Example 1)	1560 nucleotides	N1 to N3
3	wt rClfA A Region - full length aa sequence (Example 1)	520 aa	N1 to N3
4	rClfAPYI A Region (Example 1)	520 aa	N1 to N3
5	rClfAPYII A Region (Example 1)	520aa	N1 to N3
6	wt rClfA A Region - full length aa sequence with additional N and C terminal residues ¹ (Example 2)	530aa	N1 to N3
7	rClfAPYI A Region with additional N and C terminal residues ¹ (Example 1)	530aa	N1 to N3
8	rClfAPYII A Region with additional N and C terminal residues	530aa	N1 to N3
9	rClfA 221-559 (Example 2)	339 aa	N2 and N3
10	rClfA 221-559 with additional N and C terminal residues ¹ (Example 2)	349 aa	N2 and N3
11	rClfA PY 221-559 (Example 2)	339aa	N2 and N3
12	rClfA PY 221-559 with additional N and C terminal residues ¹ (Example 2)	349aa	N2 and N3
13	rClfA 221-531 (delta latch truncate) with additional N and C terminal residues ² (Example 2)	321aa	N2 and N3 ³
14	rClfAPY 221-531 (delta latch truncate)	311 aa	N2 and N3 ³
¹ Additional N residues (N-terminal extension (6 x His tag and additional residues) comprise 6 His residues, followed by Gly and Ser. Additional C terminal residues comprise Lys followed by Leu (other additional N and C terminal residues may be used - depending on the primer used or N/C terminal tags required) ² Additional N residues (6 x His tag and additional residues) comprise 6 His residues, followed by Gly and Ser. Additional C terminal residues comprise Arg followed by Ser (other additional N and C terminal residues may be used - depending on the primer used or N/C terminal tags required)) ³ without the latching peptide corresponding to aa residues 532 to 538 and remainder A Region C-terminal residues i.e. lacking amino acid residues 532 to 559.			

[0096] Ideally, the recombinant Staphylococcal fibrinogen binding protein comprises the amino acid sequence according to any of SEQ ID Nos. 1 to 3 wherein residue P₃₃₆ and/or Y₃₃₈ are substituted with either serine and/or alanine, or a fragment thereof.

[0097] Alternatively, the fragment of the recombinant Staphylococcal fibrinogen binding protein comprises the amino acid sequence according to any of SEQ ID No. 4 to SEQ ID No. 14. SEQ ID NOs 4 and 5 correspond to the ClfA A

domain N1, N2, N3 only, rClfA P₃₃₆S Y₃₃₈A and rClfA P₃₃₆A Y₃₃₈S respectively as outlined in the table above.

[0098] It is also postulated, based on the substitutions in the latch which were made in SdrG, that substitutions in the latch that are defective in the conformational change or beta strand complementation will also be defective in ligand binding. Thus, ideally, the substitutions are in amino acid residues 532 to 538 which correspond to the latching peptide and affect the ability of the peptide to undergo conformational change, or bind the ligand or both. Alternatively, the alteration may comprise removing the amino acid residues 532 to 538 (delta latch peptide) altogether, to give similar results. Additionally, a C-terminal truncation mutant lacking amino acid residues 532 to 559 (including the latching peptide residues) will also effect binding to the ligand.

[0099] However, it will also be contemplated that other amino acid residues could be substituted other than those specifically recited above. For example, Glu 526, Val 527, Tyr 256 and Lys 389 may be substituted to alter the fibrinogen binding properties of the protein or fragment thereof. Thus, any substitution which reduces binding ability may be contemplated. Ideally, such substitutions or deletions effect the hydrophobic pocket and associated mechanism for binding the ligand in the hydrophobic trench such as homologues Val527 in ClfA and N526 in ClfB. In ClfB, Q235 and N526 have been studied to shown to reduce binding. A similar study was done with FnBPA where N304 and F306 were shown to be important for Fg binding. Thus, mutations in these amino acid residues will affect ligand binding.

[0100] The treatment (vaccine, antibody or pharmaceutical composition etc) may comprise the complete Fibrinogen Binding Region or a fragment thereof.

[0101] In the specification, the terms "comprise, comprises, comprised and comprising" or any variation thereof and the terms "include, includes, included and including" or any variation thereof are considered to be totally interchangeable and they should all be afforded the widest possible interpretation.

[0102] The invention is not limited to the embodiment hereinbefore described, but may be varied in both construction and detail within the scope of the claims.

[0103] The present invention will now be described with reference to the following non-limiting figures and examples.

[0104] Figures 1 to 15 show the results of Example 1.

Figure 1 shows the severity of arthritis (A), measured as arthritic index, and weight loss (B) in mice inoculated with *S. aureus* strain Newman, and *clfAPYI*, *clfAPYII*, and *clfA* null mutants. 3.2×10^6 - 6.0×10^6 cfu of *S. aureus* strains were inoculated. Data are presented as medians (squares or center lines), interquartile ranges (boxes), and 80% central ranges (whiskers). Data from three experiments are pooled. $N_{\text{Newman}} = 27 - 30$, $N_{\text{clfAPYI}} = 30$, $N_{\text{clfAPYII}} = 10$, and $N_{\text{clfA}} = 16 - 20$.

Figure 2 shows the bacterial growth in kidneys in mice 7-8 days after inoculation with 3.2×10^6 - 6.0×10^6 cfu of *S. aureus* strain Newman, and *clfAPYI*, *clfAPYII*, and *clfA* null mutants. Data are presented as cfu per kidney pair. Where no growth was detectable, the count was put to highest possible count according to what dilution was used. Data from three experiments are pooled.

$$N_{\text{Newman}} = 26, N_{\text{clfAPYI}} = 30, N_{\text{clfAPYII}} = 10, \text{ and } N_{\text{clfA}} = 15.$$

Figure 3 shows the survival of mice after inoculation with 5.2, 5.1 or 3.3×10^7 cfu of *S. aureus* strain Newman, *clfAPYI* mutant or *clfA* null mutant, respectively. $N = 10$ per group from start.

Figure 4 shows the survival of mice after inoculation with 9.4, 7.9, 10.7 or 9.8×10^6 cfu of *S. aureus* strain LS-1, and *clfAPYI*, *clfAPYII* or *clfA* null mutants, respectively. $N = 15$ per group from start.

Figure 5 shows the survival of mice immunized with BSA, recombinant ClfA or recombinant ClfAPY (i.e. ClfAPYI recombinant protein A domain) and inoculated with 2.3×10^7 cfu of *S. aureus* Newman. $N = 15$ per group from start.

Figure 6 shows the frequency of arthritic mice inoculated with 3.2×10^6 - 6.0×10^6 cfu of *S. aureus* strain Newman wild-type, and *clfAPYI*, *clfAPYII*, and *clfA* null mutants. Data from three experiments are pooled. $N_{\text{Newman}} = 27 - 30$, $N_{\text{clfAPYI}} = 30$, $N_{\text{clfAPYII}} = 10$, and $N_{\text{clfA}} = 16 - 20$.

Figure 7 shows the severity of arthritis measured as arthritic index in mice inoculated with 5.2, 5.1 or 3.3×10^7 cfu of *S. aureus* strain Newman wild-type, *clfAPYI* mutant or *clfA* null mutant, respectively. Data are presented as medians (squares), interquartile ranges (boxes), and 80% central ranges (whiskers). $N_{\text{Newman}} = 0-10$, $N_{\text{clfAPYI}} = 9-10$, and $N_{\text{clfA}} = 0-10$.

Figure 8 shows the weight loss in mice inoculated with 5.2 , 5.1 or 3.3×10^7 cfu of *S. aureus* strain Newman wild-type, *clfAPYI* mutant or *clfA* null mutant, respectively. Data are presented as medians (center line), interquartile ranges (boxes), and 80% central ranges (whiskers). $N_{\text{Newman}} = 0-10$, $N_{\text{clfAPYI}} = 9-10$, and $N_{\text{clfA}} = 0-10$.

Figure 9 shows the severity of arthritis measured as arthritic index in mice immunized with BSA, recombinant ClfA or recombinant ClfAPY (i.e. ClfAPYI recombinant protein A domain) and inoculated with 4.0×10^8 cfu of *S. aureus* Newman. Data are presented as medians (squares), interquartile ranges (boxes), and 80% central ranges (whiskers). $N_{\text{BSA}} = 14$, $N_{\text{clfAPY}} = 14$, and $N_{\text{clfA}} = 15$ per group from start.

Figure 10 gives the nucleotide and amino acid sequence of wild-type ClfA A domain protein (rClfA), domains N123 only, with the residues highlighted which are altered in the following examples (P_{338} and Y_{338}) to give rise to rClfAPYI/II (SEQ ID No.3). It is this recombinant protein A domain which was used in vaccination in the following examples.

Figure 11 shows an illustrative representation of the structure of FnBPA, ClfB, ClfA and SdrG proteins. Region A is the fibrinogen binding region, S is the signal sequence, W is the cell wall spanning domain, M is the membrane anchor including the LPXTG motif, + represent positively charged residues and R is the repeat region. In ClfA Region A comprises N123 (not shown). The BCD region of FnBPA (and the shorter CD region of FnBPB - not shown) binds fibronectin.

Figure 12 shows the specific antibody responses to recombinant ClfAPY40-559 in serum samples of mice immunized with bovine serum albumin (BSA), recombinant ClfA40-559 (rClfA), or recombinant ClfAPY40-559 (rClfAPY), 9 days after the second booster immunization, which was one day before infection with 2.3×10^7 cfu/mouse of *S. aureus* strain Newman wildtype for induction of sepsis. Data are presented as medians (center lines), interquartile ranges (boxes), and 80% central ranges (whiskers). $N_{\text{BSA}} = 13-15$, $N_{\text{rClfA}} = 15$, and $N_{\text{rClfAPY}} = 15$.

Figure 13 shows the specific antibody responses to recombinant ClfA40-559 in serum samples of mice immunized with bovine serum albumin (BSA), recombinant ClfA40-559 (rClfA), or recombinant ClfAPY40-559 (rClfAPY), 9 days after the second booster immunization, which was one day before infection with 2.3×10^7 cfu/mouse of *S. aureus* strain Newman wildtype for induction of sepsis. Data are presented as medians (center lines), interquartile ranges (boxes), and 80% central ranges (whiskers). $N_{\text{BSA}} = 13-15$, $N_{\text{rClfA}} = 15$, and $N_{\text{rClfAPY}} = 15$.

Figure 14 shows the specific antibody responses to recombinant ClfAPY40-559 in serum samples of mice immunized with bovine serum albumin (BSA), recombinant ClfA40-559 (rClfA), or recombinant ClfAPY40-559 (rClfAPY), 9 days after the second booster immunization, which was one day before infection with 4.0×10^6 cfu/mouse of *S. aureus* strain Newman wildtype for induction of septic arthritis. Data are presented as medians (center lines), interquartile ranges (boxes), and 80% central ranges (whiskers). $N_{\text{BSA}} = 14-15$, $N_{\text{rClfA}} = 15$, and $N_{\text{rClfAPY}} = 15$.

Figure 15 shows the specific antibody responses to recombinant ClfA40-559 in serum samples of mice immunized with bovine serum albumin (BSA), recombinant ClfA40-559 (rClfA), or recombinant ClfAPY40-559 (rClfAPY), 9 days after the second booster immunization, which was one day before infection with 4.0×10^8 cfu/mouse of *S. aureus* strain Newman wildtype for induction of septic arthritis. Data are presented as medians (center lines), interquartile ranges (boxes), and 80% central ranges (whiskers). $N_{\text{BSA}} = 14-15$, $N_{\text{rClfA}} = 15$, and $N_{\text{rClfAPY}} = 15$.

Figure 16 of Example 2 shows the specific antibody responses to recombinant ClfAPY221-559 in serum samples of mice immunized with bovine serum albumin (BSA), recombinant ClfA221-559 (rClfA221-559), or recombinant ClfAPY221-559 (rClfAPY221-559), 9 days after the second booster immunization. Data are presented as medians (center lines), interquartile ranges (boxes), and 80% central ranges (whiskers). $N_{\text{BSA}} = 15$, $N_{\text{rClfA221-559}} = 14-15$, and $N_{\text{rClfAPY221-559}} = 14-15$.

Figure 17 of Example 2 shows the specific antibody responses to recombinant ClfA221-559 in serum samples of mice immunized with bovine serum albumin (BSA), recombinant ClfA221-559 (rClfA221-559), or recombinant ClfAPY221-559 (rClfAPY221-559), 9 days after the second booster immunization. Data are presented as medians (center lines), interquartile ranges (boxes), and 80% central ranges (whiskers). $N_{\text{BSA}} = 15$, $N_{\text{rClfA221-559}} = 14-15$, and $N_{\text{rClfAPY221-559}} = 14-15$.

Figure 18 of Example 3 shows the specific antibody responses to recombinant ClfA221-531 in serum samples of mice immunized with recombinant ClfAPY221-531 (rClfAPY221-531), 9 days after the second booster immunization. Data are presented as medians (center lines), interquartile ranges (boxes), and 80% central ranges (whiskers).

$$N_{\text{rClfA221-531}} = 14-15.$$

Examples

Example 1

rClfA A region truncates comprising N1, N2 and N3 (amino acids 40-559)

MATERIAL AND METHODS

[0105] Full details of the numeric references in brackets given in the Examples are provided at the end of this section.

Mice

[0106] NMRI mice were obtained from Scanbur BK (Sollentuna, Sweden) and were maintained in the animal facility of the Department of Rheumatology, University of Göteborg, Sweden. Göteborg animal experiment ethical board approved the experiments. They were housed up to 10 animals per cage with a 12 h light-dark cycle, and were fed standard laboratory chow and water ad libitum. The animals were 6 to 16 weeks old at the start of the experiments.

Bacterial strains

[0107] For infection of animals the *S. aureus* wildtype strains Newman (14) and LS-1 (11) and constructed derivatives thereof were used. The *clfA* P₃₃₆SY₃₃₈A (*clfAPYI*) and *clfA* P₃₃₆AY₃₃₈S (*clfAPYII*) derivatives were constructed in strain Newman and transduced to strain LS-1 (see below). The deletion mutants Newman *clfA2::Tn917* mutant DU5876 (3) and LS-1 *clfA2::Tn917* mutant (J.R. Fitzgerald et al., unpublished) were also used. Bacteria were grown on blood agar plates for 48 h, harvested, and kept frozen at -20°C in PBS containing 5% (wt/vol) BSA (Sigma Chemicals) and 10% (vol/vol) dimethyl sulfoxide. Before injection into animals, the bacterial suspensions were thawed, washed in PBS, and adjusted to appropriate cell concentrations. The number of viable bacteria was measured in conjunction with each challenge by cultivation on blood agar plates and counting colonies.

Construction of *clfAPYI* and *clfAPYII* mutations in *S. aureus* Newman and LS-1

[0108] In this experiment, a full length ClfA A region truncate, comprising N1, N2 and N3, corresponding to amino acids 40 to 559, was used. In the following description and figures :

- ClfA may also be referred to as rClfA 40-559 (SEQ ID NO 3);
- ClfA P₃₃₆SY₃₃₈A may also be referred to as *clfAPYI*, *rlcfAPY* or *rlcfAPYI* (i.e. *clfAPYI* 40-559) (SEQ ID NO 4); and
- ClfA P₃₃₆AY₃₃₈S may also be referred to as *clfAPYII*, *rlcfAPYII* (i.e. *clfAPYII* 40-559) (SEQ ID NO 5).

[0109] A 1.02 kb *PstI*-*Bam*HI fragment of pCF77 PY (Loughman *et al.*, 2005) containing the mutations P₃₃₆S and Y₃₃₈A in *clfA* was cloned into pBluescriptII SK- (Stratagene). This plasmid was linearised with *Hind*III and ligated to *Hind*III-cut pTsermC (J. Higgins, unpublished) to generate plasmid pARM, which is a temperature sensitive *E. coli*-*S. aureus* shuttle vector containing the P₃₃₆S and Y₃₃₈A substitutions.

[0110] In order to reduce the risk of unknowingly generating a functional or immunoreactive epitope by substituting P₃₃₆ and Y₃₃₈, we generated a second mutant, in which the order of the substitutions was reversed, yielding P₃₃₆A and Y₃₃₈S. To generate this a plasmid pJH2, analogous to pARM but containing the P₃₃₆A and Y₃₃₈S substitutions, was generated. Overlap primer PCR was used with the same flanking primers used to make pCF77 PY (6), and a different pair of overlapping mutagenic primers:

F3: GCA**AA**CTTTGACCATG**G**CCGCTT**C**TATTGACCCTGAAAATG and

R3: CATTTTCAGGGTCAATAG**GA**AGCGG**C**CATGGTCAAAGTTGC

(mutations in bold and underlined) to generate pCF77 PYII. The 1.02 kb *PstI*-*Hind*III fragment of this plasmid was used as described above to generate pJH2, a temperature sensitive *E. coli*-*S. aureus* shuttle vector containing the P₃₃₆A and Y₃₃₈S substitutions.

[0111] Both pARM and pJH2 were transferred to RN4220 (15) by electroporation and subsequently transduced using phage 85 (16) to *S. aureus* Newman (14) and LS-1 (11). In these strains the plasmids were induced to insert into the

chromosome and then excise, leaving the mutations in the chromosome of a proportion of transformants, generating Newman *clfAPYI*, Newman *clfAPYII*, LS-1 *clfAPYI* and LS-1 *clfAPYII*. Transformants were screened for loss of the plasmid and a loss of fibrinogen-binding activity. Integrity of the *clfA* gene was verified by Southern hybridisation using a *clfA* probe (data not shown). Expression of an immunoreactive protein (ClfAPY) was verified by Western immunoblotting using anti-ClfA region A polyclonal rabbit antiserum (data not shown). The mutations were verified by PCR across the *KpnI-BamHI* fragments from genomic DNA and commercial sequencing of the products. The about 700 bases of the *clfA* gene of strain LS-1 that were sequenced were identical to the corresponding bases in the Newman *clfA* gene of strain Newman.

Production of Recombinant ClfA and ClfAPY

[0112] His-tagged recombinant ClfA region A, domains N123 (amino acids 40-559), was produced from pCF40 as previously described (17), with an additional polishing step through an anion-exchange column. Plasmid pCF77 PY (6) was used as template to clone *clfAPYI* domains N123 into pQE30 to generate pCF40PY. Using this plasmid, recombinant ClfAPY was also produced by nickel affinity chromatography and anion exchange chromatography, as was described for rClfA. Eluates were dialysed against two changes of PBS before concentration and freeze-drying.

Septic arthritis and sepsis experiments

[0113] In experiments 1-3 all the mice (n=10 per group) were infected with strain Newman to trigger arthritis. In experiments 4 and 5, the mice were infected with strain Newman and LS-1, respectively, to induce sepsis (n=10 per group).

[0114] Experiment 1 Mice were infected by intravenous injection with 3.5×10^6 cfu/mouse of *S.aureus* strain Newman or with 4.3×10^6 cfu/mouse of Newman *clfAPYI* mutant, both in 200 μ l PBS. Clinical arthritis and weight change was followed until day 7. Mice were sacrificed day 8, kidney growth of bacteria were assessed and serum IL-6 and total IgG levels were measured. Synovitis and bone destruction was studied histologically on the joints of fore and hind legs.

[0115] Experiment 2 Mice were infected with 5.0×10^6 cfu, 6.0×10^6 cfu or 4.3×10^6 cfu of *S.aureus* strain Newman, *clfAPYI* mutant or Newman *clfA::Erm^R* (*clfA* null mutant), respectively. Clinical arthritis and weight change was followed until day 7. Mice were sacrificed day 7, kidney growth of bacteria were assessed and serum IL-6 and total IgG levels were measured. Synovitis and bone destruction was studied histologically on the joints of fore and hind legs.

[0116] Experiment 3 Mice were infected with 4.7×10^6 cfu, 3.2×10^6 cfu, 3.9×10^6 cfu or 4.8×10^6 cfu of *S.aureus* strain Newman, *clfAPYI* mutant, Newman *clfAPYII* mutant or Newman *clfA* null mutant, respectively. Clinical arthritis and weight change was followed until day 7. Mice were sacrificed day 8 and kidney growth of bacteria were assessed.

[0117] The outcome of the experiments 1-3 were very similar, so data were pooled and presented together.

[0118] In Experiment 4 mice were injected intravenously with 5.2×10^7 cfu, 5.1×10^7 cfu or 3.3×10^7 cfu of *S.aureus* strain Newman, *clfAPYI* mutant or *clfA* null mutant, respectively. Mortality, weight change and clinical arthritis were followed until day 10.

[0119] In Experiment 5 mice were infected with 9.4×10^6 cfu, 7.9×10^6 cfu, 10.7×10^6 cfu or 9.8×10^6 cfu of *S.aureus* strain LS-1, LS-1 *clfAPYI* mutant, LS-1 *clfAPYII* mutant, or LS-1 *clfA* null mutant, respectively. Mortality, clinical arthritis and weight change was followed until day 16.

Intra-articular Injection of bacteria

[0120] One knee joint per mouse was injected with 2.4×10^4 cfu, 2.4×10^4 cfu, or 3.4×10^4 cfu of strain Newman wildtype, *clfAPYI* mutant or *clfA* knockout mutant, respectively, in 20 μ l PBS. N = 10 per group. Mice were sacrificed 3 days later, and the knee joints were collected for histopathological examination.

Vaccination with wild-type and mutant recombinant ClfA

[0121] Purified rClfA40-559, rClfAPY 40-559 (i.e. rClfAPYI) or BSA were dissolved in physiologic saline and emulsified 1:1 in Freund's complete adjuvant (Difco Laboratories). Two hundred μ l of the emulsion containing 30 μ g (= 0.53 nmol) of protein was injected subcutaneously (s.c.) on day 0. First booster immunization with 30 μ g of protein in physiologic saline in incomplete Freund's adjuvant was performed on day 11. Second booster immunization was done day 21. On day 30 the mice were bled and sera were frozen for later analysis of antibody responses.

[0122] On day 31, 14-15 mice per group were infected by i.v. injection of 4.0×10^6 cfu/mouse for induction of septic arthritis, or by 2.3×10^7 cfu/mouse for induction of sepsis. Clinical arthritis, weight change and mortality were followed for 11 and 15 days, respectively. Bacterial growth in kidneys was assessed in the septic arthritis experiment.

Clinical evaluation of infected mice

[0123] The clinical evaluation was performed in a blinded manner. Each limb was inspected visually. The inspection yielded a score of 0 to 3 (0, no swelling and erythema; 1, mild swelling and/or erythema; 2, moderate swelling and/or erythema; 3 marked swelling and/or erythema). The arthritic index was constructed by adding the scores from all four limbs of an animal. The overall condition of each mouse was also examined by assessing signs of systemic inflammation, i.e., weight decrease, reduced alertness, and ruffled coat. In cases of severe systemic infection, when a mouse was judged too ill to survive another 24 h, it was killed by cervical dislocation and considered dead due to sepsis.

Histological examination

[0124] Histological examination of joints was performed using a modification (8) of a previously described method (18).

Bacteriologic examination of infected kidneys

[0125] Kidneys were aseptically dissected, kept on ice, homogenised, serially diluted in PBS and spread on blood agar plates. After 24 h of incubation in 37°C the number of cfu per kidney pair was determined.

Measurement of serum IgG

[0126] Levels in serum of total IgG were measured by the radial immunodiffusion technique (19). Goat-Anti-Mouse-IgG and mouse IgG standard were purchased from Southern Biotech, Birmingham, AL

Specific antibodies - ELISA

[0127] Serum samples from immunized mice were obtained 9 days after the second booster immunization. The serum specific antibody response against rClfA and rClfAPY was measured by ELISA. Microplates (96-well; Nunc) were coated with 5 µg/ml of recombinant protein in PBS. Blocking agent, serum samples, biotinylated antibodies, and ExtrAvidin-proxidase were all diluted in PBS. The assay was run according to a previous description (8). All serum samples were diluted 1:20000, and antibody response was monitored as absorbance at 405 nm.

[0128] In a second run, to get a more accurate measure of the specific antibody responses in the different immunization groups, the responses were determined at several serum dilutions. Thus, all serum samples were diluted 1:5000, 1:20000, 1:80000 and 1:320000, and antibody response was monitored as absorbance at 405 nm.

IL-6 analysis

[0129] Serum IL-6 was detected by a method previously described (20).

Statistical analysis

[0130] Statistical evaluation was done by using the Mann-Whitney U test.. $P < 0.05$ was considered to be significant. Data are reported as medians, interquartile ranges, and 80% central ranges, unless otherwise mentioned.

RESULTS**Exchange of two amino acids necessary for ClfA binding to fibrinogen hampers development of septic arthritis and sepsis**

[0131] Two amino acids (P336 and Y338) that are known to be required for fibrinogen binding by ClfA were altered by allelic exchange to create mutants of strains Newman and LS1 that expressed a non-fibrinogen-binding ClfA protein on the cell surface. The level of expression and integrity of the protein was measured by Western blotting which established that there was good expression of the mutant proteins on the bacterial surface and expressed protein was the right size.

[0132] The ability of Newman wild-type and Newman *clfA* P₃₃₆S Y₃₃₈A (*clfAPYI*) to provoke septic arthritis was investigated. Septic arthritis was induced by intravenous inoculation of 3.5×10^6 to 5.0×10^6 colony-forming units (cfu) and 3.2×10^6 to 6.0×10^8 cfu of Newman wild-type and the *clfAPYI* mutant, respectively. The development of arthritis was studied clinically for 7 days. The *clfAPYI* mutant provoked significantly less severe arthritis than the wild-type strain over the entire experimental period ($P > 0.001$, Fig. 1 A). The frequency of arthritis was lower for Newman *clfAPYI* at most time points (Fig. 6).

[0133] Unexpectedly, it appears that the new amino acid composition in the ClfAPYI molecule fits for interaction with a host anti-bacterial defence. To check for this possibility, a new construct was made where different amino acids were substituted for P336 and Y338 (*clfA* P₃₃₆A Y₃₃₈S: *clfAPYII*). Mice that were inoculated with 3.9×10^6 cfu of Newman *clfAPYII* developed arthritis to the same low extent as the *clfAPYI* mutant (Fig. 1 A), and with a similar frequency (Fig.

[0134] It is possible that ClfA is involved in the development of arthritis by mechanisms that do not involve fibrinogen binding. To test this a *ClfA* deletion mutant lacking the ClfA protein was compared to mutants expressing the modified non-fibrinogen binding ClfA protein. However, mice that were infected with 4.3×10^6 to 4.8×10^6 cfu of *clfA* null mutant developed arthritis in a manner not different from the *clfAPYI* and *clfAPYII* mutant infected mice (Fig. 1 A). The frequency of arthritis was also indistinguishable (Fig. 6).

[0135] Infected joints were also investigated histologically. The synovitis in Newman *clfAPYI*-infected mice was significantly milder than in wild-type infected mice in both experiment 1 and 2 ($P = 0.02$ and 0.001 , respectively). Bone destruction, a major cause of sequels in human septic arthritis, was almost absent in the Newman *clfAPYI*-infected samples (Experiment 2, $P = 0.001$). The synovitis and bone destruction induced by the Newman *clfA* null mutant were also less pronounced compared to mice infected with Newman wild-type ($P = 0.003$ and 0.006 , respectively), but somewhat more severe than in the Newman *clfAPYI* group, although not significantly so.

[0136] Next, the metabolic consequences of the *clfA* mutations for the infectious process were analysed. Mice infected with the Newman wild-type strain lost up to about 30% of their body weight during the experimental period. Mice that were infected with the fibrinogen binding-deficient mutants Newman *clfAPYI* and Newman *clfAPYII* lost hardly any weight at all ($P > 0.0001$ versus wild-type). In contrast, the Newman *clfA* null mutant had an intermediate effect on the weight loss, causing significantly less than the wild-type strain, but significantly more than the *clfAPYI* and *clfAPYII* mutant strains ($P \leq 0.02$ in most cases, Fig. 1 B).

[0137] The serum levels of IL-6, a measure of systemic inflammatory response, were analyzed at day 7-8 of infection. The pattern of IL-6 expression was similar to weight changes. Newman wild-type evoked high levels of serum IL-6 (4.8 (2.8, 5.7) ng/ml), the Newman *clfAPYI* mutant evoked considerably lower IL-6 (0.2 (0.07, 2.4) ng/ml, $P < 0.0001$) while the Newman *clfA* null mutant gave rise to an intermediate response (2.5 (1.3, 3.2) ng/ml) with significant differences to both the wild-type and *clfAPYI* mutant group ($P = 0.009$ and $P = 0.008$, respectively) (median, interquartile range).

[0138] The growth of bacteria in kidneys was significantly greater in Newman wild-type-infected mice, compared to both of the Newman *clfAPY* mutants and the Newman *clfA* null mutant ($P < 0.0001$, $P = 0.011$, and $P = 0.005$, respectively; Figure 2). The Newman *clfA* null mutant-infected mice had significantly more bacterial growth in kidneys than Newman *clfAPYI*-infected mice ($P = 0.0005$, Fig. 2).

[0139] Total IgG in sera was measured in mice on day 7-8 of infection. There was a significantly lower increase of IgG levels in both the Newman *clfAPYI*- and Newman *clfA* null mutant-infected groups as compared to mice infected with the wild-type strain (3.1 (1.2, 4.9); 2.3 (1.0, 2.6); and 6.4 (5.0, 11.0), respectively (median, interquartile range); $P \leq 0.0003$). There were no significant differences between the two mutant groups.

[0140] The mortality was 17% in the Newman wild type-infected mice, 0% in the Newman *clfAPYI* and *clfAPYII* mutant groups and 30% in the Newman *clfA* null mutant group. There were significant differences in mortality between the wild-type and the *clfAPYI* groups, and between the *clfAPYI* and *clfA* null mutant groups ($P < 0.05$ and $P < 0.01$, respectively).

[0141] It appears that direct and indirect signs of systemic inflammation are lower in mice infected with *S.aureus* expressing ClfA that is deficient in fibrinogen binding. Unexpectedly, the strain which lacked ClfA expression altogether induced more systemic inflammation than a ClfAPY mutant-expressing strain.

[0142] Sepsis was induced in mice by increasing the inoculation dose of *S. aureus*. Mice were infected with 5.2×10^7 cfu of Newman wild type, 5.1×10^7 cfu of the Newman *clfAPYI* mutant and 3.3×10^7 cfu of the Newman *clfA* null mutant. Within 5 days all wild-type infected mice were dead, but only one *clfAPYI* mutant mouse out of ten were dead after 10 days of infection ($P < 0.0001$, Fig. 3). Mice infected with the *clfA* null mutant also survived a significantly shorter time than the *clfAPYI* mutant- infected mice ($P < 0.0001$, Fig. 3). In this experiment the mice challenged with the *clfA* null mutant developed significantly more arthritis than the *clfAPYI* mutant group, while at the same time they lost significantly more weight (Fig. 7 and 8). Thus, by analogy with the measures of systemic inflammation in the septic arthritis experiments, the survival of the mice is prolonged if the ClfA molecule is expressed, as long as it lacks fibrinogen binding properties.

Injection of bacteria into joints

[0143] To test if the inflammatory reaction in the joint is dependent on fibrinogen binding, Newman wild-type, Newman *clfAPYI* or Newman *clfA* null were injected directly into a knee joint of mice, thereby by-passing the systemic compartment. Synovitis, including polymorphonuclear infiltration of the joint cavity, and bone destruction was studied by histology 3 days later. The mice received 2.4×10^4 cfu of wild-type, 2.4×10^4 cfu of the *clfA* null mutant, or 3.4×10^4 cfu of *clfAPYI* mutant in one knee. The synovitis and the polymorphonuclear infiltration histologic index in the joint cavity was 0.25 (0, 3.0) for knees infected with wild-type, 2.38 (0.25, 3.0) for the *clfA* null mutant and 0.25 (0, 0.25) for the *clfAPYI* mutant

(median, interquartile range). The histologic index for destruction of bone was 0 (0, 1.0) for wild-type, 1.0 (0, 1.0) for the *clfA* null mutant, and 0 (0, 0) for the *clfAPYI* mutant (median, interquartile range; $P = 0.01$ between the *clfAPYI* mutant and the *clfA* null mutant). Since the *clfAPYI* mutant evoked very little synovitis and destruction, despite the fact that 42% more of that strain was given to mice than the other strains, it is concluded that ClfA-promoted fibrinogen binding is needed for the maximal inflammatory response within the joint. Again, the absence of ClfA expression enhanced inflammation compared to the fibrinogen binding deficient ClfA mutant.

PY mutation in strain LS-1

[0144] To determine if the ability of ClfA to bind fibrinogen affects virulence of other strains of *S. aureus*, the *clfAPYI*, *clfAPYII* and *clfA* null mutations were transduced to the TSST-1 expressing *S. aureus* strain LS-1. Mice were challenged with 9.4×10^6 cfu of LS-1 wild-type, 7.9×10^6 cfu of LS-1 *clfAPYI*, 10.7×10^6 cfu of LS-1 *clfAPYII*, or 9.4×10^6 cfu of the LS-1 *clfA* null mutant. Sepsis was studied by following the survival rate. After 16 days only 40% of mice challenged with the wild-type strain were alive while 90% of the mice challenged with the *clfAPYI* mutant and *clfA* null mutant groups and 80% mice infected with the *clfAPYII* mutant were alive (Fig. 4). The *clfAPYI* mutants and the *clfA* null mutant of LS-1 were significantly less virulent ($P = 0.014$, $P = 0.05$ and $P = 0.03$, respectively).

Immunization with recombinant ClfA proteins

[0145] The effect of vaccination with recombinant wild-type ClfA A domain protein (rClfA) and mutant ClfAPYI protein (rClfAPY) was studied in both the septic arthritis model and the sepsis model. Mice were sensitized and then boosted twice with control protein BSA, rClfA, or rClfAPY, and subsequently infected with 4.0×10^6 cfu of *S. aureus* strain Newman to induce septic arthritis, or with 2.3×10^7 cfu of strain Newman to induce sepsis. Immunization with rClfAPY (i.e. ClfAPYI recombinant protein A domain) protected significantly against septic death as compared to control mice ($P = 0.01$, Fig. 5) while rClfA immunization did not achieve significant protection. One day before bacterial infection there was a much higher specific serum antibody response to both rClfAPY and rClfA in mice immunized with rClfAPY ($A_{405} = 0.39$ (0.33, 0.56) and 0.71 (0.52, 0.81)) as compared to mice immunized with rClfA ($A_{405} = 0.13$ (0.07, 0.17) and 0.15 (0.10, 0.24), $P < 0.0001$ in both comparisons (median, interquartile range)). Control immunized animals had only background levels ($A_{405} \text{ nm} = 0$ and 0.01 (0, 0.01) (median, interquartile range)). The immunized mice which were to be infected with the lower, arthritic bacterial dose had similar antibody responses to rClfA and rClfAPY as the mice in which sepsis were induced (data not shown). Immunization with both rClfA and rClfAPY protected against the development of arthritis, although the protection was not significant (Fig. 9).

[0146] During day 5 to 9 after infection the weight loss was significantly reduced in the rClfAPY and rClfA immunized mice, as compared to the control mice (data not shown).

[0147] A trend to diminished bacterial growth in kidneys of mice immunized with rClfAPY or rClfA at day 11 after infection (BSA: 38 (3, 436); rClfAPY: 7 (2, 17); rClfA: 10 (7, 54) $\times 10^7$ cfu / kidney pair) was observed.

[0148] To get a more accurate measure of the specific antibody responses in the different immunization groups, the responses were determined at several serum dilutions (the second run). Data shows that there were very likely higher titers of specific antibodies in sera from rClfAPY immunized mice to both the rClfAPY and rClfA wildtype antigens, in both the mice which were to be infected with the septic and the arthritic bacterial dose, respectively, than in sera from rClfA wildtype immunized mice, since there was significantly higher antibody responses measured as absorbance in mice immunized with rClfAPY at each serum dilution in all comparisons ($P < 0.0001$ to $P = 0.008$, Figure 12-15). BSA immunization evoked only a background antibody response.

CONCLUSION

[0149] The results strongly suggest that the ClfA - fibrinogen interaction is crucial for the bacterial virulence and disease outcome. The ability of ClfA to bind fibrinogen was associated with enhanced virulence in terms of the ability to cause septic death. In both staphylococcal strains tested, a *clfAPY* mutant induced less septic death than the wild-type. Also, the severity of arthritis was strongly reduced in mice infected with the non-fibrinogen binding *clfAPY* mutant.

[0150] A likely mechanism for the promotion of virulence by the fibrinogen - bacterial cell surface interaction is inhibition of neutrophil phagocytosis (5). Neutrophils are crucial for the host defence in the early phase of *S. aureus* infection (13). Without neutrophils, bacterial growth is strongly augmented in blood and kidneys, and the frequency of arthritis and mortality increases. Fibrinogen mediated inhibition of neutrophil phagocytosis by ClfA could explain at least in part the more pronounced virulence of wildtype *S. aureus* compared to the *clfAPY* mutants. Binding of fibrinogen to ClfA could decrease opsonophagocytosis by neutrophils by reducing opsonin deposition or access to opsonins by neutrophil receptors. Alternatively bound fibrinogen might block the binding of an unknown protective host factor to *S. aureus*. Another option is that the fibrinogen - ClfA interaction promotes bacterial passage from blood vessel into the tissue or promotes

colonization in tissues.

[0151] Unexpectedly, our data also show the ClfA null mutant was more virulent than the *clfAPY* mutant strains. Possibly the ClfA protein has functions in vivo other than interacting with fibrinogen. This interaction is clearly disadvantageous for the host as shown in this study. Other functions of ClfA are presently not well mapped but non-fibrinogen dependent platelet aggregation exerted by ClfA might result in trapping of big amounts of *S. aureus* in circulation with subsequent elimination of the bacterial-platelet complexes through the reticuloendothelial system. Such platelet aggregation mediated elimination of staphylococci would readily occur in the wild-type and *clfAPY* mutated strains but not in the *clfA* knockout. Whereas in the wild-type strain the fibrinogen interaction would overshadow the other events, in the *clfAPY* mutants such bacterial elimination might be highly beneficial to the host.

[0152] The *clfA* knockout mutant protected against septic death to the same degree as the *clfAPY* mutation in *S. aureus* strain LS-1, but protected less, if at all, in strain Newman. The overall impact of ClfA expression on bacterial virulence could differ between different *S. aureus* strains depending on the level of expression and the presence of other virulence factors.

[0153] The issue whether the *clfAPY* mutant displays equal or lower virulence once in the joint cavity is of certain importance having in mind that in inflamed synovial fluid fibrinogen and fibrin are abundant. Our data suggest that the *clfAPY* mutant is less destructive for cartilage and bone.

[0154] The protective effect of recombinant ClfA A domain non-fibrinogen binding P₃₃₈Y₃₃₈ mutant was greater than for wildtype rClfA. Immunization with ClfAPY very likely induced a better immune response since higher specific antibody responses were evoked against both the immunogen and the wildtype ClfA protein. More importantly, it induced a greater protective immune response against septic death than wildtype ClfA.

[0155] In conclusion, our results show that rClfAPY is a better vaccine candidate than wild type recombinant ClfA. We hypothesize that binding of fibrinogen by wild-type ClfA protein during the immunization phase decreases antigen presentation due to hiding of important epitopes on the ClfA molecule and hence impairs specific antibody production.

Example 2

rClfA A region truncate comprising N2 and N3 (rClfA 221-559)

MATERIALS & METHODS:

[0156] The protocols outlined in Example 1 were followed in this example which utilized

- rClfA 221-559 (i.e. ClfA A region truncate comprising N2 and N3 corresponding to amino acids 220-559)
- rClfAPY221-559; and
- BSA.

[0157] There were 15 female NMRI mice per group who were 8 weeks old at start of experiments. In this Example, the constructs used for immunization were ClfA wild type/native N2N3 truncate, ClfA N2N3 truncate with mutation PY as defined in Example 1. BSA was used as the control.

Vaccination with wild-type and mutant recombinant ClfA

[0158] The mice were immunized with rClfA 221-559, rClfAPY 221-559 or BSA in accordance with the protocol of Example 1.

[0159] Purified rClfA221-559, rClfAPY221-559 (i.e. ClfAPYI recombinant protein A subdomains N2 and N3) or BSA were dissolved in PBS and emulsified 1:1 in Freund's complete adjuvant. Two hundred μ l of the emulsion containing 30 μ g (= 0.79 nmol) of protein was injected s.c. on day 0. First booster immunization with 30 μ g of protein in physiologic saline in incomplete Freund's adjuvant was performed on day 12. Second booster immunization was done day 22. On day 31 the mice were bled and sera were frozen for later analysis of antibody responses.

Specific antibodies - ELISA

[0160] Serum samples from immunized mice were obtained 9 days after the second booster immunization. The serum specific antibody response against rClfA221-559 and rClfAPY221-559 was measured by ELISA. Microplates (96-well; Nunc) were coated with 5 μ g/ml of recombinant protein in PBS. Blocking agent, serum samples, biotinylated antibodies, and ExtrAvidin-proxidase were all diluted in PBS. The assay was run according to a previous description (8). All serum samples were diluted 1:5000, 1:20000, 1:80000 and 1:320000, and antibody response was monitored as absorbance at 405 nm.

RESULTS:**SPECIFIC ANTIBODY RESPONSE:**

[0161] The antibody response was measured by absorbance in an ELISA-assay, as per Example 1, with four different serum dilutions. The data obtained was very similar to the data in the Example 1.

[0162] It was found that rClfAPY221-559 immunization very likely gave rise to higher titers of specific antibodies to both native rClfA221-559 and rClfAPY221-559, as compared to native rClfA221-599 immunization, since there were significantly higher antibody responses measured as absorbance in mice immunized with rClfAPY221-559 at each serum dilution in all comparisons but one ($P=0.001$ to 0.025 , see Figures 16 and 17). BSA immunization evoked only background levels of antibody response.

CONCLUSION

[0163] We found that immunization with a rClfAPY221-559 protein gave rise to significantly higher antibody responses to both the immunogen and the wildtype ClfA protein, than immunization with the native protein.

[0164] Based on these findings, we conclude that PY-immunization, regardless if the PY protein comprises amino acids 40 to 550 as in Example 1 or amino acids 221 to 559 as in Example 2, induces a better immune response than immunization with native ClfA of the corresponding size.

Example 3**ClfA A region truncate (δ /delta latch truncate)****MATERIALS & METHODS:**

[0165] The protocols outlined in Example 1 were followed in this example which utilized the following construct:

- rClfA 221-531 (i.e. rClfA A region truncate comprising N2 and N3 amino acids 220-559 but without the latching peptide amino acids 532-538 and the subsequent proline-rich residues.

[0166] There were 15 female NMRI mice in the group who were 8 weeks old at start of experiment. In this Example, the above construct was used for immunization. The mice were immunized with the above truncate in accordance with the protocol of Example 1.

Vaccination with wild-type and mutant recombinant ClfA

[0167] Purified rClfA221-531 was dissolved in PBS and emulsified 1:1 in Freund's complete adjuvant. Two hundred μ l of the emulsion containing 0.79 nmol of protein was injected s.c. on day 0. First booster immunization with 0.79 nmol of protein in physiologic saline in incomplete Freund's adjuvant was performed on day 12. Second booster immunization was done day 22. On day 31 the mice were bled and sera were frozen for later analysis of antibody responses.

Specific antibodies - ELISA

[0168] Serum samples from immunized mice were obtained 9 days after the second booster immunization. The serum levels of specific antibodies was measured by ELISA. Microplates (96-well; Nunc) were coated with 4.6 μ g/ml of rClfA221-531 protein which is equimolar to 5 μ g/ml of rClfA221-559 and rClfAPY221-559 from Examples 1 and 2.. Blocking agent, serum samples, biotinylated antibodies, and ExtrAvidin-proxidase were all diluted in PBS. The assay was run according to a previous description (8). All serum samples were diluted 1:5000, 1:20000, 1:80000 and 1:320000, and antibody response was monitored as absorbance at 405 nm.

RESULTS:

[0169] The antibody response was measured by absorbance in an ELISA-assay, as per Example 1. It was found that rClfA221-531 immunization gave rise to an immune response, measured as a specific antibody response (Figure 18).

CONCLUSION:

[0170] We found that rClfA221-531 works as an immunogen, since the antigen evokes a specific antibody response.

REFERENCES

[0171]

1. Peacock SJ, Moore CE, Justice A, Kantzanou M, Story L, Mackie K, O'Neill G, Day NPJ (2002) Virulent combinations of adhesin and toxin genes in natural populations of *Staphylococcus aureus*. *Infect Immun* 70:4987-4996.
2. McDevitt D, Nanavaty T, House-Pompeo K, Bell E, Turner N, McEntire L, Foster T, Höök M (1997) Characterization of the interaction between the *Staphylococcus aureus* clumping factor (ClfA) and fibrinogen. *Eur J Biochem* 247:416-424.
3. McDevitt D, Francois P, Vaudaux P, Foster TJ (1994) Molecular characterization of the clumping factor (fibrinogen receptor) of *Staphylococcus aureus*. *Mol Microbiol* 11:237-248.
4. Palmqvist N, Patti JM, Tarkowski A, Josefsson E (2004) Expression of staphylococcal clumping factor A impedes macrophage phagocytosis. *Microb Infect* 6:188-195.
5. Higgins J, Loughman A, van Kessel KPM, van Strijp JAG, Foster TJ (2006) Clumping factor A of *Staphylococcus aureus* inhibits phagocytosis by human polymorphonuclear leukocytes. *FEMS Microbiol Lett* 258:290-296.
6. Loughman A, Fitzgerald JR, Brennan MP, Higgins J, Downer R, Cox D, Foster TJ (2005) Roles of fibrinogen, immunoglobulin and complement in platelet activation promoted by *Staphylococcus aureus* clumping factor A. *Mol Microbiol* 57:804-818.
7. O'Brien L, Kerrigan SW, Kaw G., Hogan M., Penadés J., Litt D., Fitzgerald D.J., Foster T.J. & Cox D. (2002) Multiple mechanisms for the activation of human platelet aggregation by *Staphylococcus aureus*: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. *Mol Microbiol* 44, 1033-1044.
8. Josefsson E., Hartford O., O'Brien L, Patti JM, Foster T (2001) Protection against experimental *Staphylococcus aureus* arthritis by vaccination with clumping factor A, a novel virulence determinant. *J Infect Dis* 184:1572-1580.
9. Palmqvist N, Foster T, Fitzgerald R, Josefsson E, Tarkowski A (2005) Fibronectin-binding proteins and fibrinogen-binding clumping factors play distinct roles in staphylococcal arthritis and systemic inflammation. *J Inf Dis* 191:791-798.
10. Deivanayagam CCS, Wann ER, Chen W, Carson M, Rajashankar KR, Höök M, Narayana SVL (2002) A novel variant of the immunoglobulin fold in surface adhesins of *Staphylococcus aureus*: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A. *The EMBO Journal* 21:6660-6672.
11. Bremell T, Lange S, Yacoub A, Ryden C, Tarkowski A (1991) Experimental *Staphylococcus aureus* arthritis in mice. *Infect Immun* 59:2615-2623.
12. Sakiniene E, Bremell T, Tarkowski A (1996) Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental *Staphylococcus aureus* arthritis. *Arthritis Rheumatism* 39:1596-1605.
13. Verdrengh M, Tarkowski A (1997) Role of neutrophils in experimental septicemia and septic arthritis induced by *Staphylococcus aureus*. *Infect Immun* 65:2517-2521.
14. Duthie ES, Lorenz LL (1952) Staphylococcal coagulase: mode of action and antigenicity. *J Gen Microbiol* 6:95-107.
15. Kreiswirth BN, Löfdahl S, Betley MJ, O'Reilly M, Schlievert PM, Bergdoll MS, Novick RP (1983) The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. *Nature* 305:709-712.
16. Foster TJ (1998) in *Methods in Microbiology* Vol. 27: Bacterial Pathogenesis, eds Williams P, Ketley J, Salmond G (Academic Press, London), pp 433-454.
17. O'Connell DP, Nanavaty T, McDevitt D, Gurusiddappa S, Höök M, Foster TJ (1998) The fibrinogen-binding MSCRAMM (clumping factor) of *Staphylococcus aureus* has a Ca²⁺⁺-dependent inhibitory site. *J Biol Chem* 273:6821-6829.
18. Sakiniene E, Bremell T, Tarkowski A (1999) Complement depletion aggravates *Staphylococcus aureus* septicemia and septic arthritis. *Clin Exp Immunol* 115:95-102.
19. Mancini G, Carbonara AO, Heremans JF (1965) Immunochemical quantitation of antigens by single radial immunodiffusion. *Immunochemistry* 2:235-254.
20. Bremell T, Abdelnour A, Tarkowski A (1992) Histopathological and serological progression of experimental *Staphylococcus aureus* arthritis. *Infect Immun* 60:2976-2985.

SEQUENCE LISTING

[0172]

EP 2 244 722 B1

<110> The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity Of Queen Elizabeth Near Dublin

<120> Treatment of Microbial Infections

<130> 31546WO

<160> 14

<170> Patent In version 3.3

<210> 1

<211> 933

<212> PRT

<213> Artificial

<220>

<223> recombinant ClfA (wild type) full length protein sequence

<400> 1

Met Asn Met Lys Lys Lys Glu Lys His Ala Ile Arg Lys Lys Ser Ile
1 5 10 15

Gly Val Ala Ser Val Leu Val Gly Thr Leu Ile Gly Phe Gly Leu Leu
20 25 30

Ser Ser Lys Glu Ala Asp Ala Ser Glu Asn Ser Val Thr Gln Ser Asp
35 40 45

Ser Ala Ser Asn Glu Ser Lys Ser Asn Asp Ser Ser Ser Val Ser Ala
50 55 60

Ala Pro Lys Thr Asp Asp Thr Asn Val Ser Asp Thr Lys Thr Ser Ser
65 70 75 80

Asn Thr Asn Asn Gly Glu Thr Ser Val Ala Gln Asn Pro Ala Gln Gln
85 90 95

Glu Thr Thr Gln Ser Ser Ser Thr Asn Ala Thr Thr Glu Glu Thr Pro
100 105 110

Val Thr Gly Glu Ala Thr Thr Thr Thr Thr Asn Gln Ala Asn Thr Pro
115 120 125

Ala Thr Thr Gln Ser Ser Asn Thr Asn Ala Glu Glu Leu Val Asn Gln
130 135 140

Thr Ser Asn Glu Thr Thr Phe Asn Asp Thr Asn Thr Val Ser Ser Val
145 150 155 160

EP 2 244 722 B1

	Asn	Ser	Pro	Gln	Asn	Ser	Thr	Asn	Ala	Glu	Asn	Val	Ser	Thr	Thr	Gln	
					165					170					175		
5	Asp	Thr	Ser	Thr	Glu	Ala	Thr	Pro	Ser	Asn	Asn	Glu	Ser	Ala	Pro	Gln	
				180					185					190			
10	Ser	Thr	Asp	Ala	Ser	Asn	Lys	Asp	Val	Val	Asn	Gln	Ala	Val	Asn	Thr	
			195					200					205				
15	Ser	Ala	Pro	Arg	Met	Arg	Ala	Phe	Ser	Leu	Ala	Ala	Val	Ala	Ala	Asp	
	210						215					220					
20	Ala	Pro	Ala	Ala	Gly	Thr	Asp	Ile	Thr	Asn	Gln	Leu	Thr	Asn	Val	Thr	
	225					230					235					240	
25	Val	Gly	Ile	Asp	Ser	Gly	Thr	Thr	Val	Tyr	Pro	His	Gln	Ala	Gly	Tyr	
					245					250					255		
30	Val	Lys	Leu	Asn	Tyr	Gly	Phe	Ser	Val	Pro	Asn	Ser	Ala	Val	Lys	Gly	
				260					265					270			
35	Asp	Thr	Phe	Lys	Ile	Thr	Val	Pro	Lys	Glu	Leu	Asn	Leu	Asn	Gly	Val	
			275					280					285				
40	Thr	Ser	Thr	Ala	Lys	Val	Pro	Pro	Ile	Met	Ala	Gly	Asp	Gln	Val	Leu	
	290					295						300					
45	Ala	Asn	Gly	Val	Ile	Asp	Ser	Asp	Gly	Asn	Val	Ile	Tyr	Thr	Phe	Thr	
	305				310						315					320	
50	Asp	Tyr	Val	Asn	Thr	Lys	Asp	Asp	Val	Lys	Ala	Thr	Leu	Thr	Met	Pro	
				325						330					335		
55	Ala	Tyr	Ile	Asp	Pro	Glu	Asn	Val	Lys	Lys	Thr	Gly	Asn	Val	Thr	Leu	
			340					345						350			
60	Ala	Thr	Gly	Ile	Gly	Ser	Thr	Thr	Ala	Asn	Lys	Thr	Val	Leu	Val	Asp	
			355					360					365				
65	Tyr	Glu	Lys	Tyr	Gly	Lys	Phe	Tyr	Asn	Leu	Ser	Ile	Lys	Gly	Thr	Ile	
	370						375					380					
70	Asp	Gln	Ile	Asp	Lys	Thr	Asn	Asn	Thr	Tyr	Arg	Gln	Thr	Ile	Tyr	Val	
	385					390					395					400	

EP 2 244 722 B1

	Asn	Pro	Ser	Gly	Asp	Asn	Val	Ile	Ala	Pro	Val	Leu	Thr	Gly	Asn	Leu	
					405					410					415		
5	Lys	Pro	Asn	Thr	Asp	Ser	Asn	Ala	Leu	Ile	Asp	Gln	Gln	Asn	Thr	Ser	
				420					425					430			
10	Ile	Lys	Val	Tyr	Lys	Val	Asp	Asn	Ala	Ala	Asp	Leu	Ser	Glu	Ser	Tyr	
			435					440					445				
15	Phe	Val	Asn	Pro	Glu	Asn	Phe	Glu	Asp	Val	Thr	Asn	Ser	Val	Asn	Ile	
		450					455					460					
20	Thr	Phe	Pro	Asn	Pro	Asn	Gln	Tyr	Lys	Val	Glu	Phe	Asn	Thr	Pro	Asp	
	465					470					475					480	
25	Asp	Gln	Ile	Thr	Thr	Pro	Tyr	Ile	Val	Val	Val	Asn	Gly	His	Ile	Asp	
					485				490						495		
30	Pro	Asn	Ser	Lys	Gly	Asp	Leu	Ala	Leu	Arg	Ser	Thr	Leu	Tyr	Gly	Tyr	
			500						505					510			
35	Asn	Ser	Asn	Ile	Ile	Trp	Arg	Ser	Met	Ser	Trp	Asp	Asn	Glu	Val	Ala	
		515					520						525				
40	Phe	Asn	Asn	Gly	Ser	Gly	Ser	Gly	Asp	Gly	Ile	Asp	Lys	Pro	Val	Val	
	530					535						540					
45	Pro	Glu	Gln	Pro	Asp	Glu	Pro	Gly	Glu	Ile	Glu	Pro	Ile	Pro	Glu	Asp	
	545					550					555					560	
50	Ser	Asp	Ser	Asp	Pro	Gly	Ser	Asp	Ser	Gly	Ser	Asp	Ser	Asn	Ser	Asp	
				565						570					575		
55	Ser	Gly	Ser	Asp	Ser	Gly	Ser	Asp	Ser	Thr	Ser	Asp	Ser	Gly	Ser	Asp	
			580					585					590				
60	Ser	Ala	Ser	Asp	Ser	Asp	Ser	Ala	Ser	Asp	Ser	Asp	Ser	Ala	Ser	Asp	
		595					600						605				
65	Ser	Asp	Ser	Ala	Ser	Asp	Ser	Asp	Ser	Ala	Ser	Asp	Ser	Asp	Ser	Asp	
	610					615					620						
70	Asn	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	
	625				630					635					640		

EP 2 244 722 B1

	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
					645				650				655	
5	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
					660				665				670	
10	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
					675				680				685	
15	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
					690				695				700	
20	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
	705					710				715				720
25	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
					725				730				735	
30	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Ala
					740				745				750	
35	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Ala
					755				760				765	
40	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
					770				775				780	
45	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
					785				790				795	800
50	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Glu	Ser	Asp	Ser	Asp	Ser	Glu
					805				810				815	
55	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
					820				825				830	
60	Ser	Asp	Ser	Asp	Ser	Ala	Ser	Asp	Ser	Asp	Ser	Gly	Ser	Asp
					835				840				845	
65	Ser	Ser	Ser	Asp	Ser	Asp	Ser	Glu	Ser	Asp	Ser	Asn	Ser	Asp
					850				855				860	
70	Ser	Gly	Ser	Asn	Asn	Asn	Val	Val	Pro	Pro	Asn	Ser	Pro	Lys
					865				870				875	880
75	Thr	Asn	Ala	Ser	Asn	Lys	Asn	Glu	Ala	Lys	Asp	Ser	Lys	Glu
														Pro
														Leu

EP 2 244 722 B1

	885	890	895	
5	Pro Asp Thr Gly Ser Glu Asp Glu Ala Asn Thr Ser Leu Ile Trp Gly			
	900	905	910	
10	Leu Leu Ala Ser Ile Gly Ser Leu Leu Leu Phe Arg Arg Lys Lys Glu			
	915	920	925	
	Asn Lys Asp Lys Lys			
	930			
15	<210> 2			
	<211> 1560			
	<212> DNA			
	<213> Artificial			
20	<220>			
	<223> recombinant ClfA A domain (wild type) Regions N1 N2 N3			
	<220>			
	<221> CDS			
25	<222> (1)..(1560)			
	<400> 2			
30	agt gaa aat agt gtt acg caa tct gat agc gca agt aac gaa agc aaa			48
	Ser Glu Asn Ser Val Thr Gln Ser Asp Ser Ala Ser Asn Glu Ser Lys			
	1 5 10 15			
35	agt aat gat tca agt agc gtt agt gct gca cct aaa aca gac gac aca			96
	Ser Asn Asp Ser Ser Ser Val Ser Ala Ala Pro Lys Thr Asp Asp Thr			
	20 25 30			
40	aac gtg agt gat act aaa aca tcg tca aac act aat aat ggc gaa acg			144
	Asn Val Ser Asp Thr Lys Thr Ser Ser Asn Thr Asn Asn Gly Glu Thr			
	35 40 45			
45	agt gtg gcg caa aat cca gca caa cag gaa acg aca caa tca tca tca			192
	Ser Val Ala Gln Asn Pro Ala Gln Gln Glu Thr Thr Gln Ser Ser Ser			
	50 55 60			
50	aca aat gca act acg gaa gaa acg ccg gta act ggt gaa gct act act			240
	Thr Asn Ala Thr Thr Glu Glu Thr Pro Val Thr Gly Glu Ala Thr Thr			
	65 70 75 80			
55	acg aca acg aat caa gct aat aca ccg gca aca act caa tca agc aat			288
	Thr Thr Thr Asn Gln Ala Asn Thr Pro Ala Thr Thr Gln Ser Ser Asn			
	85 90 95			
	aca aat gcg gag gaa tta gtg aat caa aca agt aat gaa acg act ttt			336
	Thr Asn Ala Glu Glu Leu Val Asn Gln Thr Ser Asn Glu Thr Thr Phe			
	100 105 110			
60	aat gat act aat aca gta tca tct gta aat tca cct caa aat tct aca			384
	Asn Asp Thr Asn Thr Val Ser Ser Val Asn Ser Pro Gln Asn Ser Thr			
	115 120 125			

EP 2 244 722 B1

	aat gcg gaa aat gtt tca aca acg caa gat act tca act gaa gca aca Asn Ala Glu Asn Val Ser Thr Thr Gln Asp Thr Ser Thr Glu Ala Thr 130 135 140	432
5	cct tca aac aat gaa tca gct cca cag agt aca gat gca agt aat aaa Pro Ser Asn Asn Glu Ser Ala Pro Gln Ser Thr Asp Ala Ser Asn Lys 145 150 155 160	480
10	gat gta gtt aat caa gcg gtt aat aca agt gcg cct aga atg aga gca Asp Val Val Asn Gln Ala Val Asn Thr Ser Ala Pro Arg Met Arg Ala 165 170 175	528
15	ttt agt tta gcg gca gta gct gca gat gca ccg gca gct ggc aca gat Phe Ser Leu Ala Ala Val Ala Ala Asp Ala Pro Ala Ala Gly Thr Asp 180 185 190	576
	att acg aat cag ttg acg aat gtg aca gtt ggt att gac tct ggt acg Ile Thr Asn Gln Leu Thr Asn Val Thr Val Gly Ile Asp Ser Gly Thr 195 200 205	624
20	act gtg tat ccg cac caa gca ggt tat gtc aaa ctg aat tat ggt ttt Thr Val Tyr Pro His Gln Ala Gly Tyr Val Lys Leu Asn Tyr Gly Phe 210 215 220	672
25	tca gtg cct aat tct gct gtt aaa ggt gac aca ttc aaa ata act gta Ser Val Pro Asn Ser Ala Val Lys Gly Asp Thr Phe Lys Ile Thr Val 225 230 235 240	720
30	cct aaa gaa tta aac tta aat ggt gta act tca act gct aaa gtg cca Pro Lys Glu Leu Asn Leu Asn Gly Val Thr Ser Thr Ala Lys Val Pro 245 250 255	768
	cca att atg gct gga gat caa gta ttg gca aat ggt gta atc gat agt Pro Ile Met Ala Gly Asp Gln Val Leu Ala Asn Gly Val Ile Asp Ser 260 265 270	816
35	gat ggt aat gtt att tat aca ttt aca gac tat gta aat act aaa gat Asp Gly Asn Val Ile Tyr Thr Phe Thr Asp Tyr Val Asn Thr Lys Asp 275 280 285	864
40	gat gta aaa gca act ttg acc atg ccc gct tat att gac cct gaa aat Asp Val Lys Ala Thr Leu Thr Met Pro Ala Tyr Ile Asp Pro Glu Asn 290 295 300	912
	gtt aaa aag aca ggt aat gtg aca ttg gct act ggc ata ggt agt aca Val Lys Lys Thr Gly Asn Val Thr Leu Ala Thr Gly Ile Gly Ser Thr 305 310 315 320	960
45	aca gca aac aaa aca gta tta gta gat tat gaa aaa tat ggt aag ttt Thr Ala Asn Lys Thr Val Leu Val Asp Tyr Glu Lys Tyr Gly Lys Phe 325 330 335	1008
50	tat aac tta tct att aaa ggt aca att gac caa atc gat aaa aca aat Tyr Asn Leu Ser Ile Lys Gly Thr Ile Asp Gln Ile Asp Lys Thr Asn 340 345 350	1056
55	aat acg tat cgt cag aca att tat gtc aat cca agt gga gat aac gtt Asn Thr Tyr Arg Gln Thr Ile Tyr Val Asn Pro Ser Gly Asp Asn Val 355 360 365	1104
	att gcg ccg gtt tta aca ggt aat tta aaa cca aat acg gat agt aat	1152

EP 2 244 722 B1

	Ile	Ala	Pro	Val	Leu	Thr	Gly	Asn	Leu	Lys	Pro	Asn	Thr	Asp	Ser	Asn	
	370						375					380					
5	gca	tta	ata	gat	cag	caa	aat	aca	agt	att	aaa	gta	tat	aaa	gta	gat	1200
	Ala	Leu	Ile	Asp	Gln	Gln	Asn	Thr	Ser	Ile	Lys	Val	Tyr	Lys	Val	Asp	
	385					390					395					400	
10	aat	gca	gct	gat	tta	tct	gaa	agt	tac	ttt	gtg	aat	cca	gaa	aac	ttt	1248
	Asn	Ala	Ala	Asp	Leu	Ser	Glu	Ser	Tyr	Phe	Val	Asn	Pro	Glu	Asn	Phe	
					405					410					415		
15	gag	gat	gtc	act	aat	agt	gtg	aat	att	aca	ttc	cca	aat	cca	aat	caa	1296
	Glu	Asp	Val	Thr	Asn	Ser	Val	Asn	Ile	Thr	Phe	Pro	Asn	Pro	Asn	Gln	
				420					425					430			
20	tat	aaa	gta	gag	ttt	aat	acg	cct	gat	gat	caa	att	aca	aca	ccg	tat	1344
	Tyr	Lys	Val	Glu	Phe	Asn	Thr	Pro	Asp	Asp	Gln	Ile	Thr	Thr	Pro	Tyr	
			435					440					445				
25	ata	gta	gtt	gtt	aat	ggg	cat	att	gat	ccg	aat	agc	aaa	ggg	gat	tta	1392
	Ile	Val	Val	Val	Asn	Gly	His	Ile	Asp	Pro	Asn	Ser	Lys	Gly	Asp	Leu	
		450				455						460					
30	gct	tta	cgt	tca	act	tta	tat	ggg	tat	aac	tcg	aat	ata	att	tgg	cgc	1440
	Ala	Leu	Arg	Ser	Thr	Leu	Tyr	Gly	Tyr	Asn	Ser	Asn	Ile	Ile	Trp	Arg	
	465					470					475					480	
35	tct	atg	tca	tgg	gac	aac	gaa	gta	gca	ttt	aat	aac	gga	tca	ggg	tct	1488
	Ser	Met	Ser	Trp	Asp	Asn	Glu	Val	Ala	Phe	Asn	Asn	Gly	Ser	Gly	Ser	
					485					490					495		
40	ggg	gac	ggg	atc	gat	aaa	cca	gtt	gtt	cct	gaa	caa	cct	gat	gag	cct	1536
	Gly	Asp	Gly	Ile	Asp	Lys	Pro	Val	Val	Pro	Glu	Gln	Pro	Asp	Glu	Pro	
				500				505						510			
45	ggg	gaa	att	gaa	cca	att	cca	gag									1560
	Gly	Glu	Ile	Glu	Pro	Ile	Pro	Glu									
			515					520									
50	<210> 3																
	<211> 520																
	<212> PRT																
	<213> Artificial																
55	<220>																
	<223> Synthetic Construct																
60	<400> 3																
65	Ser	Glu	Asn	Ser	Val	Thr	Gln	Ser	Asp	Ser	Ala	Ser	Asn	Glu	Ser	Lys	
	1				5					10				15			
70	Ser	Asn	Asp	Ser	Ser	Ser	Val	Ser	Ala	Ala	Pro	Lys	Thr	Asp	Asp	Thr	
				20					25					30			
75	Asn	Val	Ser	Asp	Thr	Lys	Thr	Ser	Ser	Asn	Thr	Asn	Asn	Gly	Glu	Thr	
			35					40					45				

EP 2 244 722 B1

	Ser	Val	Ala	Gln	Asn	Pro	Ala	Gln	Gln	Glu	Thr	Thr	Gln	Ser	Ser	Ser	
	50						55					60					
5	Thr	Asn	Ala	Thr	Thr	Glu	Glu	Thr	Pro	Val	Thr	Gly	Glu	Ala	Thr	Thr	
	65					70					75					80	
10	Thr	Thr	Thr	Asn	Gln	Ala	Asn	Thr	Pro	Ala	Thr	Thr	Gln	Ser	Ser	Asn	
					85					90					95		
15	Thr	Asn	Ala	Glu	Glu	Leu	Val	Asn	Gln	Thr	Ser	Asn	Glu	Thr	Thr	Phe	
				100					105					110			
20	Asn	Asp	Thr	Asn	Thr	Val	Ser	Ser	Val	Asn	Ser	Pro	Gln	Asn	Ser	Thr	
			115					120					125				
25	Asn	Ala	Glu	Asn	Val	Ser	Thr	Thr	Gln	Asp	Thr	Ser	Thr	Glu	Ala	Thr	
	130						135					140					
30	Pro	Ser	Asn	Asn	Glu	Ser	Ala	Pro	Gln	Ser	Thr	Asp	Ala	Ser	Asn	Lys	
	145					150					155					160	
35	Asp	Val	Val	Asn	Gln	Ala	Val	Asn	Thr	Ser	Ala	Pro	Arg	Met	Arg	Ala	
					165					170					175		
40	Phe	Ser	Leu	Ala	Ala	Val	Ala	Ala	Asp	Ala	Pro	Ala	Ala	Gly	Thr	Asp	
				180					185					190			
45	Ile	Thr	Asn	Gln	Leu	Thr	Asn	Val	Thr	Val	Gly	Ile	Asp	Ser	Gly	Thr	
			195					200					205				
50	Thr	Val	Tyr	Pro	His	Gln	Ala	Gly	Tyr	Val	Lys	Leu	Asn	Tyr	Gly	Phe	
	210					215						220					
55	Ser	Val	Pro	Asn	Ser	Ala	Val	Lys	Gly	Asp	Thr	Phe	Lys	Ile	Thr	Val	
	225					230					235					240	
60	Pro	Lys	Glu	Leu	Asn	Leu	Asn	Gly	Val	Thr	Ser	Thr	Ala	Lys	Val	Pro	
				245						250					255		
65	Pro	Ile	Met	Ala	Gly	Asp	Gln	Val	Leu	Ala	Asn	Gly	Val	Ile	Asp	Ser	
				260					265					270			
70	Asp	Gly	Asn	Val	Ile	Tyr	Thr	Phe	Thr	Asp	Tyr	Val	Asn	Thr	Lys	Asp	
			275					280					285				

EP 2 244 722 B1

	Asp	Val	Lys	Ala	Thr	Leu	Thr	Met	Pro	Ala	Tyr	Ile	Asp	Pro	Glu	Asn
	290						295					300				
5	Val	Lys	Lys	Thr	Gly	Asn	Val	Thr	Leu	Ala	Thr	Gly	Ile	Gly	Ser	Thr
	305					310					315					320
10	Thr	Ala	Asn	Lys	Thr	Val	Leu	Val	Asp	Tyr	Glu	Lys	Tyr	Gly	Lys	Phe
					325					330					335	
15	Tyr	Asn	Leu	Ser	Ile	Lys	Gly	Thr	Ile	Asp	Gln	Ile	Asp	Lys	Thr	Asn
				340					345					350		
20	Asn	Thr	Tyr	Arg	Gln	Thr	Ile	Tyr	Val	Asn	Pro	Ser	Gly	Asp	Asn	Val
			355					360					365			
25	Ile	Ala	Pro	Val	Leu	Thr	Gly	Asn	Leu	Lys	Pro	Asn	Thr	Asp	Ser	Asn
	370						375					380				
30	Ala	Leu	Ile	Asp	Gln	Gln	Asn	Thr	Ser	Ile	Lys	Val	Tyr	Lys	Val	Asp
	385					390					395					400
35	Asn	Ala	Ala	Asp	Leu	Ser	Glu	Ser	Tyr	Phe	Val	Asn	Pro	Glu	Asn	Phe
					405					410					415	
40	Glu	Asp	Val	Thr	Asn	Ser	Val	Asn	Ile	Thr	Phe	Pro	Asn	Pro	Asn	Gln
				420					425					430		
45	Tyr	Lys	Val	Glu	Phe	Asn	Thr	Pro	Asp	Asp	Gln	Ile	Thr	Thr	Pro	Tyr
			435					440					445			
50	Ile	Val	Val	Val	Asn	Gly	His	Ile	Asp	Pro	Asn	Ser	Lys	Gly	Asp	Leu
	450						455					460				
55	Ala	Leu	Arg	Ser	Thr	Leu	Tyr	Gly	Tyr	Asn	Ser	Asn	Ile	Ile	Trp	Arg
	465					470					475					480
60	Ser	Met	Ser	Trp	Asp	Asn	Glu	Val	Ala	Phe	Asn	Asn	Gly	Ser	Gly	Ser
					485					490					495	
65	Gly	Asp	Gly	Ile	Asp	Lys	Pro	Val	Val	Pro	Glu	Gln	Pro	Asp	Glu	Pro
				500					505					510		
70	Gly	Glu	Ile	Glu	Pro	Ile	Pro	Glu								
			515					520								

<210> 4
<211> 520

EP 2 244 722 B1

<212> PRT

<213> Artificial

<220>

5 <223> ClfA A domain Regions N1 N2 N3 with alterations (ClfA P336S Y338A)

<400> 4

10	Ser Glu Asn Ser Val Thr Gln Ser Asp Ser Ala Ser Asn Glu Ser Lys	1 5 10 15
15	Ser Asn Asp Ser Ser Ser Val Ser Ala Ala Pro Lys Thr Asp Asp Thr	20 25 30
20	Asn Val Ser Asp Thr Lys Thr Ser Ser Asn Thr Asn Asn Gly Glu Thr	35 40 45
25	Ser Val Ala Gln Asn Pro Ala Gln Gln Glu Thr Thr Gln Ser Ser Ser	50 55 60
30	Thr Asn Ala Thr Thr Glu Glu Thr Pro Val Thr Gly Glu Ala Thr Thr	65 70 75 80
35	Thr Thr Thr Asn Gln Ala Asn Thr Pro Ala Thr Thr Gln Ser Ser Asn	85 90 95
40	Thr Asn Ala Glu Glu Leu Val Asn Gln Thr Ser Asn Glu Thr Thr Phe	100 105 110
45	Asn Asp Thr Asn Thr Val Ser Ser Val Asn Ser Pro Gln Asn Ser Thr	115 120 125
50	Asn Ala Glu Asn Val Ser Thr Thr Gln Asp Thr Ser Thr Glu Ala Thr	130 135 140
55	Pro Ser Asn Asn Glu Ser Ala Pro Gln Ser Thr Asp Ala Ser Asn Lys	145 150 155 160
	Asp Val Val Asn Gln Ala Val Asn Thr Ser Ala Pro Arg Met Arg Ala	165 170 175
	Phe Ser Leu Ala Ala Val Ala Ala Asp Ala Pro Ala Ala Gly Thr Asp	180 185 190
	Ile Thr Asn Gln Leu Thr Asn Val Thr Val Gly Ile Asp Ser Gly Thr	195 200 205

EP 2 244 722 B1

	Thr	Val	Tyr	Pro	His	Gln	Ala	Gly	Tyr	Val	Lys	Leu	Asn	Tyr	Gly	Phe	
	210						215					220					
5	Ser	Val	Pro	Asn	Ser	Ala	Val	Lys	Gly	Asp	Thr	Phe	Lys	Ile	Thr	Val	
	225					230					235					240	
10	Pro	Lys	Glu	Leu	Asn	Leu	Asn	Gly	Val	Thr	Ser	Thr	Ala	Lys	Val	Pro	
				245						250					255		
15	Pro	Ile	Met	Ala	Gly	Asp	Gln	Val	Leu	Ala	Asn	Gly	Val	Ile	Asp	Ser	
				260					265					270			
20	Asp	Gly	Asn	Val	Ile	Tyr	Thr	Phe	Thr	Asp	Tyr	Val	Asn	Thr	Lys	Asp	
			275					280					285				
25	Asp	Val	Lys	Ala	Thr	Leu	Thr	Met	Ser	Ala	Ala	Ile	Asp	Pro	Glu	Asn	
		290					295					300					
30	Val	Lys	Lys	Thr	Gly	Asn	Val	Thr	Leu	Ala	Thr	Gly	Ile	Gly	Ser	Thr	
	305				310						315					320	
35	Thr	Ala	Asn	Lys	Thr	Val	Leu	Val	Asp	Tyr	Glu	Lys	Tyr	Gly	Lys	Phe	
				325						330					335		
40	Tyr	Asn	Leu	Ser	Ile	Lys	Gly	Thr	Ile	Asp	Gln	Ile	Asp	Lys	Thr	Asn	
			340						345					350			
45	Asn	Thr	Tyr	Arg	Gln	Thr	Ile	Tyr	Val	Asn	Pro	Ser	Gly	Asp	Asn	Val	
			355					360					365				
50	Ile	Ala	Pro	Val	Leu	Thr	Gly	Asn	Leu	Lys	Pro	Asn	Thr	Asp	Ser	Asn	
	370					375						380					
55	Ala	Leu	Ile	Asp	Gln	Gln	Asn	Thr	Ser	Ile	Lys	Val	Tyr	Lys	Val	Asp	
	385				390						395					400	
60	Asn	Ala	Ala	Asp	Leu	Ser	Glu	Ser	Tyr	Phe	Val	Asn	Pro	Glu	Asn	Phe	
				405						410					415		
65	Glu	Asp	Val	Thr	Asn	Ser	Val	Asn	Ile	Thr	Phe	Pro	Asn	Pro	Asn	Gln	
				420				425						430			
70	Tyr	Lys	Val	Glu	Phe	Asn	Thr	Pro	Asp	Asp	Gln	Ile	Thr	Thr	Pro	Tyr	
		435						440					445				

EP 2 244 722 B1

	Ile	Val	Val	Val	Asn	Gly	His	Ile	Asp	Pro	Asn	Ser	Lys	Gly	Asp	Leu
	450						455					460				
5	Ala	Leu	Arg	Ser	Thr	Leu	Tyr	Gly	Tyr	Asn	Ser	Asn	Ile	Ile	Trp	Arg
	465					470				475						480
10	Ser	Met	Ser	Trp	Asp	Asn	Glu	Val	Ala	Phe	Asn	Asn	Gly	Ser	Gly	Ser
					485					490					495	
15	Gly	Asp	Gly	Ile	Asp	Lys	Pro	Val	Val	Pro	Glu	Gln	Pro	Asp	Glu	Pro
				500					505					510		
20	Gly	Glu	Ile	Glu	Pro	Ile	Pro	Glu								
			515					520								
25	<210> 5															
	<211> 520															
	<212> PRT															
	<213> Artificial															
30	<220>															
	<223> ClfA A domain Regions N1 N2 N3 with alterations (ClfA P336A Y338S)															
35	<400> 5															
40	Ser	Glu	Asn	Ser	Val	Thr	Gln	Ser	Asp	Ser	Ala	Ser	Asn	Glu	Ser	Lys
	1				5					10					15	
45	Ser	Asn	Asp	Ser	Ser	Ser	Val	Ser	Ala	Ala	Pro	Lys	Thr	Asp	Asp	Thr
				20					25					30		
50	Asn	Val	Ser	Asp	Thr	Lys	Thr	Ser	Ser	Asn	Thr	Asn	Asn	Gly	Glu	Thr
			35					40					45			
55	Ser	Val	Ala	Gln	Asn	Pro	Ala	Gln	Gln	Glu	Thr	Thr	Gln	Ser	Ser	Ser
	50						55					60				
60	Thr	Asn	Ala	Thr	Thr	Glu	Glu	Thr	Pro	Val	Thr	Gly	Glu	Ala	Thr	Thr
	65					70					75					80
65	Thr	Thr	Thr	Asn	Gln	Ala	Asn	Thr	Pro	Ala	Thr	Thr	Gln	Ser	Ser	Asn
					85					90					95	
70	Thr	Asn	Ala	Glu	Glu	Leu	Val	Asn	Gln	Thr	Ser	Asn	Glu	Thr	Thr	Phe
				100					105					110		
75	Asn	Asp	Thr	Asn	Thr	Val	Ser	Ser	Val	Asn	Ser	Pro	Gln	Asn	Ser	Thr
			115					120					125			

EP 2 244 722 B1

	Asn	Ala	Glu	Asn	Val	Ser	Thr	Thr	Gln	Asp	Thr	Ser	Thr	Glu	Ala	Thr	
	130						135					140					
5	Pro	Ser	Asn	Asn	Glu	Ser	Ala	Pro	Gln	Ser	Thr	Asp	Ala	Ser	Asn	Lys	
	145					150					155					160	
10	Asp	Val	Val	Asn	Gln	Ala	Val	Asn	Thr	Ser	Ala	Pro	Arg	Met	Arg	Ala	
					165					170					175		
15	Phe	Ser	Leu	Ala	Ala	Val	Ala	Ala	Asp	Ala	Pro	Ala	Ala	Gly	Thr	Asp	
				180					185					190			
20	Ile	Thr	Asn	Gln	Leu	Thr	Asn	Val	Thr	Val	Gly	Ile	Asp	Ser	Gly	Thr	
			195					200					205				
25	Thr	Val	Tyr	Pro	His	Gln	Ala	Gly	Tyr	Val	Lys	Leu	Asn	Tyr	Gly	Phe	
		210					215					220					
30	Ser	Val	Pro	Asn	Ser	Ala	Val	Lys	Gly	Asp	Thr	Phe	Lys	Ile	Thr	Val	
	225					230					235					240	
35	Pro	Lys	Glu	Leu	Asn	Leu	Asn	Gly	Val	Thr	Ser	Thr	Ala	Lys	Val	Pro	
					245					250					255		
40	Pro	Ile	Met	Ala	Gly	Asp	Gln	Val	Leu	Ala	Asn	Gly	Val	Ile	Asp	Ser	
				260					265					270			
45	Asp	Gly	Asn	Val	Ile	Tyr	Thr	Phe	Thr	Asp	Tyr	Val	Asn	Thr	Lys	Asp	
			275					280					285				
50	Asp	Val	Lys	Ala	Thr	Leu	Thr	Met	Ala	Ala	Ser	Ile	Asp	Pro	Glu	Asn	
		290					295					300					
55	Val	Lys	Lys	Thr	Gly	Asn	Val	Thr	Leu	Ala	Thr	Gly	Ile	Gly	Ser	Thr	
	305					310					315					320	
60	Thr	Ala	Asn	Lys	Thr	Val	Leu	Val	Asp	Tyr	Glu	Lys	Tyr	Gly	Lys	Phe	
					325					330					335		
65	Tyr	Asn	Leu	Ser	Ile	Lys	Gly	Thr	Ile	Asp	Gln	Ile	Asp	Lys	Thr	Asn	
				340					345					350			
70	Asn	Thr	Tyr	Arg	Gln	Thr	Ile	Tyr	Val	Asn	Pro	Ser	Gly	Asp	Asn	Val	
			355					360					365				

EP 2 244 722 B1

	Ile	Ala	Pro	Val	Leu	Thr	Gly	Asn	Leu	Lys	Pro	Asn	Thr	Asp	Ser	Asn	
	370						375					380					
5	Ala	Leu	Ile	Asp	Gln	Gln	Asn	Thr	Ser	Ile	Lys	Val	Tyr	Lys	Val	Asp	
	385					390					395					400	
10	Asn	Ala	Ala	Asp	Leu	Ser	Glu	Ser	Tyr	Phe	Val	Asn	Pro	Glu	Asn	Phe	
					405					410						415	
15	Glu	Asp	Val	Thr	Asn	Ser	Val	Asn	Ile	Thr	Phe	Pro	Asn	Pro	Asn	Gln	
				420					425					430			
20	Tyr	Lys	Val	Glu	Phe	Asn	Thr	Pro	Asp	Asp	Gln	Ile	Thr	Thr	Pro	Tyr	
			435					440					445				
25	Ile	Val	Val	Val	Asn	Gly	His	Ile	Asp	Pro	Asn	Ser	Lys	Gly	Asp	Leu	
	450						455					460					
30	Ala	Leu	Arg	Ser	Thr	Leu	Tyr	Gly	Tyr	Asn	Ser	Asn	Ile	Ile	Trp	Arg	
	465					470					475					480	
35	Ser	Met	Ser	Trp	Asp	Asn	Glu	Val	Ala	Phe	Asn	Asn	Gly	Ser	Gly	Ser	
					485					490					495		
40	Gly	Asp	Gly	Ile	Asp	Lys	Pro	Val	Val	Pro	Glu	Gln	Pro	Asp	Glu	Pro	
				500					505					510			
45	Gly	Glu	Ile	Glu	Pro	Ile	Pro	Glu									
			515					520									
	<210> 6																
	<211> 530																
	<212> PRT																
	<213> ARTIFICIAL																
	<220>																
	<223> wt rClfA A region with additional N and C terminal residues																
	<400> 6																
50	His	His	His	His	His	His	Gly	Ser	Ser	Glu	Asn	Ser	Val	Thr	Gln	Ser	
	1				5					10					15		
55	Asp	Ser	Ala	Ser	Asn	Glu	Ser	Lys	Ser	Asn	Asp	Ser	Ser	Ser	Val	Ser	
				20					25					30			
	Ala	Ala	Pro	Lys	Thr	Asp	Asp	Thr	Asn	Val	Ser	Asp	Thr	Lys	Thr	Ser	
			35					40					45				

EP 2 244 722 B1

	Ser	Asn	Thr	Asn	Asn	Gly	Glu	Thr	Ser	Val	Ala	Gln	Asn	Pro	Ala	Gln	
	50						55					60					
5	Gln	Glu	Thr	Thr	Gln	Ser	Ser	Ser	Thr	Asn	Ala	Thr	Thr	Glu	Glu	Thr	
	65					70					75					80	
10	Pro	Val	Thr	Gly	Glu	Ala	Thr	Thr	Thr	Thr	Thr	Asn	Gln	Ala	Asn	Thr	
					85					90					95		
15	Pro	Ala	Thr	Thr	Gln	Ser	Ser	Asn	Thr	Asn	Ala	Glu	Glu	Leu	Val	Asn	
				100					105					110			
20	Gln	Thr	Ser	Asn	Glu	Thr	Thr	Phe	Asn	Asp	Thr	Asn	Thr	Val	Ser	Ser	
			115					120					125				
25	Val	Asn	Ser	Pro	Gln	Asn	Ser	Thr	Asn	Ala	Glu	Asn	Val	Ser	Thr	Thr	
		130					135					140					
30	Gln	Asp	Thr	Ser	Thr	Glu	Ala	Thr	Pro	Ser	Asn	Asn	Glu	Ser	Ala	Pro	
	145					150					155					160	
35	Gln	Ser	Thr	Asp	Ala	Ser	Asn	Lys	Asp	Val	Val	Asn	Gln	Ala	Val	Asn	
					165					170					175		
40	Thr	Ser	Ala	Pro	Arg	Met	Arg	Ala	Phe	Ser	Leu	Ala	Ala	Val	Ala	Ala	
				180					185					190			
45	Asp	Ala	Pro	Ala	Ala	Gly	Thr	Asp	Ile	Thr	Asn	Gln	Leu	Thr	Asn	Val	
			195					200					205				
50	Thr	Val	Gly	Ile	Asp	Ser	Gly	Thr	Thr	Val	Tyr	Pro	His	Gln	Ala	Gly	
	210						215					220					
55	Tyr	Val	Lys	Leu	Asn	Tyr	Gly	Phe	Ser	Val	Pro	Asn	Ser	Ala	Val	Lys	
	225					230					235					240	
60	Gly	Asp	Thr	Phe	Lys	Ile	Thr	Val	Pro	Lys	Glu	Leu	Asn	Leu	Asn	Gly	
					245					250					255		
65	Val	Thr	Ser	Thr	Ala	Lys	Val	Pro	Pro	Ile	Met	Ala	Gly	Asp	Gln	Val	
				260					265					270			
70	Leu	Ala	Asn	Gly	Val	Ile	Asp	Ser	Asp	Gly	Asn	Val	Ile	Tyr	Thr	Phe	
			275					280					285				

EP 2 244 722 B1

	Thr	Asp	Tyr	Val	Asn	Thr	Lys	Asp	Asp	Val	Lys	Ala	Thr	Leu	Thr	Met
	290						295					300				
5	Pro	Ala	Tyr	Ile	Asp	Pro	Glu	Asn	Val	Lys	Lys	Thr	Gly	Asn	Val	Thr
	305					310					315					320
10	Leu	Ala	Thr	Gly	Ile	Gly	Ser	Thr	Thr	Ala	Asn	Lys	Thr	Val	Leu	Val
				325						330					335	
15	Asp	Tyr	Glu	Lys	Tyr	Gly	Lys	Phe	Tyr	Asn	Leu	Ser	Ile	Lys	Gly	Thr
				340					345					350		
20	Ile	Asp	Gln	Ile	Asp	Lys	Thr	Asn	Asn	Thr	Tyr	Arg	Gln	Thr	Ile	Tyr
			355					360					365			
25	Val	Asn	Pro	Ser	Gly	Asp	Asn	Val	Ile	Ala	Pro	Val	Leu	Thr	Gly	Asn
	370						375					380				
30	Leu	Lys	Pro	Asn	Thr	Asp	Ser	Asn	Ala	Leu	Ile	Asp	Gln	Gln	Asn	Thr
	385					390					395					400
35	Ser	Ile	Lys	Val	Tyr	Lys	Val	Asp	Asn	Ala	Ala	Asp	Leu	Ser	Glu	Ser
					405					410					415	
40	Tyr	Phe	Val	Asn	Pro	Glu	Asn	Phe	Glu	Asp	Val	Thr	Asn	Ser	Val	Asn
				420					425					430		
45	Ile	Thr	Phe	Pro	Asn	Pro	Asn	Gln	Tyr	Lys	Val	Glu	Phe	Asn	Thr	Pro
			435					440					445			
50	Asp	Asp	Gln	Ile	Thr	Thr	Pro	Tyr	Ile	Val	Val	Val	Asn	Gly	His	Ile
	450						455					460				
55	Asp	Pro	Asn	Ser	Lys	Gly	Asp	Leu	Ala	Leu	Arg	Ser	Thr	Leu	Tyr	Gly
	465					470					475					480
60	Tyr	Asn	Ser	Asn	Ile	Ile	Trp	Arg	Ser	Met	Ser	Trp	Asp	Asn	Glu	Val
					485					490					495	
65	Ala	Phe	Asn	Asn	Gly	Ser	Gly	Ser	Gly	Asp	Gly	Ile	Asp	Lys	Pro	Val
				500					505					510		
70	Val	Pro	Glu	Gln	Pro	Asp	Glu	Pro	Gly	Glu	Ile	Glu	Pro	Ile	Pro	Glu
			515				520						525			

Lys Leu
530

5

<210> 7

<211> 530

<212> PRT

<213> ARTIFICIAL

10

<220>

<223> wt rClfAPYI A region with additional N and C terminal residues

15

<400> 7

20

25

30

35

40

45

50

55

EP 2 244 722 B1

	His	His	His	His	His	His	Gly	Ser	Ser	Glu	Asn	Ser	Val	Thr	Gln	Ser	
	1				5					10					15		
5	Asp	Ser	Ala	Ser	Asn	Glu	Ser	Lys	Ser	Asn	Asp	Ser	Ser	Ser	Val	Ser	
				20					25					30			
10	Ala	Ala	Pro	Lys	Thr	Asp	Asp	Thr	Asn	Val	Ser	Asp	Thr	Lys	Thr	Ser	
			35					40					45				
	Ser	Asn	Thr	Asn	Asn	Gly	Glu	Thr	Ser	Val	Ala	Gln	Asn	Pro	Ala	Gln	
15		50					55					60					
	Gln	Glu	Thr	Thr	Gln	Ser	Ser	Ser	Thr	Asn	Ala	Thr	Thr	Glu	Glu	Thr	
	65					70					75					80	
20	Pro	Val	Thr	Gly	Glu	Ala	Thr	Thr	Thr	Thr	Thr	Asn	Gln	Ala	Asn	Thr	
					85					90					95		
	Pro	Ala	Thr	Thr	Gln	Ser	Ser	Asn	Thr	Asn	Ala	Glu	Glu	Leu	Val	Asn	
25				100					105					110			
	Gln	Thr	Ser	Asn	Glu	Thr	Thr	Phe	Asn	Asp	Thr	Asn	Thr	Val	Ser	Ser	
30			115					120					125				
	Val	Asn	Ser	Pro	Gln	Asn	Ser	Thr	Asn	Ala	Glu	Asn	Val	Ser	Thr	Thr	
		130					135					140					
35	Gln	Asp	Thr	Ser	Thr	Glu	Ala	Thr	Pro	Ser	Asn	Asn	Glu	Ser	Ala	Pro	
	145					150					155					160	
	Gln	Ser	Thr	Asp	Ala	Ser	Asn	Lys	Asp	Val	Val	Asn	Gln	Ala	Val	Asn	
40					165					170					175		
	Thr	Ser	Ala	Pro	Arg	Met	Arg	Ala	Phe	Ser	Leu	Ala	Ala	Val	Ala	Ala	
45				180					185					190			

EP 2 244 722 B1

	Asp	Ala	Pro	Ala	Ala	Gly	Thr	Asp	Ile	Thr	Asn	Gln	Leu	Thr	Asn	Val	
			195					200					205				
5	Thr	Val	Gly	Ile	Asp	Ser	Gly	Thr	Thr	Val	Tyr	Pro	His	Gln	Ala	Gly	
		210					215					220					
10	Tyr	Val	Lys	Leu	Asn	Tyr	Gly	Phe	Ser	Val	Pro	Asn	Ser	Ala	Val	Lys	
	225					230					235					240	
15	Gly	Asp	Thr	Phe	Lys	Ile	Thr	Val	Pro	Lys	Glu	Leu	Asn	Leu	Asn	Gly	
					245					250					255		
20	Val	Thr	Ser	Thr	Ala	Lys	Val	Pro	Pro	Ile	Met	Ala	Gly	Asp	Gln	Val	
				260					265					270			
25	Leu	Ala	Asn	Gly	Val	Ile	Asp	Ser	Asp	Gly	Asn	Val	Ile	Tyr	Thr	Phe	
		275						280					285				
30	Thr	Asp	Tyr	Val	Asn	Thr	Lys	Asp	Asp	Val	Lys	Ala	Thr	Leu	Thr	Met	
	290						295					300					
35	Ser	Ala	Ala	Ile	Asp	Pro	Glu	Asn	Val	Lys	Lys	Thr	Gly	Asn	Val	Thr	
	305					310					315					320	
40	Leu	Ala	Thr	Gly	Ile	Gly	Ser	Thr	Thr	Ala	Asn	Lys	Thr	Val	Leu	Val	
				325						330					335		
45	Asp	Tyr	Glu	Lys	Tyr	Gly	Lys	Phe	Tyr	Asn	Leu	Ser	Ile	Lys	Gly	Thr	
				340					345					350			
50	Ile	Asp	Gln	Ile	Asp	Lys	Thr	Asn	Asn	Thr	Tyr	Arg	Gln	Thr	Ile	Tyr	
		355						360					365				
55	Val	Asn	Pro	Ser	Gly	Asp	Asn	Val	Ile	Ala	Pro	Val	Leu	Thr	Gly	Asn	
	370						375					380					
60	Leu	Lys	Pro	Asn	Thr	Asp	Ser	Asn	Ala	Leu	Ile	Asp	Gln	Gln	Asn	Thr	
	385					390					395					400	
65	Ser	Ile	Lys	Val	Tyr	Lys	Val	Asp	Asn	Ala	Ala	Asp	Leu	Ser	Glu	Ser	
				405						410					415		
70	Tyr	Phe	Val	Asn	Pro	Glu	Asn	Phe	Glu	Asp	Val	Thr	Asn	Ser	Val	Asn	
				420					425					430			

EP 2 244 722 B1

	Ile	Thr	Phe	Pro	Asn	Pro	Asn	Gln	Tyr	Lys	Val	Glu	Phe	Asn	Thr	Pro	
			435					440					445				
5	Asp	Asp	Gln	Ile	Thr	Thr	Pro	Tyr	Ile	Val	Val	Val	Asn	Gly	His	Ile	
	450						455					460					
10	Asp	Pro	Asn	Ser	Lys	Gly	Asp	Leu	Ala	Leu	Arg	Ser	Thr	Leu	Tyr	Gly	
	465					470					475					480	
15	Tyr	Asn	Ser	Asn	Ile	Ile	Trp	Arg	Ser	Met	Ser	Trp	Asp	Asn	Glu	Val	
				485						490					495		
20	Ala	Phe	Asn	Asn	Gly	Ser	Gly	Ser	Gly	Asp	Gly	Ile	Asp	Lys	Pro	Val	
				500					505					510			
25	Val	Pro	Glu	Gln	Pro	Asp	Glu	Pro	Gly	Glu	Ile	Glu	Pro	Ile	Pro	Glu	
			515					520					525				
30	Lys	Leu															
		530															
	<210> 8																
	<211> 530																
	<212> PRT																
	<213> ARTIFICIAL																
	<220>																
	<223> wt rClfAPYII A region with additional N and C terminal residues																
35	<400> 8																
40	His	His	His	His	His	His	Gly	Ser	Ser	Glu	Asn	Ser	Val	Thr	Gln	Ser	
	1				5					10					15		
45	Asp	Ser	Ala	Ser	Asn	Glu	Ser	Lys	Ser	Asn	Asp	Ser	Ser	Ser	Val	Ser	
				20					25					30			
50	Ala	Ala	Pro	Lys	Thr	Asp	Asp	Thr	Asn	Val	Ser	Asp	Thr	Lys	Thr	Ser	
			35					40					45				
55	Ser	Asn	Thr	Asn	Asn	Gly	Glu	Thr	Ser	Val	Ala	Gln	Asn	Pro	Ala	Gln	
	50						55					60					
60	Gln	Glu	Thr	Thr	Gln	Ser	Ser	Ser	Thr	Asn	Ala	Thr	Thr	Glu	Glu	Thr	
	65				70						75					80	
65	Pro	Val	Thr	Gly	Glu	Ala	Thr	Thr	Thr	Thr	Thr	Asn	Gln	Ala	Asn	Thr	
					85					90					95		

EP 2 244 722 B1

	Pro	Ala	Thr	Thr	Gln	Ser	Ser	Asn	Thr	Asn	Ala	Glu	Glu	Leu	Val	Asn	
				100					105					110			
5	Gln	Thr	Ser	Asn	Glu	Thr	Thr	Phe	Asn	Asp	Thr	Asn	Thr	Val	Ser	Ser	
			115					120					125				
10	Val	Asn	Ser	Pro	Gln	Asn	Ser	Thr	Asn	Ala	Glu	Asn	Val	Ser	Thr	Thr	
		130					135					140					
15	Gln	Asp	Thr	Ser	Thr	Glu	Ala	Thr	Pro	Ser	Asn	Asn	Glu	Ser	Ala	Pro	
	145					150					155					160	
20	Gln	Ser	Thr	Asp	Ala	Ser	Asn	Lys	Asp	Val	Val	Asn	Gln	Ala	Val	Asn	
				165						170					175		
25	Thr	Ser	Ala	Pro	Arg	Met	Arg	Ala	Phe	Ser	Leu	Ala	Ala	Val	Ala	Ala	
				180					185					190			
30	Asp	Ala	Pro	Ala	Ala	Gly	Thr	Asp	Ile	Thr	Asn	Gln	Leu	Thr	Asn	Val	
			195					200					205				
35	Thr	Val	Gly	Ile	Asp	Ser	Gly	Thr	Thr	Val	Tyr	Pro	His	Gln	Ala	Gly	
	210						215					220					
40	Tyr	Val	Lys	Leu	Asn	Tyr	Gly	Phe	Ser	Val	Pro	Asn	Ser	Ala	Val	Lys	
	225					230					235					240	
45	Gly	Asp	Thr	Phe	Lys	Ile	Thr	Val	Pro	Lys	Glu	Leu	Asn	Leu	Asn	Gly	
				245						250				255			
50	Val	Thr	Ser	Thr	Ala	Lys	Val	Pro	Pro	Ile	Met	Ala	Gly	Asp	Gln	Val	
				260					265					270			
55	Leu	Ala	Asn	Gly	Val	Ile	Asp	Ser	Asp	Gly	Asn	Val	Ile	Tyr	Thr	Phe	
			275					280					285				
60	Thr	Asp	Tyr	Val	Asn	Thr	Lys	Asp	Asp	Val	Lys	Ala	Thr	Leu	Thr	Met	
	290						295					300					
65	Ala	Ala	Ser	Ile	Asp	Pro	Glu	Asn	Val	Lys	Lys	Thr	Gly	Asn	Val	Thr	
	305					310					315					320	
70	Leu	Ala	Thr	Gly	Ile	Gly	Ser	Thr	Thr	Ala	Asn	Lys	Thr	Val	Leu	Val	
				325						330					335		

EP 2 244 722 B1

	Asp	Tyr	Glu	Lys	Tyr	Gly	Lys	Phe	Tyr	Asn	Leu	Ser	Ile	Lys	Gly	Thr	
				340					345					350			
5	Ile	Asp	Gln	Ile	Asp	Lys	Thr	Asn	Asn	Thr	Tyr	Arg	Gln	Thr	Ile	Tyr	
			355					360					365				
10	Val	Asn	Pro	Ser	Gly	Asp	Asn	Val	Ile	Ala	Pro	Val	Leu	Thr	Gly	Asn	
		370					375					380					
15	Leu	Lys	Pro	Asn	Thr	Asp	Ser	Asn	Ala	Leu	Ile	Asp	Gln	Gln	Asn	Thr	
	385					390					395					400	
20	Ser	Ile	Lys	Val	Tyr	Lys	Val	Asp	Asn	Ala	Ala	Asp	Leu	Ser	Glu	Ser	
					405					410					415		
25	Tyr	Phe	Val	Asn	Pro	Glu	Asn	Phe	Glu	Asp	Val	Thr	Asn	Ser	Val	Asn	
				420					425					430			
30	Ile	Thr	Phe	Pro	Asn	Pro	Asn	Gln	Tyr	Lys	Val	Glu	Phe	Asn	Thr	Pro	
			435					440					445				
35	Asp	Asp	Gln	Ile	Thr	Thr	Pro	Tyr	Ile	Val	Val	Val	Asn	Gly	His	Ile	
	450						455					460					
40	Asp	Pro	Asn	Ser	Lys	Gly	Asp	Leu	Ala	Leu	Arg	Ser	Thr	Leu	Tyr	Gly	
	465					470					475					480	
45	Tyr	Asn	Ser	Asn	Ile	Ile	Trp	Arg	Ser	Met	Ser	Trp	Asp	Asn	Glu	Val	
					485					490					495		
50	Ala	Phe	Asn	Asn	Gly	Ser	Gly	Ser	Gly	Asp	Gly	Ile	Asp	Lys	Pro	Val	
				500					505					510			
55	Val	Pro	Glu	Gln	Pro	Asp	Glu	Pro	Gly	Glu	Ile	Glu	Pro	Ile	Pro	Glu	
			515					520					525				
60	Lys	Leu															
		530															
65	<210>	9															
70	<211>	339															
75	<212>	PRT															
80	<213>	ARTIFICIAL															
85	<220>																
90	<223>	rClfA residues 221-559															
95	<400>	9															

EP 2 244 722 B1

	Val	Ala	Ala	Asp	Ala	Pro	Ala	Ala	Gly	Thr	Asp	Ile	Thr	Asn	Gln	Leu	
	1				5					10					15		
5	Thr	Asn	Val	Thr	Val	Gly	Ile	Asp	Ser	Gly	Thr	Thr	Val	Tyr	Pro	His	
				20				25						30			
10	Gln	Ala	Gly	Tyr	Val	Lys	Leu	Asn	Tyr	Gly	Phe	Ser	Val	Pro	Asn	Ser	
			35					40					45				
15	Ala	Val	Lys	Gly	Asp	Thr	Phe	Lys	Ile	Thr	Val	Pro	Lys	Glu	Leu	Asn	
		50					55					60					
20	Leu	Asn	Gly	Val	Thr	Ser	Thr	Ala	Lys	Val	Pro	Pro	Ile	Met	Ala	Gly	
	65					70					75					80	
25	Asp	Gln	Val	Leu	Ala	Asn	Gly	Val	Ile	Asp	Ser	Asp	Gly	Asn	Val	Ile	
					85					90					95		
30	Tyr	Thr	Phe	Thr	Asp	Tyr	Val	Asn	Thr	Lys	Asp	Asp	Val	Lys	Ala	Thr	
				100					105					110			
35	Leu	Thr	Met	Pro	Ala	Tyr	Ile	Asp	Pro	Glu	Asn	Val	Lys	Lys	Thr	Gly	
			115					120					125				
40	Asn	Val	Thr	Leu	Ala	Thr	Gly	Ile	Gly	Ser	Thr	Thr	Ala	Asn	Lys	Thr	
		130					135					140					
45	Val	Leu	Val	Asp	Tyr	Glu	Lys	Tyr	Gly	Lys	Phe	Tyr	Asn	Leu	Ser	Ile	
	145					150					155					160	
50	Lys	Gly	Thr	Ile	Asp	Gln	Ile	Asp	Lys	Thr	Asn	Asn	Thr	Tyr	Arg	Gln	
					165					170					175		
55	Thr	Ile	Tyr	Val	Asn	Pro	Ser	Gly	Asp	Asn	Val	Ile	Ala	Pro	Val	Leu	
				180					185					190			
60	Thr	Gly	Asn	Leu	Lys	Pro	Asn	Thr	Asp	Ser	Asn	Ala	Leu	Ile	Asp	Gln	
			195					200					205				
65	Gln	Asn	Thr	Ser	Ile	Lys	Val	Tyr	Lys	Val	Asp	Asn	Ala	Ala	Asp	Leu	
		210					215					220					
70	Ser	Glu	Ser	Tyr	Phe	Val	Asn	Pro	Glu	Asn	Phe	Glu	Asp	Val	Thr	Asn	
	225					230					235					240	

EP 2 244 722 B1

	Ser	Val	Asn	Ile	Thr	Phe	Pro	Asn	Pro	Asn	Gln	Tyr	Lys	Val	Glu	Phe	
					245					250					255		
5	Asn	Thr	Pro	Asp	Asp	Gln	Ile	Thr	Thr	Pro	Tyr	Ile	Val	Val	Val	Asn	
				260					265					270			
10	Gly	His	Ile	Asp	Pro	Asn	Ser	Lys	Gly	Asp	Leu	Ala	Leu	Arg	Ser	Thr	
			275					280					285				
15	Leu	Tyr	Gly	Tyr	Asn	Ser	Asn	Ile	Ile	Trp	Arg	Ser	Met	Ser	Trp	Asp	
		290					295					300					
20	Asn	Glu	Val	Ala	Phe	Asn	Asn	Gly	Ser	Gly	Ser	Gly	Asp	Gly	Ile	Asp	
	305					310					315					320	
25	Lys	Pro	Val	Val	Pro	Glu	Gln	Pro	Asp	Glu	Pro	Gly	Glu	Ile	Glu	Pro	
					325					330					335		
30	Ile	Pro	Glu														
35																	
40																	
45																	
50																	
55																	

<210> 10
 <211> 349
 <212> PRT
 <213> ARTIFICIAL
 <220>
 <223> rClfA residues 221 to 559 with additional N and C terminal residues
 <400> 10

	His	His	His	His	His	His	Gly	Ser	Val	Ala	Ala	Asp	Ala	Pro	Ala	Ala	
	1				5					10					15		
40	Gly	Thr	Asp	Ile	Thr	Asn	Gln	Leu	Thr	Asn	Val	Thr	Val	Gly	Ile	Asp	
				20					25					30			
45	Ser	Gly	Thr	Thr	Val	Tyr	Pro	His	Gln	Ala	Gly	Tyr	Val	Lys	Leu	Asn	
			35					40					45				
50	Tyr	Gly	Phe	Ser	Val	Pro	Asn	Ser	Ala	Val	Lys	Gly	Asp	Thr	Phe	Lys	
		50					55					60					
55	Ile	Thr	Val	Pro	Lys	Glu	Leu	Asn	Leu	Asn	Gly	Val	Thr	Ser	Thr	Ala	
	65					70					75					80	
60	Lys	Val	Pro	Pro	Ile	Met	Ala	Gly	Asp	Gln	Val	Leu	Ala	Asn	Gly	Val	
					85					90					95		

EP 2 244 722 B1

	Ile	Asp	Ser	Asp	Gly	Asn	Val	Ile	Tyr	Thr	Phe	Thr	Asp	Tyr	Val	Asn
				100					105					110		
5	Thr	Lys	Asp	Asp	Val	Lys	Ala	Thr	Leu	Thr	Met	Pro	Ala	Tyr	Ile	Asp
			115					120					125			
10	Pro	Glu	Asn	Val	Lys	Lys	Thr	Gly	Asn	Val	Thr	Leu	Ala	Thr	Gly	Ile
		130					135					140				
15	Gly	Ser	Thr	Thr	Ala	Asn	Lys	Thr	Val	Leu	Val	Asp	Tyr	Glu	Lys	Tyr
	145					150					155					160
	Gly	Lys	Phe	Tyr	Asn	Leu	Ser	Ile	Lys	Gly	Thr	Ile	Asp	Gln	Ile	Asp
					165					170					175	
20	Lys	Thr	Asn	Asn	Thr	Tyr	Arg	Gln	Thr	Ile	Tyr	Val	Asn	Pro	Ser	Gly
				180					185					190		
25	Asp	Asn	Val	Ile	Ala	Pro	Val	Leu	Thr	Gly	Asn	Leu	Lys	Pro	Asn	Thr
			195					200					205			
30	Asp	Ser	Asn	Ala	Leu	Ile	Asp	Gln	Gln	Asn	Thr	Ser	Ile	Lys	Val	Tyr
		210					215					220				
	Lys	Val	Asp	Asn	Ala	Ala	Asp	Leu	Ser	Glu	Ser	Tyr	Phe	Val	Asn	Pro
	225					230					235					240
35	Glu	Asn	Phe	Glu	Asp	Val	Thr	Asn	Ser	Val	Asn	Ile	Thr	Phe	Pro	Asn
				245						250					255	
40	Pro	Asn	Gln	Tyr	Lys	Val	Glu	Phe	Asn	Thr	Pro	Asp	Asp	Gln	Ile	Thr
				260					265					270		
45	Thr	Pro	Tyr	Ile	Val	Val	Val	Asn	Gly	His	Ile	Asp	Pro	Asn	Ser	Lys
			275					280					285			
	Gly	Asp	Leu	Ala	Leu	Arg	Ser	Thr	Leu	Tyr	Gly	Tyr	Asn	Ser	Asn	Ile
		290					295					300				
50	Ile	Trp	Arg	Ser	Met	Ser	Trp	Asp	Asn	Glu	Val	Ala	Phe	Asn	Asn	Gly
	305					310					315					320
55	Ser	Gly	Ser	Gly	Asp	Gly	Ile	Asp	Lys	Pro	Val	Val	Pro	Glu	Gln	Pro
					325					330					335	

EP 2 244 722 B1

Asp Glu Pro Gly Glu Ile Glu Pro Ile Pro Glu Lys Leu
340 345

5 <210> 11
<211> 339
<212> PRT
<213> ARTIFICIAL

10 <220>
<223> rClfA PY 221 to 559

<400> 11

15 Val Ala Ala Asp Ala Pro Ala Ala Gly Thr Asp Ile Thr Asn Gln Leu
1 5 10 15

20 Thr Asn Val Thr Val Gly Ile Asp Ser Gly Thr Thr Val Tyr Pro His
20 25 30

Gln Ala Gly Tyr Val Lys Leu Asn Tyr Gly Phe Ser Val Pro Asn Ser
35 40 45

25 Ala Val Lys Gly Asp Thr Phe Lys Ile Thr Val Pro Lys Glu Leu Asn
50 55 60

30 Leu Asn Gly Val Thr Ser Thr Ala Lys Val Pro Pro Ile Met Ala Gly
65 70 75 80

35 Asp Gln Val Leu Ala Asn Gly Val Ile Asp Ser Asp Gly Asn Val Ile
85 90 95

Tyr Thr Phe Thr Asp Tyr Val Asn Thr Lys Asp Asp Val Lys Ala Thr
100 105 110

40 Leu Thr Met Ser Ala Ala Ile Asp Pro Glu Asn Val Lys Lys Thr Gly
115 120 125

45 Asn Val Thr Leu Ala Thr Gly Ile Gly Ser Thr Thr Ala Asn Lys Thr
130 135 140

50 Val Leu Val Asp Tyr Glu Lys Tyr Gly Lys Phe Tyr Asn Leu Ser Ile
145 150 155 160

Lys Gly Thr Ile Asp Gln Ile Asp Lys Thr Asn Asn Thr Tyr Arg Gln
165 170 175

55 Thr Ile Tyr Val Asn Pro Ser Gly Asp Asn Val Ile Ala Pro Val Leu
180 185 190

EP 2 244 722 B1

	Thr	Gly	Asn	Leu	Lys	Pro	Asn	Thr	Asp	Ser	Asn	Ala	Leu	Ile	Asp	Gln	
			195					200					205				
5	Gln	Asn	Thr	Ser	Ile	Lys	Val	Tyr	Lys	Val	Asp	Asn	Ala	Ala	Asp	Leu	
		210					215					220					
10	Ser	Glu	Ser	Tyr	Phe	Val	Asn	Pro	Glu	Asn	Phe	Glu	Asp	Val	Thr	Asn	
	225					230					235					240	
15	Ser	Val	Asn	Ile	Thr	Phe	Pro	Asn	Pro	Asn	Gln	Tyr	Lys	Val	Glu	Phe	
				245						250					255		
20	Asn	Thr	Pro	Asp	Asp	Gln	Ile	Thr	Thr	Pro	Tyr	Ile	Val	Val	Val	Asn	
				260					265					270			
25	Gly	His	Ile	Asp	Pro	Asn	Ser	Lys	Gly	Asp	Leu	Ala	Leu	Arg	Ser	Thr	
			275					280					285				
30	Leu	Tyr	Gly	Tyr	Asn	Ser	Asn	Ile	Ile	Trp	Arg	Ser	Met	Ser	Trp	Asp	
	290						295					300					
35	Asn	Glu	Val	Ala	Phe	Asn	Asn	Gly	Ser	Gly	Ser	Gly	Asp	Gly	Ile	Asp	
	305					310					315					320	
40	Lys	Pro	Val	Val	Pro	Glu	Gln	Pro	Asp	Glu	Pro	Gly	Glu	Ile	Glu	Pro	
					325					330					335		
45	Ile	Pro	Glu														
	<210>	12															
	<211>	349															
	<212>	PRT															
	<213>	ARTIFICIAL															
	<220>																
	<223>	rClfA PY 221 to 559 with additional N and C terminal residues															
50	<400>	12															
55	His	His	His	His	His	His	Gly	Ser	Val	Ala	Ala	Asp	Ala	Pro	Ala	Ala	
	1				5					10					15		
60	Gly	Thr	Asp	Ile	Thr	Asn	Gln	Leu	Thr	Asn	Val	Thr	Val	Gly	Ile	Asp	
			20					25						30			
65	Ser	Gly	Thr	Thr	Val	Tyr	Pro	His	Gln	Ala	Gly	Tyr	Val	Lys	Leu	Asn	

EP 2 244 722 B1

	35	40	45
5	Tyr Gly Phe Ser Val Pro Asn Ser Ala Val Lys Gly Asp Thr Phe Lys 50 55 60		
10	Ile Thr Val Pro Lys Glu Leu Asn Leu Asn Gly Val Thr Ser Thr Ala 65 70 75 80		
15	Lys Val Pro Pro Ile Met Ala Gly Asp Gln Val Leu Ala Asn Gly Val 85 90 95		
20	Ile Asp Ser Asp Gly Asn Val Ile Tyr Thr Phe Thr Asp Tyr Val Asn 100 105 110		
25	Thr Lys Asp Asp Val Lys Ala Thr Leu Thr Met Ser Ala Ala Ile Asp 115 120 125		
30	Pro Glu Asn Val Lys Lys Thr Gly Asn Val Thr Leu Ala Thr Gly Ile 130 135 140		
35	Gly Ser Thr Thr Ala Asn Lys Thr Val Leu Val Asp Tyr Glu Lys Tyr 145 150 155 160		
40	Gly Lys Phe Tyr Asn Leu Ser Ile Lys Gly Thr Ile Asp Gln Ile Asp 165 170 175		
45	Lys Thr Asn Asn Thr Tyr Arg Gln Thr Ile Tyr Val Asn Pro Ser Gly 180 185 190		
50	Asp Asn Val Ile Ala Pro Val Leu Thr Gly Asn Leu Lys Pro Asn Thr 195 200 205		
55	Asp Ser Asn Ala Leu Ile Asp Gln Gln Asn Thr Ser Ile Lys Val Tyr 210 215 220		
	Lys Val Asp Asn Ala Ala Asp Leu Ser Glu Ser Tyr Phe Val Asn Pro 225 230 235 240		
	Glu Asn Phe Glu Asp Val Thr Asn Ser Val Asn Ile Thr Phe Pro Asn 245 250 255		
	Pro Asn Gln Tyr Lys Val Glu Phe Asn Thr Pro Asp Asp Gln Ile Thr 260 265 270		
	Thr Pro Tyr Ile Val Val Val Asn Gly His Ile Asp Pro Asn Ser Lys 275 280 285		

EP 2 244 722 B1

	Gly	Asp	Leu	Ala	Leu	Arg	Ser	Thr	Leu	Tyr	Gly	Tyr	Asn	Ser	Asn	Ile
	290						295					300				
5	Ile	Trp	Arg	Ser	Met	Ser	Trp	Asp	Asn	Glu	Val	Ala	Phe	Asn	Asn	Gly
	305					310				315						320
10	Ser	Gly	Ser	Gly	Asp	Gly	Ile	Asp	Lys	Pro	Val	Val	Pro	Glu	Gln	Pro
					325					330					335	
15	Asp	Glu	Pro	Gly	Glu	Ile	Glu	Pro	Ile	Pro	Glu	Lys	Leu			
				340					345							
20	<210> 13															
	<211> 321															
	<212> PRT															
	<213> ARTIFICIAL															
25	<220>															
	<223> rClfA residues 221 to 531 with additional N and C terminal residues (delta latch truncate)															
	<400> 13															
30	His	His	His	His	His	His	Gly	Ser	Val	Ala	Ala	Asp	Ala	Pro	Ala	Ala
	1				5					10					15	
35	Gly	Thr	Asp	Ile	Thr	Asn	Gln	Leu	Thr	Asn	Val	Thr	Val	Gly	Ile	Asp
				20					25					30		
40	Ser	Gly	Thr	Thr	Val	Tyr	Pro	His	Gln	Ala	Gly	Tyr	Val	Lys	Leu	Asn
			35					40					45			
45	Tyr	Gly	Phe	Ser	Val	Pro	Asn	Ser	Ala	Val	Lys	Gly	Asp	Thr	Phe	Lys
	50						55					60				
50	Ile	Thr	Val	Pro	Lys	Glu	Leu	Asn	Leu	Asn	Gly	Val	Thr	Ser	Thr	Ala
	65					70					75					80
55	Lys	Val	Pro	Pro	Ile	Met	Ala	Gly	Asp	Gln	Val	Leu	Ala	Asn	Gly	Val
					85					90					95	
	Ile	Asp	Ser	Asp	Gly	Asn	Val	Ile	Tyr	Thr	Phe	Thr	Asp	Tyr	Val	Asn
				100					105					110		
	Thr	Lys	Asp	Asp	Val	Lys	Ala	Thr	Leu	Thr	Met	Pro	Ala	Tyr	Ile	Asp
			115					120					125			

EP 2 244 722 B1

	Pro	Glu	Asn	Val	Lys	Lys	Thr	Gly	Asn	Val	Thr	Leu	Ala	Thr	Gly	Ile	
	130						135					140					
5	Gly	Ser	Thr	Thr	Ala	Asn	Lys	Thr	Val	Leu	Val	Asp	Tyr	Glu	Lys	Tyr	
	145					150					155					160	
10	Gly	Lys	Phe	Tyr	Asn	Leu	Ser	Ile	Lys	Gly	Thr	Ile	Asp	Gln	Ile	Asp	
					165					170					175		
15	Lys	Thr	Asn	Asn	Thr	Tyr	Arg	Gln	Thr	Ile	Tyr	Val	Asn	Pro	Ser	Gly	
				180					185					190			
20	Asp	Asn	Val	Ile	Ala	Pro	Val	Leu	Thr	Gly	Asn	Leu	Lys	Pro	Asn	Thr	
			195					200					205				
25	Asp	Ser	Asn	Ala	Leu	Ile	Asp	Gln	Gln	Asn	Thr	Ser	Ile	Lys	Val	Tyr	
	210						215					220					
30	Lys	Val	Asp	Asn	Ala	Ala	Asp	Leu	Ser	Glu	Ser	Tyr	Phe	Val	Asn	Pro	
	225					230					235					240	
35	Glu	Asn	Phe	Glu	Asp	Val	Thr	Asn	Ser	Val	Asn	Ile	Thr	Phe	Pro	Asn	
				245						250					255		
40	Pro	Asn	Gln	Tyr	Lys	Val	Glu	Phe	Asn	Thr	Pro	Asp	Asp	Gln	Ile	Thr	
				260					265					270			
45	Thr	Pro	Tyr	Ile	Val	Val	Val	Asn	Gly	His	Ile	Asp	Pro	Asn	Ser	Lys	
			275					280					285				
50	Gly	Asp	Leu	Ala	Leu	Arg	Ser	Thr	Leu	Tyr	Gly	Tyr	Asn	Ser	Asn	Ile	
	290						295					300					
55	Ile	Trp	Arg	Ser	Met	Ser	Trp	Asp	Asn	Glu	Val	Ala	Phe	Asn	Asn	Arg	
	305					310					315					320	
	Ser																
	<210>	14															
	<211>	311															
	<212>	PRT															
	<213>	ARTIFICIAL															
	<220>																
	<223>	rClfA residues 221 to 531 (delta latch truncate)															
	<400>	14															

EP 2 244 722 B1

	Val	Ala	Ala	Asp	Ala	Pro	Ala	Ala	Gly	Thr	Asp	Ile	Thr	Asn	Gln	Leu	
	1				5					10					15		
5	Thr	Asn	Val	Thr	Val	Gly	Ile	Asp	Ser	Gly	Thr	Thr	Val	Tyr	Pro	His	
				20				25						30			
10	Gln	Ala	Gly	Tyr	Val	Lys	Leu	Asn	Tyr	Gly	Phe	Ser	Val	Pro	Asn	Ser	
			35					40					45				
15	Ala	Val	Lys	Gly	Asp	Thr	Phe	Lys	Ile	Thr	Val	Pro	Lys	Glu	Leu	Asn	
		50					55					60					
20	Leu	Asn	Gly	Val	Thr	Ser	Thr	Ala	Lys	Val	Pro	Pro	Ile	Met	Ala	Gly	
	65					70					75					80	
25	Asp	Gln	Val	Leu	Ala	Asn	Gly	Val	Ile	Asp	Ser	Asp	Gly	Asn	Val	Ile	
				85						90					95		
30	Tyr	Thr	Phe	Thr	Asp	Tyr	Val	Asn	Thr	Lys	Asp	Asp	Val	Lys	Ala	Thr	
				100					105					110			
35	Leu	Thr	Met	Pro	Ala	Tyr	Ile	Asp	Pro	Glu	Asn	Val	Lys	Lys	Thr	Gly	
			115					120					125				
40	Asn	Val	Thr	Leu	Ala	Thr	Gly	Ile	Gly	Ser	Thr	Thr	Ala	Asn	Lys	Thr	
		130					135						140				
45	Val	Leu	Val	Asp	Tyr	Glu	Lys	Tyr	Gly	Lys	Phe	Tyr	Asn	Leu	Ser	Ile	
	145					150					155					160	
50	Lys	Gly	Thr	Ile	Asp	Gln	Ile	Asp	Lys	Thr	Asn	Asn	Thr	Tyr	Arg	Gln	
				165						170					175		
55	Thr	Ile	Tyr	Val	Asn	Pro	Ser	Gly	Asp	Asn	Val	Ile	Ala	Pro	Val	Leu	
				180					185					190			
60	Thr	Gly	Asn	Leu	Lys	Pro	Asn	Thr	Asp	Ser	Asn	Ala	Leu	Ile	Asp	Gln	
			195					200					205				
65	Gln	Asn	Thr	Ser	Ile	Lys	Val	Tyr	Lys	Val	Asp	Asn	Ala	Ala	Asp	Leu	
		210					215					220					
70	Ser	Glu	Ser	Tyr	Phe	Val	Asn	Pro	Glu	Asn	Phe	Glu	Asp	Val	Thr	Asn	
	225					230					235					240	

Ser Val Asn Ile Thr Phe Pro Asn Pro Asn Gln Tyr Lys Val Glu Phe
245 250 255

Asn Thr Pro Asp Asp Gln Ile Thr Thr Pro Tyr Ile Val Val Val Asn
260 265 270

Gly His Ile Asp Pro Asn Ser Lys Gly Asp Leu Ala Leu Arg Ser Thr
275 280 285

Leu Tyr Gly Tyr Asn Ser Asn Ile Ile Trp Arg Ser Met Ser Trp Asp
290 295 300

Asn Glu Val Ala Phe Asn Asn
305 310

Claims

1. A recombinant staphylococcal clumping factor A (ClfA) according to SEQ ID No. 1 or a sequence with at least 85%, preferably at least 95% sequence identity to the sequence of SEQ ID No. 1 or fragment thereof comprising at least amino acid residues 221 to 531 of the fibrinogen binding region (Region A), **characterized by** at least one amino acid residue substitution or deletion at amino acid residue Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527 to result in a recombinant fibrinogen binding protein with reduced ability or lacking the ability to non-covalently bind fibrinogen which stimulates a greater immune response than the wild type ClfA protein, for use in the treatment or prophylaxis of Staphylococcal infections.
2. The recombinant staphylococcal clumping factor A (ClfA) or fragment thereof for use in the treatment or prophylaxis of Staphylococcal infections according to claim 1 wherein the infection is a *Staphylococcus aureus* infection.
3. The recombinant staphylococcal clumping factor A (ClfA) or fragment thereof for use in the treatment or prophylaxis of Staphylococcal infections according to claim 1 wherein the infection is a sepsis, septic arthritis and/or endocarditis.
4. The recombinant staphylococcal clumping factor A (ClfA) or fragment thereof for use in the treatment or prophylaxis of Staphylococcal infections according to any of claims 1 to 3 wherein the recombinant staphylococcal clumping factor A (ClfA) or fragment thereof comprises the amino acid sequence according to any of SEQ ID Nos. 3, 6, 9, 10 and 13 or sequences with at least 85%, preferably at least 95% sequence identity to a sequence of SEQ ID Nos. 3, 6, 9, 10 and 13 with at least one amino acid residue substitution or deletion at amino acid residues Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527.
5. The recombinant staphylococcal clumping factor A (ClfA) or fragment thereof for use in the treatment or prophylaxis of Staphylococcal infections according to any of claims 1 to 4 wherein the ClfA or fragment thereof comprises at least one amino acid residue substitution at amino acid residues Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527.
6. The recombinant staphylococcal clumping factor A (ClfA) or fragment thereof for use in the treatment or prophylaxis of Staphylococcal infections according to any of claims 1 to 5 wherein the ClfA or fragment thereof comprises at least one amino acid residue substitution at amino acid residues Tyr256, Pro336, Tyr338, Lys389, Glu526 and/or Val527.
7. The recombinant staphylococcal clumping factor A (ClfA) or fragment thereof, for use in the treatment or prophylaxis of Staphylococcal infections according to any of claims 1 to 6 wherein the non-covalent binding that takes place during dock, lock and latching of the protein to fibrinogen is reduced or prevented.
8. The recombinant staphylococcal clumping factor A (ClfA) for use in the treatment or prophylaxis of Staphylococcal

infections according to any of the preceding claims wherein the amino acid substitution or deletion reduces the non-covalent interaction with fibrinogen by preventing or reducing ligand binding to the hydrophobic pocket separating Region A subregions N2 and N3 of the fibrinogen binding protein.

- 5 **9.** The recombinant staphylococcal clumping factor A (ClfA) for use in the treatment or prophylaxis of Staphylococcal infections according to any of the preceding claims wherein the ClfA or fragment thereof comprises the fibrinogen binding region without the latching peptide amino acid residues.
- 10 **10.** The recombinant staphylococcal clumping factor A (ClfA) for use in the treatment or prophylaxis of Staphylococcal infections according to any of the preceding claims wherein the ClfA or fragment thereof comprises amino acid residues Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527 which are substituted with either Ala or Ser.
- 15 **11.** The recombinant staphylococcal clumping factor A (ClfA) for use in the treatment or prophylaxis of Staphylococcal infections according to any of the preceding claims wherein the recombinant Staphylococcal fibrinogen binding protein has the amino acid sequence according to any of SEQ ID Nos. 1 and 3 to 14 wherein residue P₃₃₆ and/or Y₃₃₈ of SEQ ID Nos. 1, 3, 6, 9, 10 and 13 are substituted with either serine and/or alanine to result in rClfAP₃₃₆S Y₃₃₈A or rClfAP₃₃₆A Y₃₃₈S.
- 20 **12.** The recombinant staphylococcal clumping factor A (ClfA) for use in the treatment or prophylaxis of Staphylococcal infections according to any of the preceding claims wherein the ClfA or fragment thereof comprises the fibrinogen binding protein, the fibrinogen binding region, the minimal fibrinogen binding region and/or a fragment thereof.
- 25 **13.** The recombinant staphylococcal clumping factor A (ClfA) for use in the treatment or prophylaxis of Staphylococcal infections according to any of the preceding claims wherein the ClfA or fragment thereof comprises

 Subregions N1 to N3, spanning amino acid residues 40 to 559 of the fibrinogen binding region (Region A); or
 Subregions N2 and N3, spanning amino acid residues 221 to 559 of the fibrinogen binding region of ClfA (Region A).
- 30 **14.** Use of the recombinant staphylococcal clumping factor A (ClfA) according to SEQ ID No. 1 or a sequence with at least 85%, preferably at least 95% sequence identity to the sequence of SEQ ID No. 1 or fragment thereof comprising at least amino acid residues 221 to 531 of the fibrinogen binding region (Region A), with at least one amino acid residue substitution or deletion at amino acid residues Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527 to result in a recombinant fibrinogen binding protein with reduced ability or lacking the ability to non-covalently bind fibrinogen which stimulates a greater immune response than the wild type ClfA protein in the manufacture of a medicament for the treatment or prophylaxis of Staphylococcal infections.
- 35 **15.** A nucleic acid construct, expression vector or host cell expressing a recombinant staphylococcal clumping factor A (ClfA) according to SEQ ID No. 1 or a sequence with at least 85%, preferably at least 95% sequence identity to the sequence of SEQ ID No. 1 or fragment thereof comprising at least amino acid residues 221 to 531 of the fibrinogen binding region (Region A), with at least one amino acid residue substitution or deletion at amino acid residue Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527 to result in a recombinant fibrinogen binding protein with reduced ability or lacking the ability to non-covalently bind fibrinogen which stimulates a greater immune response than the wild type ClfA protein, for use in the treatment or prophylaxis of Staphylococcal infections.
- 40 **16.** A vaccine comprising a recombinant staphylococcal clumping factor A (ClfA) according to SEQ ID No. 1 or a sequence with at least 85%, preferably at least 95% sequence identity to the sequence of SEQ ID No. 1 or fragment thereof comprising at least amino acid residues 221 to 531 of the fibrinogen binding region (Region A), with at least one amino acid residue substitution or deletion at amino acid residue Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527 to result in a recombinant fibrinogen binding protein with reduced ability or lacking the ability to non-covalently bind fibrinogen which stimulates a greater immune response than the wild type ClfA protein, for use in the treatment or prophylaxis of Staphylococcal infections.
- 45 **17.** An immunogenic pharmaceutical composition comprising a recombinant staphylococcal clumping factor A (ClfA) according to SEQ ID No. 1 or a sequence with at least 85%, preferably at least 95% sequence identity to the sequence of SEQ ID No. 1 or fragment thereof comprising at least amino acid residues 221 to 531 of the fibrinogen binding region (Region A), with at least one amino acid residue substitution or deletion at amino acid residue Ala254,
- 50
- 55

Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527 to result in a recombinant fibrinogen binding protein with reduced ability or lacking the ability to non-covalently bind fibrinogen which stimulates a greater immune response than the wild type ClfA protein, and a pharmaceutically acceptable adjuvant for use in the treatment or prophylaxis of Staphylococcal infections.

5

Patentansprüche

1. Rekombinanter Staphylokokken-Verklumpungsfaktor A (ClfA) gemäß SEQ.-ID-Nr. 1 oder einer Sequenz mit mindestens 85 %, bevorzugt mindestens 95 % Sequenzidentität mit der Sequenz von SEQ.-ID-Nr. 1, oder ein Fragment davon, der/das mindestens die Aminosäurereste 221 bis 531 der Fibrinogenbindungsregion (Region A) umfasst, **gekennzeichnet durch** mindestens eine Aminosäurerest-Substitution oder -Deletion am Aminosäurerest Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 und/oder Val527, um zu einem rekombinanten Fibrinogenbindungsprotein mit reduzierter Fähigkeit oder fehlender Fähigkeit zur nichtkovalenten Bindung von Fibrinogen zu führen, was eine größere Immunreaktion stimuliert als das Wildtyp-ClfA-Protein, für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen.
2. Rekombinanter Staphylokokken-Verklumpungsfaktor A (ClfA) oder Fragment davon für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen nach Anspruch 1, wobei die Infektion eine Infektion mit *Staphylococcus aureus* ist.
3. Rekombinanter Staphylokokken-Verklumpungsfaktor A (ClfA) oder Fragment davon für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen nach Anspruch 1, wobei die Infektion eine Sepsis, septische Arthritis und/oder Endokarditis ist.
4. Rekombinanter Staphylokokken-Verklumpungsfaktor A (ClfA) oder Fragment davon für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen nach einem der Ansprüche 1 bis 3, wobei der rekombinante Staphylokokken-Verklumpungsfaktor A (ClfA) oder das Fragment davon die Aminosäuresequenz gemäß einer der SEQ.-ID-Nr. 3, 6, 9, 10 und 13 oder Sequenzen mit mindestens 85 %, bevorzugt mindestens 95 % Sequenzidentität mit einer Sequenz der SEQ.-ID-Nr. 3, 6, 9, 10 und 13 mit mindestens einer Aminosäurerest-Substitution oder -Deletion an den Aminosäureresten Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 und/oder Val527 umfasst.
5. Rekombinanter Staphylokokken-Verklumpungsfaktor A (ClfA) oder Fragment davon für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen nach einem der Ansprüche 1 bis 4, wobei der ClfA oder das Fragment davon mindestens eine Aminosäurerest-Substitution an den Aminosäureresten Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 und/oder Val527 umfasst.
6. Rekombinanter Staphylokokken-Verklumpungsfaktor (ClfA) oder Fragment davon für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen nach einem der Ansprüche 1 bis 5, wobei der ClfA oder das Fragment davon mindestens eine Aminosäurerest-Substitution an den Aminosäureresten Tyr256, Pro336, Tyr338, Lys389, Glu526 und/oder Val527 umfasst.
7. Rekombinanter Staphylokokken-Verklumpungsfaktor A (ClfA) oder Fragment davon für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen nach einem der Ansprüche 1 bis 6, wobei die nichtkovalente Bindung, die während der Vorgänge des Annäherns, Festhaltens und Einklemmens des Proteins mit Fibrinogen stattfindet, reduziert oder verhindert ist.
8. Rekombinanter Staphylokokken-Verklumpungsfaktor A (ClfA) für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen nach einem der vorstehenden Ansprüche, wobei die Aminosäuresubstitution oder -deletion die nichtkovalente Wechselwirkung mit Fibrinogen durch Verhinderung oder Reduzierung von Ligandenbindung zu der hydrophoben Tasche, die die Unterregionen N2 und N3 der Region A des Fibrinogenbindungsproteins trennt, reduziert.
9. Rekombinanter Staphylokokken-Verklumpungsfaktor A (ClfA) für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen nach einem der vorstehenden Ansprüche, wobei der ClfA oder das Fragment davon die Fibrinogenbindungsregion ohne die einklemmenden Peptid-Aminosäurereste umfasst.

10. Rekombinanter Staphylokokken-Verklumpungsfaktor A (ClfA) für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen nach einem der vorstehenden Ansprüche, wobei der ClfA oder das Fragment davon die Aminosäurereste Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 und/oder Val527 umfasst, die mit entweder Ala oder Ser substituiert sind.

11. Rekombinanter Staphylokokken-Verklumpungsfaktor A (ClfA) für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen nach einem der vorstehenden Ansprüche, wobei das rekombinante Staphylokokken-Fibrinogenbindungsprotein die Aminosäuresequenz gemäß einer der SEQ.-ID-Nr. 1 und 3 bis 14 aufweist, wobei Rest P₃₃₆ und/oder Y₃₃₈ der SEQ.-ID-Nr. 1, 3, 6, 9, 10 und 13 mit entweder Serin und/oder Alanin substituiert sind, um zu rClfAP₃₃₆S Y₃₃₈A oder rClfAP₃₃₆A Y₃₃₈S zu führen.

12. Rekombinanter Staphylokokken-Verklumpungsfaktor A (ClfA) für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen nach einem der vorstehenden Ansprüche, wobei der ClfA oder das Fragment davon das Fibrinogenbindungsprotein, die Fibrinogenbindungsregion, die minimale Fibrinogenbindungsregion und/oder ein Fragment davon umfasst.

13. Rekombinanter Staphylokokken-Verklumpungsfaktor A (ClfA) für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen nach einem der vorstehenden Ansprüche, wobei der ClfA oder das Fragment davon Folgendes umfasst:

Unterregionen N1 bis N3, die die Aminosäurereste 40 bis 559 der Fibrinogenbindungsregion (Region A) umfassen; oder

Unterregionen N2 und N3, die die Aminosäurereste 221 bis 559 der Fibrinogenbindungsregion von ClfA (Region A) umfassen.

14. Verwendung des rekombinanten Staphylokokken-Verklumpungsfaktors A (ClfA) gemäß SEQ.-ID-Nr. 1 oder einer Sequenz mit mindestens 85 %, bevorzugt mindestens 95 % Sequenzidentität mit der Sequenz von SEQ.-ID-Nr. 1, oder des Fragments davon, der/das mindestens die Aminosäurereste 221 bis 531 der Fibrinogenbindungsregion (Region A) mit mindestens einer Aminosäurerest-Substitution oder -Deletion an den Aminosäureresten Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 und/oder Val527 umfasst, um zu einem rekombinanten Fibrinogenbindungsprotein mit reduzierter Fähigkeit oder fehlender Fähigkeit zur nichtkovalenten Bindung von Fibrinogen zu führen, was eine größere Immunreaktion stimuliert als das Wildtyp-ClfA-Protein, bei der Herstellung eines Medikaments für die Behandlung oder Prophylaxe von Staphylokokken-Infektionen.

15. Nukleinsäurekonstrukt, Expressionsvektor oder Wirtszelle, das/der/die einen rekombinanten Staphylokokken-Verklumpungsfaktor A (ClfA) gemäß SEQ.-ID-Nr. 1 oder einer Sequenz mit mindestens 85 %, bevorzugt mindestens 95 % Sequenzidentität mit der Sequenz von SEQ.-ID-Nr. 1, oder ein Fragment davon exprimiert, der/das mindestens die Aminosäurereste 221 bis 531 der Fibrinogenbindungsregion (Region A) mit mindestens einer Aminosäurerest-Substitution oder -Deletion am Aminosäurerest Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 und/oder Val527 umfasst, um zu einem rekombinanten Fibrinogenbindungsprotein mit reduzierter Fähigkeit oder fehlender Fähigkeit zur nichtkovalenten Bindung von Fibrinogen zu führen, was eine größere Immunreaktion stimuliert als das Wildtyp-ClfA-Protein, für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen.

16. Impfstoff, der einen rekombinanten Staphylokokken-Verklumpungsfaktor A (ClfA) gemäß SEQ.-ID-Nr. 1 oder einer Sequenz mit mindestens 85 %, bevorzugt mindestens 95 % Sequenzidentität mit der Sequenz von SEQ.-ID-Nr. 1, oder ein Fragment davon umfasst, der/das mindestens die Aminosäurereste 221 bis 531 der Fibrinogenbindungsregion (Region A) mit mindestens einer Aminosäurerest-Substitution oder -Deletion am Aminosäurerest Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 und/oder Val527 umfasst, um zu einem rekombinanten Fibrinogenbindungsprotein mit reduzierter Fähigkeit oder fehlender Fähigkeit zur nichtkovalenten Bindung von Fibrinogen zu führen, was eine größere Immunreaktion stimuliert als das Wildtyp-ClfA-Protein, für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen.

17. Immunogene pharmazeutische Zusammensetzung, die Folgendes umfasst: einen rekombinanten Staphylokokken-Verklumpungsfaktor A (ClfA) gemäß SEQ.-ID-Nr. 1 oder einer Sequenz mit mindestens 85 %, bevorzugt mindestens 95 % Sequenzidentität mit der Sequenz von SEQ.-ID-Nr. 1, oder ein Fragment davon, der/das mindestens die Aminosäurereste 221 bis 531 der Fibrinogenbindungsregion (Region A) mit mindestens einer Aminosäurerest-Substitution oder -Deletion am Aminosäurerest Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 und/oder Val527 umfasst, um zu einem rekombinanten Fibrinogenbindungsprotein mit reduzierter Fähigkeit oder fehlender

Fähigkeit zur nichtkovalenten Bindung von Fibrinogen zu führen, was eine größere Immunreaktion stimuliert als das Wildtyp-ClfA-Protein, und einen pharmazeutisch verträglichen Hilfsstoff für die Verwendung bei der Behandlung oder Prophylaxe von Staphylokokken-Infektionen.

5

Revendications

1. Facteur d'agglutination A (ClfA) staphylococcique recombiné selon SEQ ID n° 1 ou une séquence ayant une identité de séquence d'au moins 85%, préférablement d'au moins 95%, par rapport à la séquence de SEQ ID n° 1 ou un fragment de celle-ci comprenant au moins les résidus d'acides aminés 221 à 531 de la région de fixation au fibrinogène (Région A), **caractérisé par** au moins une substitution ou délétion de résidu d'acide aminé au niveau du résidu d'acide aminé Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 et/ou Val527, pour conduire à une protéine de fixation au fibrinogène recombinée ayant une aptitude réduite ou dépourvue de l'aptitude à fixer le fibrinogène de manière non covalente qui stimule une réponse immunitaire supérieure par rapport à la protéine ClfA de type sauvage, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques.
2. Facteur d'agglutination A (ClfA) staphylococcique recombiné ou un fragment de celui-ci, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques selon la revendication 1, où l'infection est une infection par *Staphylococcus aureus*.
3. Facteur d'agglutination A (ClfA) staphylococcique recombiné ou un fragment de celui-ci, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques selon la revendication 1, où l'infection est une sepsie, une arthrite septique et/ou une endocardite.
4. Facteur d'agglutination A (ClfA) staphylococcique recombiné ou un fragment de celui-ci, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques selon l'une quelconque des revendications 1 à 3, où le facteur d'agglutination A (ClfA) staphylococcique recombiné ou un fragment de celui-ci comprend la séquence d'acides aminés selon l'une quelconque parmi SEQ ID n° 3, 6, 9, 10 et 13 ou des séquences ayant une identité de séquence d'au moins 85%, préférablement d'au moins 95%, par rapport à une séquence de SEQ ID n° 3, 6, 9, 10 et 13 ayant au moins une substitution ou délétion de résidu d'acide aminé au niveau des résidus d'acides aminés Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 et/ou Val527.
5. Facteur d'agglutination A (ClfA) staphylococcique recombiné ou un fragment de celui-ci, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques selon l'une quelconque des revendications 1 à 4, où le ClfA ou un fragment de celui-ci comprend au moins une substitution de résidu d'acide aminé au niveau des résidus d'acides aminés Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 et/ou Val527.
6. Facteur d'agglutination A (ClfA) staphylococcique recombiné ou un fragment de celui-ci, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques selon l'une quelconque des revendications 1 à 5, où le ClfA ou un fragment de celui-ci comprend au moins une substitution de résidu d'acide aminé au niveau des résidus d'acides aminés Tyr256, Pro336, Tyr338, Lys389, Glu526 et/ou Val527.
7. Facteur d'agglutination A (ClfA) staphylococcique recombiné ou un fragment de celui-ci, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques selon l'une quelconque des revendications 1 à 6, où la fixation non covalente qui a lieu lors de l'amarrage, du verrouillage et de l'accrochage de la protéine au fibrinogène, est réduite ou empêchée.
8. Facteur d'agglutination A (ClfA) staphylococcique recombiné, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques selon l'une quelconque des revendications précédentes, où la substitution ou délétion d'acides aminés réduit l'interaction non covalente avec le fibrinogène en empêchant ou réduisant la fixation de ligand à la poche hydrophobe séparant les sous-régions N2 et N3 de Région A de la protéine de fixation au fibrinogène.
9. Facteur d'agglutination A (ClfA) staphylococcique recombiné, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques selon l'une quelconque des revendications précédentes, où le ClfA ou un fragment de celui-ci comprend la région de fixation au fibrinogène sans les résidus d'acides aminés de peptide d'accrochage.
10. Facteur d'agglutination A (ClfA) staphylococcique recombiné, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques selon l'une quelconque des revendications précédentes, où le ClfA ou un fragment

EP 2 244 722 B1

de celui-ci comprend les résidus d'acides aminés Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 et/ou Val527, qui sont substitués par Ala ou bien Ser.

- 5 11. Facteur d'agglutination A (ClfA) staphylococcique recombiné, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques selon l'une quelconque des revendications précédentes, où la protéine de fixation au fibrinogène staphylococcique recombinée possède la séquence d'acides aminés selon l'une quelconque parmi SEQ ID n° 1 et 3 à 14, où le résidu P₃₃₆ et/ou Y₃₃₈ de SEQ ID n° 1, 3, 6, 9, 10 et 13 sont substitués par de la sérine et/ou bien de l'alanine pour conduire à rClfAP₃₃₆S Y₃₃₈A ou rClfAP₃₃₆A Y₃₃₈S.
- 10 12. Facteur d'agglutination A (ClfA) staphylococcique recombiné, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques selon l'une quelconque des revendications précédentes, où le ClfA ou un fragment de celui-ci comprend la protéine de fixation au fibrinogène, la région de fixation au fibrinogène, la région minimale de fixation au fibrinogène et/ou un fragment de celles-ci.
- 15 13. Facteur d'agglutination A (ClfA) staphylococcique recombiné, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques selon l'une quelconque des revendications précédentes, où le ClfA ou un fragment de celui-ci comprend
les sous-régions N1 à N3, couvrant les résidus d'acides aminés 40 à 559 de la région de fixation au fibrinogène (Région A) ; ou
20 les sous-régions N2 et N3, couvrant les résidus d'acides aminés 221 à 559 de la région de fixation au fibrinogène du ClfA (Région A).
- 25 14. Utilisation du facteur d'agglutination A (ClfA) staphylococcique recombiné selon SEQ ID n° 1 ou d'une séquence ayant une identité de séquence d'au moins 85%, préférablement d'au moins 95%, par rapport à la séquence de SEQ ID n° 1 ou un fragment de celle-ci comprenant au moins les résidus d'acides aminés 221 à 531 de la région de fixation au fibrinogène (Région A), ayant au moins une substitution ou délétion de résidu d'acide aminé au niveau des résidus d'acides aminés Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 et/ou Val527, pour conduire à une protéine de fixation au fibrinogène recombinée ayant une aptitude réduite ou dépourvue de l'aptitude à fixer le fibrinogène de manière non covalente qui stimule une réponse immunitaire supérieure par rapport à la protéine ClfA de type sauvage, dans l'élaboration d'un médicament destiné au traitement ou à la prophylaxie d'infections staphylococciques.
- 30 15. Produit de construction d'acide nucléique, vecteur d'expression ou cellule hôte exprimant un facteur d'agglutination A (ClfA) staphylococcique recombiné selon SEQ ID n° 1 ou une séquence ayant une identité de séquence d'au moins 85%, préférablement d'au moins 95%, par rapport à la séquence de SEQ ID n° 1 ou un fragment de celle-ci comprenant au moins les résidus d'acides aminés 221 à 531 de la région de fixation au fibrinogène (Région A), ayant au moins une substitution ou délétion de résidu d'acide aminé au niveau du résidu d'acide aminé Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 et/ou Val527, pour conduire à une protéine de fixation au fibrinogène recombinée ayant une aptitude réduite ou dépourvue de l'aptitude à fixer le fibrinogène de manière non covalente qui stimule une réponse immunitaire supérieure par rapport à la protéine ClfA de type sauvage, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques.
- 35 16. Vaccin comprenant un facteur d'agglutination A (ClfA) staphylococcique recombiné selon SEQ ID n° 1 ou une séquence ayant une identité de séquence d'au moins 85%, préférablement d'au moins 95%, par rapport à la séquence de SEQ ID n° 1 ou un fragment de celle-ci comprenant au moins les résidus d'acides aminés 221 à 531 de la région de fixation au fibrinogène (Région A), ayant au moins une substitution ou délétion de résidu d'acide aminé au niveau du résidu d'acide aminé Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 et/ou Val527, pour conduire à une protéine de fixation au fibrinogène recombinée ayant une aptitude réduite ou dépourvue de l'aptitude à fixer le fibrinogène de manière non covalente qui stimule une réponse immunitaire supérieure par rapport à la protéine ClfA de type sauvage, pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques.
- 40 17. Composition pharmaceutique immunogène comprenant un facteur d'agglutination A (ClfA) staphylococcique recombiné selon SEQ ID n° 1 ou une séquence ayant une identité de séquence d'au moins 85%, préférablement d'au moins 95%, par rapport à la séquence de SEQ ID n° 1 ou un fragment de celle-ci comprenant au moins les résidus d'acides aminés 221 à 531 de la région de fixation au fibrinogène (Région A), ayant au moins une substitution ou délétion de résidu d'acide aminé au niveau du résidu d'acide aminé Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 et/ou Val527, pour conduire à une protéine de fixation au fibrinogène recombinée ayant une aptitude réduite
- 45 50 55

EP 2 244 722 B1

ou dépourvue de l'aptitude à fixer le fibrinogène de manière non covalente qui stimule une réponse immunitaire supérieure par rapport à la protéine ClfA de type sauvage, et un adjuvant pharmaceutiquement acceptable pour une utilisation dans le traitement ou la prophylaxie d'infections staphylococciques.

5

10

15

20

25

30

35

40

45

50

55




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9

wild-type ClfA A (N123) domain protein (rClfA)

agtgaaaatagtgttacgcaatctgatagcgcaagtaacgaaagcaaaagtaatgattcaagt
 S E N S V T Q S D S A S N E S K S N D S S
 agcgtttagtgctgcacctaataacagacgacacaaaacgtgagtgataactaaaacatcgta
 S V S A A P K T D D T N V S D T K T S S
 aacactaataatggcgaaaacgagtggtggcgcaaaatccagcacaacaggaacgacacaa
 N T N N G E T S V A Q N P A Q Q E T T Q
 tcatcatcaacaaatgcaactacggaagaaacgccggttaactggtgaagctactactacg
 S S S T N A T T E E T P V T G E A T T T
 acaacgaatcaagctaatacaccggcaacaactcaatcaagcaatacaaatgccggaggaa
 T T N Q A N T P A T T Q S S N T N A E E
 ttagtgaaatcaacaagtaatgaaacgacttttaatgataactaatacagtatcatctgta
 L V N Q T S N E T T F N D T N T V S S V
 aattcacctcaaaattctacaaatgcggaataatgtttcaacaacgcaagatacttcaact
 N S P T N A E N V S T T Q D T S T
 gaagcaacaccttcaacaatgaatcagctccacagagtacagatgcaagtaataaagat
 E A T P S N N E S A P Q S T D A S N K D
 gtagttaatcaagcggttaatacaagtgcgccctagaatgagagcatttagtttagcgga
 V V N Q A V N T S A P R M R A F S L A A
 gtagctgcagatgcaccggcagctggcacagatattacgaatcagttgacgaatgtgaca
 V A A D A P A A G T D I T N Q L T N V T
 gttgggtattgactctggtacgactgtgtatccgcaccaagcaggttatgtcaaaactgaat
 V G I D S G T T V Y P H Q A G Y V K L N
 tatgggtttttcagtgccctaattctgctgttaaagggtgacacattcaaaataactgtacct
 Y G F S V P N S A V K G D T F K I T V P
 aaagaattaaacttaaatggtgtaacttcaactgctaaagtgccaccaattatggctgga
 K E L N L N G V T S T A K V P P I M A G
 gatcaagtattggcaaatggtgtaatcgatagtgatggtaatgttattttatacatttaca
 D Q V L A N G V I D S D G N V I Y T F T
 gactatgtaataactaaagatgatgtaaaagcaactttgaccatgcccgccttatattgac
 D Y V N T K D D V K A T L T M A I D
 cctgaaaatgttaaaaagacaggtaatgtgacattggctactggcataggtagtacaaca
 P E N V K K T G N V T L A T G I G S T T
 gcaaacaaaacagtattagtagattatgaaaaatatggtaagttttataacttatctatt
 A N K T V L V D Y E K Y G K F Y N L S I
 aaagggtacaattgaccaaactcgataaaaacaaataatacgtatcgtcagacaatttatgtc
 K G T I D Q I D K T N N T Y R Q T I Y V
 aatccaagtggagataacggtatttgccgggttttaacaggtaatttaaaacaaatagc
 N P S G D N V I A P V L T G N L K P N T
 gatagtaatgcattaatagatcagcaaaaatacaagtattaaagtatataaagtagataat
 D S N A L I D Q Q N T S I K V Y K V D N
 gcagctgatttatctgaaagttactttgtgaatccagaaaactttgaggatgtcactaat
 A A D L S E S Y F V N P E N F E D V T N
 agtgtgaatattacattcccaaactcaaatataaagtagagtttaatacgcctgat
 S V N I T F P N P N Q Y K V E F N T P D
 gatcaaaattacaacaccgtatatagtagttgttaatgggtcatattgatccgaatagcaaa
 D Q I T T P Y I V V V N G H I D P N S K
 ggtgatttagctttacgttcaacttttatatgggtataactcgaatataaatttgccgctct
 G D L A L R S T L Y G Y N S N I I W R S
 atgtcatgggacaacgaagtagcatttaataacggatcaggttctggtgacgggtatcgat
 M S W D N E V A F N N G S G S G D G I D
 aaaccagttgttcctgaacaacctgatgagcctgggtgaaattgaaccaattccagag
 K P V V P E Q P D E P G E I E P I P E

Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14




Fig. 15




Fig. 16




Fig. 17




Fig. 18

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6008341 A [0026]
- US 6177084 B [0026]
- WO 2005116064 A [0029] [0030] [0031]

Non-patent literature cited in the description

- CHAMBERS, H.F. *Clin Microbiol Rev*, 1988, vol. 1, 173 [0007]
- MULLIGAN, M.E. et al. *Am J Med*, 1993, vol. 94, 313 [0007]
- PATTI, J. et al. *Ann Rev Microbiol*, 1994, vol. 48, 585-617 [0009]
- PATTI, J. ; HOOK, M. *Cur Opin Cell Biol.*, 1994, vol. 6, 752-758 [0009]
- PATTI ; HOOK. *Cur Opin Cell Biol*, 1994, vol. 6, 752-758 [0011]
- PEACOCK SJ ; MOORE CE ; JUSTICE A ; KANTZANOU M ; STORY L ; MACKIE K ; O'NEILL G ; DAY NPJ. Virulent combinations of adhesin and toxin genes in natural populations of *Staphylococcus aureus*. *Infect Immun*, 2002, vol. 70, 4987-4996 [0020] [0171]
- MCDEVITT D ; NANAVALY T ; HOUSE-POMPEO K ; BELL E ; TURNER N ; MCENTIRE L ; FOSTER T ; HÖÖK M. Characterization of the interaction between the *Staphylococcus aureus* clumping factor (ClfA) and fibrinogen. *Eur J Biochem*, 1997, vol. 247, 416-424 [0020] [0171]
- MCDEVITT D ; FRANCOIS P ; VAUDAUX P ; FOSTER TJ. Molecular characterization of the clumping factor (fibrinogen receptor) of *Staphylococcus aureus*. *Mol Microbiol*, 1994, vol. 11, 237-248 [0020] [0171]
- PILPA et al. Solution Structure of the NEAT (NEAr Transported) Domain from IsdH/HarA: the Human Hemoglobin Receptor in *Staphylococcus aureus*. *J. Mol. Biol.*, 2006, vol. 360, 435-447 [0023]
- PALMQVIST N ; PATTI JM ; TARKOWSKI A ; JOSEFSSON E. Expression of staphylococcal clumping factor A impedes macrophage phagocytosis. *Microb Infect*, 2004, vol. 6, 188-195 [0024] [0171]
- HIGGINS J ; LOUGHMAN A ; VAN KESSEL KPM ; VAN STRIJP JAG ; FOSTER TJ. Clumping factor A of *Staphylococcus aureus* inhibits phagocytosis by human polymorphonuclear leukocytes. *FEMS Microbiol Lett*, 2006, vol. 258, 290-296 [0024] [0171]
- LOUGHMAN A ; FITZGERALD JR ; BRENNAN MP ; HIGGINS J ; DOWNER R ; COX D ; FOSTER TJ. Roles of fibrinogen, immunoglobulin and complement in platelet activation promoted by *Staphylococcus aureus* clumping factor A. *Mol Microbiol*, 2005, vol. 57, 804-818 [0024] [0171]
- O'BRIEN L ; KERRIGAN SW ; KAW G. ; HOGAN M. ; PENADÉS J. ; LITT D. ; FITZGERALD D.J. ; FOSTER T.J. ; COX D. Multiple mechanisms for the activation of human platelet aggregation by *Staphylococcus aureus*: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. *Mol Microbiol*, 2002, vol. 44, 1033-1044 [0024] [0171]
- JOSEFSSON E. ; HARTFORD O. ; O'BRIEN L ; PATTI JM ; FOSTER T. Protection against experimental *Staphylococcus aureus* arthritis by vaccination with clumping factor A, a novel virulence determinant. *J Infect Dis*, 2001, vol. 184, 1572-1580 [0025] [0171]
- PALMQVIST N ; FOSTER T ; FITZGERALD R ; JOSEFSSON E ; TARKOWSKI A. Fibronectin-binding proteins and fibrinogen-binding clumping factors play distinct roles in staphylococcal arthritis and systemic inflammation. *J Inf Dis*, 2005, vol. 191, 791-798 [0025] [0171]
- DEIVANAYAGAM CCS ; WANN ER ; CHEN W ; CARSON M ; RAJASHANKAR KR ; HÖÖK M ; NARAYANA SVL. A novel variant of the immunoglobulin fold in surface adhesins of *Staphylococcus aureus*: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A. *The EMBO Journal*, 2002, vol. 21, 6660-6672 [0171]
- BREMELL T ; LANGE S ; YACIOUB A ; RYDEN C ; TARKOWSKI A. Experimental *Staphylococcus aureus* arthritis in mice. *Infect Immun*, 1991, vol. 59, 2615-2623 [0171]
- SAKINIENE E ; BREMELL T ; TARKOWSKI A. Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental *Staphylococcus aureus* arthritis. *Arthritis Rheumatism*, 1996, vol. 39, 1596-1605 [0171]

- **VERDRENGH M ; TARKOWSKI A.** Role of neutrophils in experimental septicemia and septic arthritis induced by *Staphylococcus aureus*. *Infect Immun*, 1997, vol. 65, 2517-2521 [0171]
- **DUTHIE ES ; LORENZ LL.** Staphylococcal coagulase: mode of action and antigenicity. *J Gen Microbiol*, 1952, vol. 6, 95-107 [0171]
- **KREISWIRTH BN ; LÖFDAHL S ; BETLEY MJ ; O'REILLY M ; SCHLIEVERT PM ; BERGDOLL MS ; NOVICK RP.** The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. *Nature*, 1983, vol. 305, 709-712 [0171]
- **FOSTER TJ.** Methods in Microbiology Vol. 27: Bacterial Pathogenesis. Academic Press, 1998, vol. 27, 433-454 [0171]
- **O'CONNELL DP ; NANAVATY T ; MCDEVITT D ; GURUSIDDAPPA S ; HÖÖK M ; FOSTER TJ.** The fibrinogen-binding MSCRAMM (clumping factor) of *Staphylococcus aureus* has a Ca²⁺⁺-dependent inhibitory site. *J Biol Chem*, 1998, vol. 273, 6821-6829 [0171]
- **SAKINIENE E ; BREMELL T ; TARKOWSKI A.** Complement depletion aggravates *Staphylococcus aureus* septicaemia and septic arthritis. *Clin Exp Immunol*, 1999, vol. 115, 95-102 [0171]
- **MANCINI G ; CARBONARA AO ; HEREMANS JF.** Immunochemical quantitation of antigens by single radial immunodiffusion. *Immunochemistry*, 1965, vol. 2, 235-254 [0171]
- **BREMELL T ; ABDELNOUR A ; TARKOWSKI A.** Histopathological and serological progression of experimental *Staphylococcus aureus* arthritis. *Infect Immun*, 1992, vol. 60, 2976-2985 [0171]



MIKROBIÁLIS FERTŐZÉSEK KEZELÉSE

SZABADALMI IGÉNYPONTOK

1. A SEQ ID No. 1 szerinti vagy a SEQ ID No. 1 szekvenciával legalább 85%-ban, előnyösen legalább 95%-ban megegyező szekvencia szerinti rekombináns staphylococcus A endokoaguláz (clumping factor - ClfA) vagy ennek egy fragmentuma, amely a fibrinogén kötőrégióinak legalább a 221–531-ig terjedő aminosav-maradékait (A régió) tartalmazza, legalább egy aminosav-maradék szubsztitúcióval vagy delécióval **jellemezve** az Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 és/vagy Val527 aminosav-maradéknál, aminek eredményeképpen a rekombináns fibrinogénkötő fehérjének csökken vagy hiányzik a képessége arra, hogy nem-kovalensen kösse a fibrinogént, ami nagyobb immunválaszt idéz elő, mint a vad típusú ClfA fehérje esetében, staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználás céljából.
2. Az 1. igénypont szerinti rekombináns staphylococcus A endokoaguláz (ClfA) vagy ennek egy fragmentuma staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználásra, ahol a fertőzés *Staphylococcus aureus* fertőzés.
3. Az 1. igénypont szerinti rekombináns staphylococcus A endokoaguláz (ClfA) vagy ennek egy fragmentuma staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználásra, ahol a fertőzés szepszis, szepikus arthritis és/vagy endocarditis.
4. Az 1–3. igénypont bármelyike szerinti rekombináns staphylococcus A endokoaguláz (ClfA) vagy ennek egy fragmentuma staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználásra, ahol a rekombináns staphylococcus A endokoaguláz (ClfA) vagy ennek egy fragmentuma a SEQ ID No. 3, 6, 9, 10 és 13 szekvenciák bármelyike szerinti vagy a SEQ ID No. 3, 6, 9, 10 és 13 szekvenciák egyikével legalább 85%-ban, előnyösen legalább 95%-ban megegyező szekvencia szerinti aminosav-szekvenciát tartalmazza, és legalább egy aminosav-maradék

szubsztitúcióval vagy delécióval rendelkezik az Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 és/vagy Val527 aminosav-maradéknál.

5. Az 1–4. igénypont bármelyike szerinti rekombináns staphylococcus A endokoaguláz (ClfA) vagy ennek egy fragmentuma staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználásra, ahol a ClfA vagy ennek egy fragmentuma legalább egy aminosav-maradék szubsztitúcióval rendelkezik az Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 és/vagy Val527 aminosav-maradéknál.
6. Az 1–5. igénypont bármelyike szerinti rekombináns staphylococcus endokoaguláz (ClfA) vagy ennek egy fragmentuma staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználásra, ahol a ClfA vagy ennek egy fragmentuma legalább egy aminosav-maradék szubsztitúcióval rendelkezik a Tyr256, Pro336, Tyr338, Lys389, Glu526 és/vagy Val527 aminosav-maradéknál.
7. Az 1–6. igénypont bármelyike szerinti rekombináns staphylococcus A endokoaguláz (ClfA) vagy ennek egy fragmentuma a staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználásra, ahol a fehérje fibrinogénhez történő dokkolása, zárása és reteszelése (dock, lock, latching) közben létrejövő nem-kovalens kötések csökkennek vagy megakadályozódnak.
8. Az előző igénypontok bármelyike szerinti rekombináns staphylococcus A endokoaguláz (ClfA) a staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználásra, ahol az aminosav-szubsztitúció vagy deléció azáltal csökkenti a nem kovalens kölcsönhatást a fibrinogénnel, hogy megelőzi vagy csökkenti a ligandumok kötődését a fibrinogénkötő fehérje A régiójának N2 és N3 alrégióját elválasztó hidrofób zsebhez.
9. Az előző igénypontok bármelyike szerinti rekombináns staphylococcus A endokoaguláz (ClfA) a staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználásra, ahol a ClfA vagy ennek egy fragmentuma a reteszelő peptid (latching peptide) aminosav-maradékai nélkül tartalmazza a fibrinogénkötő régiót.

10. Az előző igénypontok bármelyike szerinti rekombináns staphylococcus A endokoaguláz (ClfA) a staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználásra, ahol a ClfA vagy ennek egy fragmentuma Ala vagy Ser aminosavval szubsztituált Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 és/vagy Val527 aminosav-maradékokat tartalmaz.
11. Az előző igénypontok bármelyike szerinti rekombináns staphylococcus A endokoaguláz (ClfA) a staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználásra, ahol a rekombináns staphylococcus fibrinogénkötő fehérje a SEQ ID No. 1 és 3–14 szekvencia bármelyike szerinti aminosav-szekvenciával rendelkezik, ahol a SEQ ID No. 1, 3, 6, 9, 10 és 13 P₃₃₆ és/vagy Y₃₃₈ maradéka szerinnel és/vagy alaninnal szubsztituálva van, ami által rClfAP₃₃₆S Y₃₃₈A vagy rClfAP₃₃₆A Y₃₃₈S szekvenciát alkot.
12. Az előző igénypontok bármelyike szerinti rekombináns staphylococcus A endokoaguláz (ClfA) a staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználásra, ahol a ClfA vagy ennek egy fragmentuma tartalmazza a fibrinogénkötő fehérjét, a fibrinogénkötő régiót, a minimális fibrinogénkötő régiót és/vagy ennek egy fragmentumát.
13. Az előző igénypontok bármelyike szerinti rekombináns staphylococcus A endokoaguláz (ClfA) a staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználásra, ahol a ClfA vagy ennek egy fragmentuma a következőket tartalmazza:

N1–N3 alrégió, a fibrinogénkötő régió (A régió) 40–559. aminosav-maradékaig terjedően vagy

N2–N3 alrégió, a ClfA fibrinogénkötő régiójának (A régió) 221–559. aminosav-maradékaig terjedően.
14. Staphylococcus fertőzések kezelésére vagy megelőzésére szolgáló gyógyszer gyártásában való felhasználása annak a SEQ ID No. 1 szerinti vagy a SEQ ID No. 1 szekvenciával legalább 85%-ban, előnyösen legalább 95%-ban megegyező szekvencia szerinti rekombináns staphylococcus A endokoaguláznak (ClfA) vagy ennek egy fragmentumának, amely a fibrinogén kötőrégióinak legalább a 221–531-ig terjedő aminosav-maradékaik (A régió) tartalmazza, ahol legalább egy aminosav-maradék

szubsztitúció vagy deléció található az Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 és/vagy Val527 aminosav-maradéknál, aminek eredményeképpen a rekombináns fibrinogénkötő fehérjének csökken vagy hiányzik a képessége arra, hogy nem-kovalensen kösse a fibrinogént, ami nagyobb immunválaszt idéz elő, mint a vad típusú ClfA fehérje.

15. Nukleinsav-szerkezet, expressziós vektor vagy gazdasejt, amely a SEQ ID No. 1 szerinti vagy a SEQ ID No. 1 szekvenciával legalább 85%-ban, előnyösen legalább 95%-ban megegyező szekvencia szerinti rekombináns staphylococcus A endokoagulázt (ClfA) vagy ennek egy fragmentumát expresszálja, amely a fibrinogén kötőrégiójának legalább a 221–531-ig terjedő aminosav-maradékait (A régió) tartalmazza, ahol legalább egy aminosav-maradék szubsztitúció vagy deléció található az Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 és/vagy Val527 aminosav-maradéknál, aminek eredményeképpen a rekombináns fibrinogénkötő fehérjének csökken vagy hiányzik a képessége arra, hogy nem-kovalensen kösse a fibrinogént, ami nagyobb immunválaszt idéz elő, mint a vad típusú ClfA fehérje, staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználás céljából.
16. Vakcina, amely a SEQ ID No. 1 szerinti vagy a SEQ ID No. 1 szekvenciával legalább 85%-ban, előnyösen legalább 95%-ban megegyező szekvencia szerinti rekombináns staphylococcus A endokoagulázt (ClfA) vagy ennek egy fragmentumát tartalmazza, amely a fibrinogén kötőrégiójának legalább a 221–531-ig terjedő aminosav-maradékait (A régió) tartalmazza, ahol legalább egy aminosav-maradék szubsztitúció vagy deléció található az Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 és/vagy Val527 aminosav-maradéknál, aminek eredményeképpen a rekombináns fibrinogénkötő fehérjének csökken vagy hiányzik a képessége arra, hogy nem-kovalensen kösse a fibrinogént, ami nagyobb immunválaszt idéz elő, mint a vad típusú ClfA fehérje, staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználás céljából.
17. Immunogén gyógyszerészeti készítmény, amely a SEQ ID No. 1 szerinti vagy a SEQ ID No. 1 szekvenciával legalább 85%-ban, előnyösen legalább 95%-ban megegyező szekvencia szerinti rekombináns staphylococcus A endokoagulázt (ClfA) vagy ennek egy fragmentumát tartalmazza, amely a fibrinogén kötőrégiójának legalább a 221–531-ig

terjedő aminosav-maradékait (A régió) tartalmazza, ahol legalább egy aminosav-maradék szubsztitúció vagy delécio található az Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 és/vagy Val527 aminosav-maradéknál, aminek eredményeképpen a rekombináns fibrinogénkötő fehérjének csökken vagy hiányzik a képessége arra, hogy nem-kovalensen kösse a fibrinogént, ami nagyobb immunválaszt idéz elő, mint a vad típusú ClfA fehérje, valamint egy gyógyászati lág elfogadható segédanyagot, staphylococcus fertőzések kezelésében vagy megelőzésében való felhasználás céljából.